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ABSTRACT
Despite the efforts, for more than twenty years, to control malaria, the incidence of this
disease still appears to be escalating globally. At the Chris HanilBaragwanath Hospital,
data analysis of malaria admissions between January 1994 to December 1996 showed an
increasing trend :fromyear to year.
The main objective of the study was to try and provide some insight into this increasing
rate of malaria at the Chr+ ~'ani/Baragwanath Hospital. The study was structured into
two main parts: a retrospective analysis which con.centrated on malaria admissions
between and including January 1994 and March 1994, and a prospective analysis
interviewing and examining all the malaria cases that were diagnosed between. and
including January 1995 and March 1995. Both aspects of the study assessed the patients
socioeconomically, haematologically and immunologically. A detailed travel,medical and
drug history was taken through the aid of a questionnaire.
Two hundred and sixty-three patients (175 male and 88 female), of which 35% (91/263)
were children « 13 years old), were diagnosed with malaria. The clinical and
laboratory presentations were consistent with other studies. The prevalence of
complicated disease however was less than what has been described in the literature;
cerebral malaria (as defined by Warrell, 1982) was documented in 1% of patients,
hypo glycaemia (glucose < 2.2 mmolll) and renal failure (creatinine > 265 umol/l)
accounted for 5% and 3% of the cases respectively. In contrast to this 32% had
features of liver dysfunction, however it appeared that haemolysis was the main
contributing factor to the liver derangement. The most common infecting species was
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Plasmodium falciparum, alone (91.3% of the patients) or part of a mixed infection
with either P. vivax or P.ovale (3.8% of patients). More than 88% of the infections were
contracted in other African, mainly southern African countries, the most important of
which was neighbouring Mozambique (58%). About 11% were contracted in endemic
areas of South Africa i.e Northern Province, Mpumalanga and Kwazulu Natal. Twelve
percent of cases (24/203) gave a history of previous malaria, The underlying immune
status of these patients was analyzed using the Indirect Fluorescence Antibody Test
(IFAT) and compared with the total study group. The test did not reveal any striking
differences between the two groups. The previously exposed patients however did
demonstrate a much lower parasitaemia, with 71% (17/24) of cases presenting with a
parasite density :::;1%. These results may indicate the ability of these patients to clear
their parasitaemias earlier due to previous sensitization, with the subsequent
establishment of a low grade chronic infection.
Seven of 88 women admitted had a documented pregnancy at the time of diagnosis.
Foetal death was recorded in 517 cases which confirms the poor prognosis in pregnancy
associated malaria infection, reported by other authors.
Fifteen patients (13 adults and 2 children) required admission into the intensive care unit.
Indications included high parasite loads, > 5% (67%) and renal failure,
creatinine> 265 umol/l (33%).
Standard chemotherapy was administered to all the patients with the most frequently
used being quinine (94% of cases), alone or in combination with other drugs. The use of
prophylactic agents for the prevention ofmalaria was restricted to twelve patients (8%),
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with the majority of individuals being ignorant ab. o.t( malaria and therefore being
unaware that any medication along with other preventative measures, were necessary
p110rto entering , and while staying in an endemic region. It was also apparent that the
correct dosage was not adhered to as none of the patients completed their antimalarial
course after returning from the malaria mea. The most commonly used prophylactic
drugs were chloroquine, alone or in combination with proguanil and pyrimethamine plus
dapsone (Maloprim), The latter is no longer recommended routinely as a prophylactic
agent.
Following univariate analysis using Fisher's exact test and the student t-test, and a
multivariate: nalysis (using a logistic regression model), hyperparasitaemia (p=O.0070)
and renal failure (p=O.0016) were identified as significant predictors of pcor outcome.
Significant differences were also demonstrated in the mean wce and the mean HB
levels between the survivors versus the patients that died, indicating that a significantly
elevated WCC and an anaemia at presentation, may be important risk factors towards
the establishment of severe/complicated infection. The overall mortality rate was 3%.
Climatic data (which was limited to the Johannesburg area), together with evidence that
the malaria bearing Anopheles vector does not exist in Gauteng suggests that the
conditions in the city may not be suitable for local transmission of malaria during the
summer. It therefore appears that all efforts need to be channeled into the education of
our travelers who visit malaria endemic regions and upon returning succumb to
'imported' malaria. Perhaps the education of the traveler alone is not sufficient, and
medical personnel who diagnose the condition and who prescribe prophylactic agents
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need to revise their knowledge of this life threatening infection, so that their advice and
drug therapies are optimal and effective. Lastly the pharmaceutical companies that
manufacture these drugs might be persuaded to make their products more affordable for
those individuals who are most at risk. We need to utilize our limited options to the
fullest until such a time as the ultimate challenge is realised - an effective malaria
vaccine.
vi
l CKr~OWLEDGEMENTS
I would like to thank the following people:
My supervisor, Professor Heather Crewe-Brown, for her assistance 1n
preparing this document.
Professor B. VMendelow (Head of the Department ofHaematology,
SAIMR) for his encouragement and suggestions.
Professor A.F Fleming f01"his advice in the initial planning of the study.
Dr Wendy Stevens (Head of the Haematology Laboratory, SAIMR - Chris
Hani/Baragwanath Hospital) for her encouragement and support.
Ms Sakina Bibi Loonat, Mr Yega Govender and the stajfofthe
Haematology Laboratory. SAIMR, Chris HanilBaragwanath Hospital, for
their assistance in the processing of the routine blood samples.
Dr John Frean (Department of Parasitology, SAIMR) for his expert
assistance in the interpretation of results.
The staff, and especially Gilbert, of the department of Parasitology for their
assistance in the processing of blood samples for the malaria antibody
testing.
The staff, of the department of Chemical " athology, SAIMR, Johannesburg
Hospital for their assistance in the processing of blood samples for
immunoglobulin levels and protein e 'ectrophoresis.
Mr John Mansefield (Statistician) for his expert assistance with the relevant
statistical analysis.
Dr Chris van den Heever (Superintendant at the Chris Hani/Baragwanath
Hospital) for his interest in this study.
vii
The staff of the Records Department at the Chris Hani/Baragwanath
Hospital for their assistance in the procurement of the patients' past medical
records for the retrospective part of my study.
The nursing stafJofthe Community Health Services and Clinics who
encouraged referral of patients with malaria to be included inmy study.
Mrs Lily Battaglia and the staff of the SAIMR, Central Institute Library for
their assistance, often at a moment's notice.
Ms Karen Goozen of the Witwatersrand Medical School Library for her
assistance.
The members of the Photographic unit for their assistance with the
illustrations reflected in this manuscript.
viii
TABLE OF CONTENTS
DECLARATION
DEDICATION
ABSTRACT
ACKNOWLEDGEMENTS
TABLE OF CONTENTS
LIST OF FIGURES
LIST OF TABLES
LIST OF ABBREVIATIONS
PROLOGUE-The Ballad of the Plasmodium
ii
vii
ix
xv
xviii
xx
xxii
1.0 INTRODUCTION 1
1.1 HISTORICAL BACKGROUND 1
1.2 EPIDEMIOLOGY 3
1.3 I:IOLOGY 6
1.3.1 Life Cycle of the Plasmodium 9
1.3.1.1 The parasite in the vertebrate host-
invasion of the erythrocyte 11
(a) Initial interaction 11
(b) Reorientation 12
(c) Internalisation 13
1.3.1.2 The parasite in the vertebrate host-
changes in the parasitised red blood
cell 18
(a) The membrane of the parasitised
cell 18
(b) Haemoglobin degradation in the
parasitised erythrocyte 25
1.4 THE CUNICAL PRESENTATION AND 27
PATHOPHYSIOLOGY OF PLASMODIUM
FALClPARUM MALARIA
1.4.1 Fever 27
1.4.1.1 Cytokines 28
1.4.1.1.1 Tumour Necrosis Factor ex 28
1.4.2 Cerebral Malaria 30
1.4.2.1 The pathophysiology and pathology of
CerebralMalaria 31
1.4.3 Anaemia and thrombocytopenia 33
1.4.4 Renal dysfunction 3<&
1.4.5 Hypoglycaemla 35
ix
PAGE
1.5 ITh1MUNiTY IN MALARIA 35
1.6 MALARIA AND PREGNANCY 40
1.6.1 Pregnancy and immune suppression 40
1.6.2 Epidemiology of malaria in pregnancy 42
1.7 PREVENTION AGAINST MALARIA 43
1.7.1 Vector Control 44
1.7.2 Antimalarial Vaccines 44
1.7.2.1 Vaccine strategies 46
1.7.2.1.1 Target populations 46
1.7.2.1.2 Vaccine design 46
1.7.2.1.2a Cytoadherence 46
1.7.2.1.3 Transmission-blocking vaccines 48
1.7.2.1.4 Vaccines of the future 48
1.7.2.1.5 Vaccine delivery systems 50
1.8 DIAGNOSTIC TECHNIQUES 50
1.3.1 Microscopy 50
1,8.2 DNAIRNA probes and hybridization for the 52
detection of Pfalciparum malaria
1.8.3 Serology 53
1.8.3.1 ELISA (enzyme-linked immunosorbent
ussay) 53
1.8.3.2 IFAT (indirect fluorescent antibody test) 54
1.8.4 PCR (polymerase chain reaction) 55
1.8.5 Antigen detecting tests 55
1.8.6 QBC (qualitative buffy coat) 59
1.9 THE CHEMOTHERAPY OF MALARIA 59
1.9.1 Historical overview 60
1.9.1.1 Chloroquine-the drug of choice? 60
1.9.1.2 Chloroquine-Mode of action 61
1.9.1.2.1 DNA binding hypothesis 61
1.9.1.2.2 Ferriprotoporphyrin IX (FP IX)
hypothesis 61
1.9.1.2.3 Weak Base hypothesis 62
1.9.2 Rationale of Malaria Chemotherapy 62
1.9.3 Quinine- Why so special after 350 years? 63
2.0 AIMS AND OBJECTIVES OF THE STUDY 69
3.0 MATERIALS At'iD METHODS 70
x
PAGE
3.1 Ml TERIALS AND METHODS: Part I 70
(Reerospectlve study)
3.1.1 General Considerations 70
3.1.2 Data Collection 70
:U.2.1 Social history 70
3.1.2.2 Clinical aspects 71
3.1.2.3 Laboratory investigations 72
3.2 MATERIALS AND METHODS: Part IT 73
(prospective study)
3.2.1 General Considerations 73
3.2.2 Data Collection 74
3.2.2.1 Social and clinical aspects 74
3.2.2.2 Laboratory investigations 74
3.2.3 Recording of data and results 75
3.3 METHODS- Specimen Analysis 76
3.3.1 Haematologleal assessment 76
3.3.1.1 Reticulocyte counts 76
3.3.1.2 Differential counts 77
3.3.2 Preparation of malaria smears 78
3.3.2.1 Thick blood smears 79
3.3.2.1.1 Preparation of thick blood smears 79
3.3.2.1.2 Staining of thick blood smears 79
3.3.2.1.3 Examination of thick blood smears 79
3.3.2.2 Thill blood smears 80
3.3.2.2.1 Preparation of'thin blood smears 80
3.3.2.2.2 Staining of thin blood smears 81
3.3.2.2.3 Examination of thin blood smears 81
3.3.3 Determining the parasite count (parasitaemla/ 82
parasite density)
3.3.4 Serological methods - IFAT 82
3.3.4.1 Sample collection 82
3.3.4.2 Sample analysis-the IFAT 82
3.3.4.3 Interpretation of results 83
3.3.5 Estimatlon of immunoglobulin levels 84
3.3.5.1 Sample collection 84
3.3.5.2 Sample analysis- immunoglobulin levels 84
3.3.5.3 Interpretation of results 85
3.3.6 MATERIALS - Temperature and rainfall data 86
xi
PAGE
3.3.7 Analysis and interpretation of data 87
4.0 RESULTS 88
4.1 SOCIOECONOMIC ANALYSIS 92
4.2 CLINICAL PARAMETERS 92
4.2.1 Clinical presentation 9~
4.2.2 Laboratory data 94
4.2.2.1 Haematological parameters 94
4.2.2.1.1 Peripheral blood smear morphology 94
4.2.2.1.2 Bone Marrow features 101
4.2.2.2 Malaria Data 101
4.2.2.3 Chemistry results 106
4.2.2.4 Serological results 107
4.2.2.5 Pregnancy data analysis 108
4.2.2.5.1 Haematological data 108
4.2.2.5.2 Chemistry data 110
4.2.2.5.3 Malaria data 110
4.2.2.6 Data analysis ofICU admissions 110
4.2.2.6.1 Haematological and Chemistry data 110
4.2.2.6.2 Malaria data 113
4.2.2.7 Chemotherapy used in the treatment of
malaria 114
4.2.2.8 Complicated Malaria 115
4.2.2.9 Analysis of blood transfusion practise
in the malaria patients 115
4.3 UNi l'APJATE AND MUL TIV ARIATE ANALYSIS 116
OF LABORATORY DATA
4.4 TEMPEP..ATURE AND RAINFALL 118
MEASUREMENTS
5.0 mSCUSSmN 122
5.]. INCIDENCE OF MALARIA 122
5.2 MALARIA AWARENESS AND PROPHYLA.XJS 124
5.3 AVAILABILITY OF ANTIMALARIAL DRUGS 125
5.4 GENERAL PROPHYLACTIC MEASURES 127
5.5 DIAGNOSIS AND TREATMENT 127
5.S.1 CHilllicalpresentation 127
5.5.2 Laboratory analysis 128
5.5.2.1 Haematological data 128
xii
PAGE
5.5.2.1.1 Blood transfusion practise inthe
malaria patients 130
5.5.2.2 Analysis of chemistry data 131
5.5.2.3 Serological data and the assessment
of immunity 133
5.5.2.4 Analysis of pregnancy data 135
5.5.2.5 leU admissions 136
5.5.2.6 Treatment 136
6.0 CONCLUSION 140
7.0 RECOMMENDATIONS 144
8.0 REFERENCES 148
xiii
APPENDICES
APPENDIX A Informed written consent form 178
APPENDIX B Patient information sheet 179
APPENDiX C Questionnaire 180
APPENDIX D Standard Operating Procedure 183
for a DifferenHal Count
APPENDiX E Standard Operating Procedure 188
for the Indirect Fluorescent Antibody
Te§t
APPENDIX F Standard Operating Procedure 190
for the determ.nation of
Iramunoglobulin levels
APPENDIX G Excel4D data base 195
xiv
•-
LiST OF FIGURES
FIGURE PAGE
1 The worldwide distribution ~fmalaria 5
2 Malaria risk areas in South Africa 7
3 Development stages of malaria parasites in 12
Anopheles mosquitoes and in the human host
4 Schematic view of the malaria merozoite and 14
its interaction with the host red blood cell surface,
5 A model of the cytoskeletal organisation of the 18
erythrocyte
6 Schematic representation of permeation pathways 19
in the host membrane of malaria infected cells
7 Cytoskeletal organisation of an erythrocyte 21
infected with a mature stage 'knobby' parasite
8 Schematic representation of the pathogenesis of 24
cerebral malar '4
9 Proposed pathway of haemoglobin degradation 26
10 Antibody-dependent monocyte-mediated mechanisms 38
of growth inhibition of P.falciparum
11 Schematic diagram of the cell-mediated and 39
antibody-dependent mechanisms of protective
immunity to asexual erythrocyte stages of
P. falciparum
12 The ParaSight F antigen capture assay 56
13 The leT Malaria Pj. antigen capture assay 57
14 Peripheral blood (x 1000) - malaria thick smear 80
xv
FIGURE PAGE
15 The Indirect Fluorescence Antibody Test 83
16 The age distribution of'the study group 89
17 Monthly incidence of malaria cases at the 91
Chris HanilBaragwanath Hospital from January
1994 to December 1996
18 Peripheral blood smears (x 1000) demonstrating 96
early ring stages and late trophozoites
19 Peripheral blood smears (x 1000) demonstrating 97
a male (M) and female (F) gametocyte of
P .falciparum.
20 A perip' .eral blood smear (x 1000) demonstrating 99
reactive lymphocytes (L)
21 Peripheral blood smear (x 1000) demonstrating 99
an atypical plasmacytoid lymphocyte (L). The
background shows a disordered neutrophil (N)
and parasitised red blood cells, (P)
22 A peripheral blood smear (x 1000) illustrating 100
various monocytic forms noted in malaria
23 A peripheral blood smear (x WOO) illustrating 100
the phagocytic properties of'monocytes, here
engulfing haernazoin (arrow)
24 Bone marrow smear (x 1000) showing 102
dyserythropoietic features
25 A bone marrow smear (x 1000) showing 102
sideroblastic changes within erythroid precursors
26 Monthly rainfall (mm) Johannesburg,Gauteng from
January 1994 to December 1996 119
Average rainfall(mm) Maputo, Mozambique from 119
1894 to 1994 (average 100 years)
xvi
_--
FIGURE
27 Monthly temperature variation (deg C) Johannesburg,
Gauteng for January 1994 to December 1996
Monthly average temperature variation (deg C)
Maputo, Mozambique from 1977 to 1994
(average 17 years)
PAGE
120
120
xvii
LIST OF TABLES
TABLES PAGE
1 The classification of Plasmodia infecting primates 8
and other mammals
2 Plasmodium falciparum proteins which interact 22
with the erythrocytic cytoskeleton
3 Symptom's and signs of uncomplicated malaria 28
(in order of decreasing frequency)
4 Severe manifestations and complications of 29
falciparum malaria
5 The signs and symptoms of cerebral malaria 32
6 The effects of malaria on pregnancy 43
7 Candidate antigens from the malaria life-cycle, 47
targets for the development of an antimalarial vaccine
8 Antigen capture methods used in the detection 58
of malaria
9a-e Pharmacology of the commonly used chemotherapeutic 64-68
agents against malaria parasites
10 Normal haematological reference ranges for 77
adult Blacks living on the Witwatersrand
11 Normal haematological reference ranges for 78
infants and children
12 1mmunoglobulin reference ranges for Black 86
adults and children
13 Clinical signs and symptoms at presentation 93
(in order of frequency)
xviii
.~'.' -"-'-~""-~ =V::ll3r:;:-===~===;;;;;;';;;;'iiiw."'ti'iirf"- j
TABLES PAGE
14 Summary ofhaematological data for adults 95
and children
15 Regions where malaria was contracted 103
16 Drugs taken for prophylaxis 104
17 Parasitaemia frequencies for adult and paediatric 105
patients
18 Summary of biochemical results 106
19 Malaria data of patients with a history of previous 10~
infection
20 Clinical signs and symptoms within the lCU cases 111
by age group
21 Summary of'haematological and chemistry data 112
in the rcu cases by age group
22 Drugs used inthe therapy of malaria 114
23 Summary of patients receiving blood transfusions 116
24 Univariate analysis comparing survival and death 117
with regard to continuous data (mean ± standard
deviations)
xix
ALKPHOS
ALT
AST
ATP
f;AT
CNS
CREAT
CS
CQ
CQR
CQS
CVS
DALYs
DB
DDT
DIC
DNA
EBA-175
EDTA
FEC
FITC
'foP IX
y-GT
GLUC
G6PD
HbIHB
HBcAg
HBsAg
HCT
HLA
IB
ICAM-!
ICU
IFAT
IFNy
Ig
IL
LiST OF ABBREVIATIONS
Alkaline phosphatase
Alanine transaminase
Aspa-. 'e transaminase
Adenosine tri phosphate
Catalase
Central Nervous System
Creatinine
Circumsporozoite
Chloroquine
Chloroquine Resistant
Chloroquine Sensitive
Cardiovascular System
Disability adjusted life years
Direct bilirubin
Dichloro-dipheryl-trichloroethane
Disseminated Intravascular Coagulation
Deoxyribonucleic acid
Erythrocyte Binding Antigen - 175
Ethylenediamine tetracetate
Full Blood Count
Fluoroscein Isothiocyanate
Ferritoprotoporphyrin IX
y-Glutamyltransferase
Glucose
Glucose-o-Phosphate Dehydrogenase
Haemoglobin
Hepatitis B core antigen
Hepatitis B surface antigen
Haematocrit
Human Leucocyte Antigen
Indirect bilirubin
Intracellular Acne-' on Molecule-I
Intensive Care U'it
Indirect Fluorescen "tibody Test
Interferon y (gar> na..
Immunoglobulin
Interleukin
xx
LOC
LSA-I
LTa
Max
MAPs
MCH
MCReMev
MEPs
MESA
Min
MSP/A-l
NO
NOS
peR
PCT
pers.corom.
PjEl'vlP-1
PjHRP-1
PLTs
P:M.MSA
'PRBC
PUO
PVM
RBC
rDNA
RESA
RNA
rRNA
SEA
SERA
SOP
SSP~2
SID
TB
TNFa.
TP
TSP
U+E
VCAM-1
WCC
Loss of consciousness
Liver Stage-specific Antigen -1
Lymphotoxin a. (alpha)
Maximum
Multiple antigen peptide system
Mean Cell Haemoglobin
Mean Cell Haemoglobin Concentration
Mean Cell Volume
Multiple epitope peptide system
Mature parasite infected Erythrocyte Surface Antigen
Minimum
Merozoite Surface Protein! Antigen - 1
Nitric Oxide
Nitric Oxide Synthase
Polymerase chain reaction
Parasite clearance time
personal communication
Plasmodium falciparum Erythrocyte Membrane Protein -1
Plasmodium falciparum Histidine Rich Protein-I
Platelets
Plasmodium Major Merozoite Surface Antigen
Parasitised red blood cell
Pyrexia of unknown origin
Parasitophorous vacuole membrane
red blood cell
ribosomal deoxyribonucleic acid
Ring infected Erythrocyte Surface Antigens
Ribonucleic acid
ribosomal ribonucleic acid
South East Asian
Serine Repeat Antigen
Standard operating procedure
Sporozoite Surface Protein - 2
Standard deviation
Total bilirubin
Tumour Necrosis Factor a (alpha)
Total protein
Thrombospondin
Urea and electrolytes
Vascular Cell Adhesion Molecule -1
White cell count
xxi
The Ballad of the Plasmodium
Plasmodium has a lot in store
And works in stages by the score.
Anopheles that probes your <~jn
Pumps many sporozoites i'"
They lose no time, move into liver
And settle down before you shiver,
Some hypnozoites go to sleep
A late relapse intending to keep.
But others grow.olvlde like mad
And move from liver into blood.
In red cells do their very worst
Expanding to make each cell burst
As merozoites they are vexed
By being greatly undersexed.
Their life is tedious.rather stale
Without a female and a male
This truth they soon will realize
And change assuming larger size
So now, when a mosquito bites
It must suck up gametocytes
And microgametes being sucked
Can now perform the amorous act
When in the stomach of'the gnat
They find a macrogamete fat
Their love' s great feat is now complete
As female ookinete
Then losing all her self-control
She goes through the insect's stomach wall.
And there encys ...d feels more able
To raise a new Plasmodium stable
When thousand sporozoites fit
wm prove that she has done her bit
To salivary glands they wend
And start again: there is no end.
The moral of this age-old story
Is that we can't aspire to glory
Until our principal objective
Will make control much more effective
And faced with chloroquine resistance
We must depend 011more assistance
And find new medicament
To solve our great predicament
A compound that in all event
Is active cheap.polyvalent.
Perhaps we need a proper vaccine
With antigens that science mucks in
And adjuvants that w. 1not itch
And antibody God knows which.
Or to develop other means
To fight those vicious little fiends
That no one who is from Mankind Could e'er defend, ifsound of mind.
Leonard Bruce-Chwatt
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1.0 INTRODUCTION
In 1094 and 1995 the total number of malaria cases reported in South Africa were
over 10 000 and 9 000 respectively (Sharp and Ie Sueur ;1996). Despite the many
efforts to eradicate this disease worldwide, the number of cases detected every year
continue to increase. This can be attributed to heavy seasonal rainfalls, resistance of the
mosquitoes to insecticides, and resistance of the parasite to the standard
chemotherapeutic t;gents used, ego Chloroquine . Another postulate is that, the
populations that are being exposed to malaria may have now lost a previously semi-
immune state to the parasitic infections.
Malaria remains the most important tropical parasitic disease , with major social and
economic implications in developing countries. The document that follows discusses
the incidence of malaria at the Chris HanilBaragwanath Hospital in Gauteng, South
Africa.
1.1 mSTORICAL BACKGROUND
Earliest records of malaria date back to the 5 th century B.C. when Hippocrates
differentiated types of fevers and coincidentally described the clinical picture of malaria
and some of its complications.
In southern Africa malaria appears to have been around from the time of the
explorers, it is also probable that the disease may have originated on the continent
(Gilles, 1993).
The important milestones in the history of malaria (adapted from Gilles H.M. in Bruce-
Chwatt's Essential Malariology, 1993, p.4 ) are listed below:
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30 MiUion years BC
500BC
1600 AD
1810
1880
1386
1889 -1890
1891
1898 -1899
1899
1901
1922
1934
1935 -1939
1944
Milestones in the History of Malaria
Fossil mosquitoes found Yil geological strata.
Hippocrates describes the clinical picture
of malaria. He observes an association between
the emergence of intermittent fevers, seasons
of the year, and swampy / stagnant watery
environments.
Jesuit missionary records the use of the/ever
tree bark (Jesuit's Powder) - Ch-chona tree,
fcr the treatment of certain fevers (agnes).
The alkaloids quinine aed emchonhre l> ere
isolated from thll bark of the Cinchona tree,
by two frenchmen.
A French army surgeon in Algeria, first saw
and described malaria parasites in the RBC
of human blood,
P.vivax and Panalariae were described.
P.falciparum was described.
The Russlaa Romanowsky developed a new
method fol1'staining malaria parasites in tile
blood.
Manson puts ferward Ids theory thDltmalarfa
is transmitted from one person to another VJia
a mesquite,
The Italians Grassi et al described the cycle of
human malarll) in the Anopheles mosquito.
The first autllarva] programmes were started
in Siena Leone.
The existence of 11 pre - erythroe; phase in
the life cycle of the malaria parasite was
hypothesised.
P. oV(JJie was described,
Chlorequine W3§ developed in Germany.
lFuu- ~ applleatlon of insecficndal measures
(iucUuding DDT) (GIr tlie eontrel
of mala I'm.
Progunnil was developed in England.
2
1949 ShOl11tet ai described the pre- erythrocytic
stage of P. /alcipamm in the ~umon JiveI'.
1952 Pyrfmethamine aad primaquine were
developed in the USA.
1957 The WHO launches a gRobll1campaign for
the control of malaria.
1961-1965 Emergence of cbioroquine resistant strains of
P. jalcipamm.
1971-1975 Intreductiou of mefloquiue into malarial
treatment,
1978 Riekmann Introduees a mieretest for the
detection of chloroquine resistance in P.
/aiciporum.
1979 -1982 Development of the quinghaosu
antimalarials.
1985 -1986 WHO recommends that malaria eonrrol
should be developed as an integY':dpart of
national primary health care systems,
1989 Halofan~rane was Introduced,
1990- Artenusate and artemether are used in
clinical trials
PeR used to detect malarla; may be used to
provide illiformfltion re;';llrding phenotypic
eharaeteristies of various Plasmodium
strains.
A simple rapid manual dipstick test
(pARASIGHT - F) to detectP.lafcipamm
infeciiml§, is described.
Patarreyo's field trials of the S Pi66 vaccine
show it to be safe. Protective efficacy against
P. jaicipamffl, however was found not to be
optimal in areas oli high malarial endemicity.
1.2 EPIDEMIOLOGY
Of the total world population of +1- 5 000 million people, 41% (+1- 2 200 million
people) live inmalarial areas (Murphy and Oldfield, 1996; WHO Bulletin. 1992).
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Figure 1 shows the worldwide distribution of malaria. Countries in tropical Africa
account for >80% of the +/- 120 million clinical cases reported annually, and for >9,)%
of the nearly 300 million parasite carriers. III Africa alone, malaria displaces pneumonia
as the first ranked cause of lost DALYs - disability-adjusted life-years (World Bank.
World Development Report ,1993).
The disease can affect any age, however children and pregnant women are often at a
greater risk. A current estimate of childhood deaths in Africa is 800.000/year, killing
one out of twenty children before they reach 5 years of age (Murphy et al, 1996).
Malaria may also be imported into non-malarious areas by travellers returning from
endemic regions, and occasionally within mosquitoes . Here the mosquito (Anopheles
species) survives trips on airplanes, boats, and minibus taxis', giving rise to airport/taxi -
rank malaria.(Subramanian et al, 1992; Wyler, 1993; Layton et al, 1995).
Increased population migration (of parasite carriers) as a result of factors such as
family tie'S, war, famine, and job seeking behaviour also facilitates the transmission of
disease between countries (Ie Sueur et al, 1996; Sharp and Ie Sueur, 1996). Very
infrequently, infection may be acquired congenitally from an infected mother, or
through blood transfusion (Bruce-Chwatt, 1982; Babinet et aI, 1991; Norse, 1993;
Miller and Telfor, 1996; Lane and Edwards, 1997).
Reports of'nosocomial transmission have also been documented recently (Abulrahi et al,
1997).
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Figure 1: The Worldwhle Distribution of Malaria
WHO Bulletill, 1992
The degree of malarial transmission can v, .y greatly from one region of a country to
another, where variables such as altitude, terrain and temperature influence the mosquito
vector. In other areas transmission of malaria is seasonal due to fluctuations in rainfall,
as this can influence mosquito breeding. Recent climatological changes like global
warming and the EI Nino effect are thought to contribute to the increasing malarial
problem by providing circumstances favourable to malaria transmission (Lindsey and
Birley, 1996; Olliaro et al, 1996). With increasing population in areas at high risk for
malaria, and with malaria occurring in previously transmission-free regions due to the
human impact on. and interaction with the environment the predicted effect of
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this disease in terms of numbers of infected individuals could increase dramatically
during the next decade.
In South Africa malaria is found in the lower altitude areas of the Northern Province,
Mpumalanga, and Kwazulu-Natal (Figure 2), where it has had devastating effects on
the communities, tourism, agricultural and industrial development in these provinces;
especially the Kwazulu Natal and Mpumalanga regions. In 1932 22 000 malaria
related deaths were reported in KwazuIu Natal, in one of the worst epidemics to be
described in this country (Sharp and le Sueur, 1996). High risk areas include all border
regions, indicating the importance of imported malaria.
Imported cases of malaria have been reported from all countries of southern Africa, with
the majority appearing to originate from Mozambique. Sharp and le Sueur (1996) in a
recent South African Medical Journal publication highlighted the importance of viewing
malaria as a regional problem and not just a country-specific one.
1.3 BIOLOGY
The infection is caused by four species of protozoal parasites of the genus Plasmodium
(Table 1) . TIlls genus has been defined on the basis of a) the type of asexual
multiplication (schizogony), by division occurring in cells other than the erythrocytes of
the vertebrate host (exo-erythrocytic schizogony) and b) the mosquito hosts, which
are various species of Diptera The zoological classification of Plasmodia is complex
and there appears to be a lot of difference of opinion regarding the position of parasite
species within groups and sub-genera (Service, 1993) .
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Different Plasmodium species predominate in different geographic regions. For
example Plasmodium falciparum accounts for most of the clinically significant infections
inAfrica, and for over a third of infections in the rest of the world. Plasmodium vivax
remains the major species transmitted in parts of India, and is virtually absent inAfrica
(as most Africans lack the Duffy blood group antigens that define susceptibility to this
parasitic species). P.malariae has a patchy distribution in China, has also been
described in East and West Africa, and in some parts of South America. P.ovale has
been associated with mixed infections inTropical Africa.
Table 1: The classification of Plasmodia infecting
primates and other mammals
Genus: Plasmodium
Sub-genus: Plasmodium
Group: Vivax Species: P. vivax+Picynomolgi
P. eylesi, P. pithed
P. gonderi, Phylobati
P. jeffeyi, P. schwetzi
Psimium, P. sylvaticum
Pi youngi
Species: P. ovate", Pi fieldi
P. simiovale
Group: Ovale
Group: Malariae Species: P. malariae*,P.inui
Pibrasillanum
Group: Uncertain Species: P. catneyi, P. fragile
P. knowlesi
Sub-genus: Laverania Species: Pi fulciparum",
P. reicheno
Sub-genus: Vincheia Species: large number of
species infecting,lemurs,rodents
bats and other animals.
* signifies Plasmodia infecting human
Service, 1993
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All four Plasmodium species are transmitted by a mosquito vector of the genus
Anopheles. These insects have a few important characteristics that may be relevant for
the transmission of infection:
CI Feed from dusk to dawn,
• Only the female mosquito feeds on vertebrates ( blood is needed for egg
production).
• The mosquitoes survive long enough ( 9-22 days) after feeding to transmit the
infection (this is dependent on temperature, predators [bats,birds], and vector
controlling methods [insecticides] ).
• Elevations above 6000 feet are not conducive to transmission.
3 Mosquitoes are resilient enough to survive travel inmotor vehicles and airplanes,to
transmit infection.
1.3.1 Life Cycle of the Plasmodiuvn
Infection is initiated when the female anopheline injects saliva and malaria sporozoites
into the skin of the victim during feeding (blood meal). The sporozoites are rapidly
cleared by the liver,and within minutes they penetrate hepatocytes and transform into
hepatic exo-erythrocytic forms or tissue schizonts. After - 1 week each tissue schizont
has produced thousands of daughter merozoites which are reJeased from the liver into
the circulation. The intrahepatic development results in no symptoms or a mild
derangement of liver function. In patients with P.vivax and P. ovale infections, the
exo-erythrocytic forms can remain dormant (hypnozoites) for weeks or months after the
initial malarial attack. These hypnozoites can later become activated and continue their
development into merozoites, resulting in relapses of disease which often occur
repeatedly.
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Once in the circulation the merozoites invade erythrocytes and start the intra-
erythrocytic cycle, forming ring (early) trophozoites. The intracellular parasites feed on
the haemoglobin, and through the process of schizogony (asexual replication) give rise
to mature blood schizonts (up to 32 daughter .nerozoites per schizont). This
development occurs over - 48 hours ( longer in P. malariae - 72 hours) . Schizogony
progresses from the initial ring form (one or two characteristic purplish chromatin dots
attached to a bluish, ring shaped cytoplasm) 10 late trophozoites (larger and lacier - the
cytoplasm has an amoeboid appearance and the chromatin is less dense) to the early
blood schizonts (with several merozoites whose individual nuclei may be seen) and
:finally to the mature schizont. Lysis of the erythrocyte releases the merozoites which
then invade other red cells. After about two to three cycles parasitaemias become
detectable on microscopy.
The period from inoculation of the parasite by the mosquito to the appearance of
parasitaemia (prepatent period) is usually 9 - 13 days, but longer periods are possible.
The time from inoculation to the first symptoms of disease is the incubation period and
its length usually depends upon the patient's immune status. Normally the incubation
period is - 11-15 days. In non-immune patients symptoms of the infection may develop
prior to the detection of a parasitaemia. The other extreme occurs in areas with heavy
malarial transmission where patients have developed immunity to the infection; here
parasitaemias may be detected in the absence of any symptoms.
After several cycles some of the late trophozoites, within the erythrocytes, develop into
sex cells - gametocytes.. The mature gametocytes have different forms in different
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~>Jecies of Plasmodia. In P. falciparum for example they are usually crescent-
shaped/banana-shaped while in the other species they appear round. Gametocytes can
remain in the circulation for long periods of time after the asexual intraerythrocytic
stages .~cleared. They cause no clinical symptoms and require no treatment, but these
forms are infectious to the Anopheles mosquito. If male and female gametocytes are
taken up by the anopheline during a blood meal, they can mate and form oocysts (this
developme-nt usually takes place outside the wall of the midgut). The oocyst gradually
increases in size and starts to subdivide eventually leading to the formation of elongated
spindle -shaped sporozoites. The sporozoites emerge fr0!11. the oocysts, invade the body
cavity of the mosquito and migrate to the salivary glands, where they remain until the
next blood meal. The mosquito cycle (Figure 3) is completed within 2 weeks to 25
days.
Since P .falciparum is the most important human parasite.from the clinical point of
view, I have confined the rest of my discussion mainly to this species,
1. 3.1.:u. The parasite in the vertebrate host - invasion oCtlle erythrocyte
( a ) Initial interaction
The merozoite is the form of the malaria parasite that attaches to and enters the
erythrocyte. It is a lemon shaped structure ~ 2 pm in length, covered by a coat of
protein bristles (- 195 kDa major merozoite surface proteins - PMMSA; MSP-1) which
are loosely rooted in the membrane. It is these sites which are thought to be involved in
the initial interaction with the host cell. As the merozoite collides with the red blood cell,
a weak ( electrostatic) surface interaction occurs. Figure 4 shows the interaction
between the merozoite and the red blood cell.
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( b ) Reorientation
The randomly adhering merozoite then orientates itself such that its apical end is in
apposition with the red cell membrane.The flattened conical - shaped apical region
contains the rhoptries, a pair of dub shaped.membrane- bound and electron dense
internal organelles, and the tubular structures known as micronemes.
Figure 3: Developmental stages of the Malaria Parasite
in Anopheles mosquitoes and in the human
host.
In: Gilles H.M., Warreil I).A., editors. Bruce-Chwatt's Essential Malariology.
Third Edition. London: Edward Arnold. 12
Identification of the molecules on the red cell surface to which the merozoites bind has
been the subject of intense research (Pasvol, Clough and Carlsson, 1992). The sialic
acid rich glycophorins especially Glycophorin A and Glycophorin B have been shown to
play a major role in the invasion of the erythrocyte by malaria parasites, especially
P.falciparum. Other antigens expressed on the red cell surface have been implicated in
malaria invasion e.g the DuftY antigens which are important in P. vivax infection.
Efficient and successful invasion by the merozoite requires the release of erythrocyte
binding proteins. EBA - 175, erythrocyte binding antigen-175 , is a 175 kDa molecule
which has been localised to the micronemes. This protein binds to the sialic acid linked
tetrasaccharides of the glycophorins . A specialised conserved region , EBA peptide 4
has been identified within this molecule. It is postulated that this region (44 amino acid
residues in length) is particularly important for red cell entry as antibodies manufactured
to this peptide blocked the binding of the parent molecule to the erythrocyte and
inhibited invasion by the merozoite (Sim , 1995).
( c ) Intemalisation
After attachment and reorientation of the merozoite occurs, an invagination develops
opposite the apex of the parasite. This invagination deepens gradually so that eventually
the merozoite slips into the erythrocyte. The point of contact with the host cell
membrane is defined by an electron-dense "junction" . This ''junction'' contains a high
concentration of Intramembrane molecules e.g glycophorins and band 3 .The area
however that is bound by this annular junction is devoid of the red cell intramembrane
13
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components. The mechanism which results in the outward diffusion of these molecules
to create this 'bare zone' is not clear. The contraction of the cytoskeletal components
appears to be coupled to ankyrin and/or protein 4.1 and seems to be an ATP-dependent
step. Simultaneously the micronemes and the rhoptries discharge their contents into the
membrane resulting in a local expansion of the membrane and eventually the formation
of the parasitophorous vacuole membrane (PVM) (Sam- Yellowe, 1996).
The merozoite slowly moves into the invagination and developing vacuole through the
hmction" (which appears to "slide" backwards along the surface of the parasite); during
tins process there is loss of the outer two membranes, and the parasite starts to assume a
rounded form. Once the parasite is engulfed the dense granules which are also
distributed at the apical region are released. It is thought that the proteins contained by
the granules e.g Pfl5SlRESA (ring-infected erythrocyte surface antigen of 155kDa)
may playa role in enabling the trailing end of the invaginated red cell membrane to fuse,
forming a plug thereby enclosing the merozoite completely within the parasitophoro- S
vacuole (Foley and Tilley,1995). To date there is a controversy as to the origin of the
PVM. There are arguments that support a host cell derivation as well as possible that the
vacuole arises from elements contributed by both the parasite and the host cell.
Although "he red cell is capable of endocytosis the structured way that the merozoite
enters the host cell suggests a specific mechanism of invasion that is determined by
both parasite and red cell factors:
(i) Metabolic pathways
Researchers have demonstrated that invasion appears to be dependent on the presence
inside the red blood cell of ca'cium (Ca2+) , magnesium (I',1g2+) and adenosine
triphosphate (ATP), which is particularly important by maintaining the assymetric
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distribution of the phospholipid bilayer and for its role in the
phosphorylation/dephosphorylation of the cytoskeletal components of the RBC
membrane (Wasserman, 1990; Wilson, 1990; Gratzer and Dluzewski, 1993; Haynes,
1993).
(ii) Proteases and Proteolysis
A number of parasite proteases have been identified ,which are involved in numerous
physiological events like the digestion of haemoglobin (this will be discussed in detail
later in the text), or the invasion of the RBC and probably in the release of the parasite
from the host cell (Schrevel et al, 1990; Gratser and Dluzewski, 1993; Haynes, 1993).
The infected RBC contain numerous compartments with different pH ranges which
result in varying protease activities.
( iii) Membrane rigidity and abnormal red cells
It has been well documented that certain individuals are less susceptible to malaria
infection, and some of this resistance is based on genetic features that affect several
stages of the intraerythrocytic cycle of the plasmodia (Hill, 1992; Yathavong and
Wilairat, 1993; 00 et al, 1995). Certain haemoglobinopathies like HbS, HbE, alpha and
beta thalassaemia , and enzymeopathies like G6PD deficiency are protective to the
carriers because they inhibit the intraerythrocytic growth period. A number of
mechanisms have been suggested for the rednced survival of the parasite under these
conditions (Nagel, 1990), these include metabolic disturbances in the red blood cells of
the 'sickling disorders'; oxidant damage and increased susceptibility for cell mediated
removal from the circulation. The abnormal haemoglobins including the presence of
persistently high HbF, are thought to be a poor substrate for the parasite proteases.
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Another red cell factor that determines whether invasion by the parasite will be
successful is the mechanical rigidity of the RBC membrane (Gratzer and Dluzewski,
1993; Haynes, 1993; Pasvol et al, 1993). Disorders like Southeast Asian ovalocytosis,
(an abnormality within band 3). Hereditary Elliptocytosis (deficiency of protein 4.1) and
Hereditary Pyropoikilocytosis (abnormalities in the spectrin molecules) result in
disruption of the cytoskeletalnetwork (Figure 5) and lead to decreases in membrane
elasticity, and reduced susceptibility for invasion (Nurse, Coetzer and Palek, 1992).
(iv) Abe of host cell
It is thought that as the rbc ages it becomes less susceptible to invasion, hence
reticulocytes are a favoured target. This theory may not to be entirely correct as the type
of cell that becomes invaded may be species specific.
There appear to be properties inherent to the red cell e.g small differences in the physical
properties of the membrane, like the elimination of elements from the glycocalyx
(including receptors), and increasing cell density which may all be a fimction of age; as
well as parasite specific factors which may influence the type of cell that is infected.
(Gratzer and Dluzewski.,1993).
(v) Merozoite motility
Several motor proteins have been identified which are thought to be involved in
propelling the merozoite into the RBC (Bannister and Dluzewski, 1990; Glatzer and
Dluzewski, 1993). Using an immunofluorescence technique actin has been found in a
soluble form in the cytoplasm of the merozoite, and mem 'Y;W1 bound in the form of
filaments.
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Ired cell membrane
Figure S: A model of the eytoskeletal organisation Qf
tbe erythrocyte.
Reproduced from Foley and Tilley, 1995
1.3.1.2 Tbe parllsnte in the vertebrate host - chan1!;es in the pllr.!lsitised Ired
blood ceil
Even after invasion of the RBC, the parasite continues to modify its host.
(1') Vie membrane of theparasitised cell
(i) Transport functions of the parasitised erythrocyte membrane.
Several differences have been identified in the parasitised cell membrane, which are
illustrated in Figure 6. These include various permeation pathways, membranous
vesicles and tubules which have been created between the PVM and the RBC membrane
to facilitate increased movement of nutrients and substrates in and out of the cell
(Barnwell, 1990; Atkinson and Aikawa, 1990; Schrevel et al, 1990; Haynes, 1993).
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(ii) Lipid changes in the parasttised membrane.
The intraerythrocytic development of the Plasmodium within the mature erythrocyte is
associated with active membrane biogenesis of neutral lipids and phospholipids. to
ensure the increase in the size of the parasite and the parasitophorous vacuolar
membranes. Notably the phospholipid composition appears to differ markedly from
that of the original host cell membrane (Vial et al, 1990; Pasvol et al, 1992). The mature
uninfected erythrocyte is essentially incapable of any lipid biosynthetic activity. The
parasite accumulates lipids and fatty acids from the serum , and even uses the red cell
membrane as substrate, to synthesise its own lipids.
RED CELL PATHWAYS PARASITE INDUCED PATHWAYS
CARRIERS Band 3
PUMPS
amino acids
nucleosldes
ANTIMALARIAL DRUGS
Figure 6: Schematic representation of permeation
pathways in tine host membrane of malaria
infected cells.
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(iii) Cytoadherence and Rosetting
Once the red cell is infected with mature parasites it gains the ability to 'bind' or adhere
to : 1) endothelial cells, mainly in the capillaries of key organs like the brain, heart, liver,
lung and kidney ,and no longer circulates in the peripheral blood (this phenomenon is
known as sequestration) ; 2) other red blood cells to form rosettes ; and 3) different
types of cells in the circulation, such as monocytes, neutrophils and lymphocytes,
Cooke et al (1994) suggest that the above interactions may represent a strategy
.'rveloped by the parasite to avoid destruction in the reticuloendothelial system. It is
these interactions, nevertheless, that are thought to be responsible for the severe
pathology of falciparum malaria (this will be discussed further in the clinical
section).
The mechanism of cytoadhesion is multifactorial. With the aid of electronmicroscopy a
number of regular, symmetrically arranged "knobs" (Figure 7) have been identified on
the surface of the parasitised red blood cell (PRBC). (Pasvol et al, 1992; Gratzer and
Dluzewski, 1993). These knobs are cone shaped and comprise of intramembrane
particles, which form clusters that eventually become a raised densely packed central
zone. Immunofluorescent labelling suggests an elevated concentration of band 3,
b. ophorin, and spectrin in these regions. (Pasvol et a1, 1992; Gratzer and Dluzewski,
1993; Haynes, 1993; Atkinson and Aikawa, 1990). Other ultrastructural alterations
have also been described: caveolae and caveola-vesicle complexes (in non-falciparum
species), and cytoplasmic clefts (Atkinson and Aikawa, 1990). These will not be
discussed further.
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mOdifieu band 3
a- -r.cytoadhell'ence
motif
Figure 7: Cytoskeletal organisation of an erythrocyte
infected with a mature stage "knobby" parasite
[MESA: mature parasite infected erythrocyte surface
antigen]; please refer also to flgure 5, page 18
Reproduced from Foley and Tilley, 1995
Several proteins/antigens have been associated with the knob-associated electron-dense
material in P.falciparum (Foley and Tille,1995). Table 2 summarises the proteins that
interact with the erythrocyte cytoskeleton.
Cytoadherence to the vascular endothelium and rosetting of Plasmodium falciparum -
infected red blood cells appears to he a major factor in the pathogenesis of severe
malaria. Several molecules have been shown to be potential receptors on the endothelial
cells and erythrocytes for infected red blood cells (Roberts, Sherwood and Spitalnick et
al, 1985; Barnwell, Asch and Nachman et al, 1989; Berendt, Ferguson and Newbold,
1990; Ockenhouse, Tegoshi and Maeno et al, 1992; Cooke et al, 1994; Wahlgren et al,
1994; Cooke and Coppel, 1995; Land et al, 1995; Gardner et al, 1996).
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Table 2: Plasmodium Islcipsrum proteins which interact with the erythrocyte cytoskeleton
Apparent molecular
mass (kDa)
Stage, Location,
Properties
ReferencesProtclns Host
Receptors
RESA( Pf155) 155 Ring stage; cytoplasmic surface; interacts
with spectrin.
Mature stages; cytoplasmic surfaces; insoluble
aggregate; interacts with spectrin may affect
adhesion qualities of the cell.
MESA(PfEMP 2) 250-300
PfEMP 1
( sequestrin)
250-300 Mature stages; exposed on external surface;
may traverse membrane and interact with
the membrane skeleton; capable of antigenic
diversity.
Mature stages; I" ozoite surface and
parasitophorous vacuole surface; interacts
with spectrin in vitro.
Mature stages; expc 'ed on external surface;
found exclusively in seqi.- stering parasites
and may play a role in cytoadherence and
obstruction of the microvasculature.
MSA 1 (MSP 1) 190
Rosettins 22-28
I
\
1\
li
r\[I
11
A
I
Modified Band 3 Red blood cell cytoskeleton; contains regions
(adhesins) that function in the attachment
of the rbc to the endothelium.
PfHRP 1 90 Ring stages; mature stages; attached to the
cytoskeleton on the cytoplasmic face of the
"knobs"; associated with spectr in and actin
molecules; has a highly charged region which
may participate in clustering and formation
of the "knobs". Responsible for cytoadherence?
A knobless phenotype has been described with
altered cytoadher ing properties.
CD36
TSP
ICAM-l
VCAM-l
E-Selectin
CD36
ABO Ag
Foley and Tilley, 1995
Foley and Tilley, :995
Baruch et aI., 1996
Cooke et aI., 1994
Cooke and Cappel, 1995
Gardner et al., 1996
Gratser and
Dluzewski, 1993
Land et al., 1995
Nowak, 1995
Pasvol et al., 1992
Wahlgren tal., 1994
Land er al., 1995
Fologe and Ravetch, 1986
N
N ;a Abbreviations: RESA, ring-infected erythrocyte surface antigen; MESA, mature parasite-infected erythrocyte surface antigen; HRP 1, histidine-rich
protein 1; PfEMPi, Plasmodium Ialaipnrum erythrocyte membrane protein 1; MSA I, merozoite surface antigen 1; TSP,
Thrombospondin; ICAM-I, intracellular adhesion molecule 1; VCAM-l, vascular cell adhesion molecule 1; rbc, red blood cell.
+ CD36
• ICAM - 1 (intracellular adhesion molecule 1)
• TSP (thrombospondin)
+ VCAM-l (vascular cell adhesion molecule 1)
+ E-Selectin
• ABO Blood Groups
The roles of Ute various receptors in vivo is not entirely clear, however a stepwise
process to cellular adhesion, analogous to the way in which leucocytes achieve
immobilization has been suggested. The expression of the receptors is often upregulated
by inflammatory cytokines, for e.g TNFa. (tumour necrosis factor c). With ICAM-l
readily detected on endothelial cells in the cerebral microvasculature) sequestration of
PRBC occurs at these sites and this together with the mechanism of red cell rosetting, is
an attractive model (Figure 8) for the pathogenesis of cerebral malaria (see section
1.4.1.1).
The type of blood group (A,B,AB,O) also appears to determine the risk of developing
cerebral malaria. Hill et al have demonstrated a significant degree of protection against
cerebral malaria amongst children with blood group 0 as compared to blood group A or
B (Wahlgren et al.,1994). The protective effect conferred by blood group 0 may be
related to the formation of smaller and weaker rosettes by blood group 0 red cells
resulting in a less efficient "plugging" of the microvasculature of the brain.
Finally several investigators believe that the phopholipid composition of the PRBC
membrane (i.e exposure of phospbatidylserine at the outer surface) may alter the RBC
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surface charge thereby enhancing the adhesion of the infected erythrocyte to the
endothelium and to other erythrocytes (pasvol et al, 19Y2).
Activation of NO synthetase
Endothelial cells
Rosette formation
TOXin/
Schizont ruptures
releasing toxin
Receptors
upregulated Flow impededTrophozoite binds
to receptor
Schizont develops TNF produced
by mononuclear
cells
Figure 8: Schematic representation of the pathogenesis of
cerebral malaria
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(b) Haemoglobin degradation in the parasitised erythrocyte
Haemoglobin is degraded/digested in the Plasmodium digestive (food) vacuole, an acidic
(pH-5) proteolytic compartment which is central to the metabolism of the parasite
(Olliaro and Goldberg, 1995). Three proteases (2 aspartic and one cysteine) have been
localised to the digestive vacuole . Together they account for the majority of
haemoglobin degradation (Goldberg et al, 1991), which is illustrated in Figure 9. The
aim of this haemoglobinolytic process is a source of amino acids which are required for
pars netabolism and growth. As a by-product of haemoglobin degradation an iron-
rich hem group (ferriprotoporphyrin IX) is released. This is toxic to the parasite and is
effectively removed by polymerising these residues into pigmented crystalline structures
called haemazoin (Sullivan a-d Meshnick, 1996; Warhurst, !9(5). The formation of
haemazoin is believed to occur 'ria haem polymerase activity, although some authors
suggest that this is achieved independently of enzymatic activity (Dorn et al, 1995).
During haemoglobin degradation and haemozoin production, there is some Iibera.ion of
haem iron. This becomes oxidised from the ferrous" to the ferric" state with the
generation of superoxides (0-2). These reactive oxygen species are neutralised by being
converted firstly to hydrogen peroxide vie. a host derived superoxide dismutase, and then
to water (H20) via the action of a catalase (CAT). Any free iron that is released is
utilised by the parasite. Iron is an essential component for some Plasmodium enzymes
e.g ribonucleotide reductase and cytochromes ( Olliaro and Goldberg, 1995).
25
I Small peptides 1-'---HSmaUand Amino Acids I peptides
f4nd
amino
acids
Plasmodium digestive vacuole
ferriprotoporphyrin
IX
haem
polymerase
IHaemazoinJ
superoxide
dismutase
Figure 9: Proposed pathway of haemoglobin degradation
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1.4 THE CLINICAL PRESENTATION AND
PATHOPHYSIOLOGY OF PLASMODIUM
FALCIPARUMMALARIA
Clinically malaria causes non-specific symptoms often manifesting initially with a flu-like
illness comprising of fever, malaise and headache. Table 3 summarises these commonly
presenting features. In many parts of the world severe and complicated malaria is the
most common clinical presentation and cause of death. Table 41ists the defining criteria
for severe / complicated disease. The discussion that follows concentrates on a few
symptoms and signs that have a major contributing effect 0:..1 the morbidity/mortality
associated with malaria.
1.4.1 .!Fever
The best 0" well known symptom of malaria is the febrile paroxysm (Warrell, 1993;
Murphy and Oldfield, 1996). Tills starts with a rise in temperature usually exceeding 39°«';.
Despite this rise inbody temperature the patients often develop a feeling of cold which is
associated with shivering (cold stage). Peripheral vasoconstriction occurs with the
development of cold, dry, pale and cyanosed extremities. The rigors can last from
between 15 mir=tes up to 1 hour. The patient is soon engulfed in a feeling of warmth
(hot stage) as peripheral vasodilation starts. The feeling is described as 'flushed' or
'burning'. During this phase which con last from 2-6 hours the patients may become
confused Idelirious and experience se...~'rethrobbing headaches as temperatures peak at
up to 41"C, The fever declines over the next 2-4 hours as the patient breaks out in a
drenching sweat with defervescence (sweating stage). The total duration of a typical
attack is between 8·j2 hours, at the end of which the patient is left exhausted (Warrell,
1993).
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Table 3: Symptoms and signs of uncomplicated
malaria (in order of decreasing frequencies)
Adapted from Warrell et al, 1990
I Symptoms: Signs: I
Fever Hyperpyrexia (>40°C)
Chills Splenomegaly
Headache Hepatomegaly
Fatigue/malaise Jaundice
Sweats
Myalgia
Gastrointestinal Symptoms:
Nausea
Vomiting
Abdominal pain
Diarrhoea
Respiratory Symptoms:
Pharyngitis
Cough ~i
Fever and the febrile paroxysms coincide with rupture of the erythrocytic schizont.
Francis and Warrell (1993) suggest that these symptoms are the result of cytokines
(potent endogenous pyrogens) released from macrophages into the circulation at the
time of schizont rupture . These cytokines act on the hypothalamus' thermoregulatory
centre initiating the physiological responses that cause fever viz. shivering, peripheral
vasoconstriction and increased metabolic rate. This is mediated via the action of
Prostaglandin E2 (Kwiatowsld, 1995).
1.4.1.1 Qvtokines
1.4.1.1.1 T amour Necrosis Factor a. (TNF c)
TNF a. is produced and secreted by activated mononuclear cells like macrophages and
monocytes, in response to parasite derived proteins and substances (malaria toxins)
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Mendis and Carter, 1995).
released by the rupturing schizonts (Jones and Hoffman, 1992; Kwietowski, 1995;
A number of studies have recorded a strong positive
correlation between plasma TNF levels and severity of disease e.g cerebral malaria
(Jones and Hoffinan, 1992; Kwiatkowski, 1995; Taylor-Robinson, 1995a) Several
mechanisms have been postulated as to how TNE"might promote cerebral disease:
(i) Upregulation of adhesion molecules e.g expression of ICAM-1 on the vascular
endothelium. (see section 1.3.1.2 (iii».
Table 4: Severe manifestations and complications of
falciparum malaria.
[ Defining Criteria of severe disease
Cerebral Malaria"
S .. ( )WHOevere normocytic anaemia H!J < 5 gldl
Renal failure (urine output < 400mli24hrs in adults;
< 12mglkgl24hrs in children;
serum creatinine >26Sllmol/l (> 3.0mgldl) )WHO
Pulmonary oedema
Hypoglycaemia ( glucose < 2.2 mmol/l ; < 40 mgldl )WHO
Circulatory collapse/shock ( systolic blood pressure < 50mm Hg in
children; < 70 mm Hg it, adults;
cold clammy skin) WHO
DIea/ spontaneous bleeding
Generalized convulsions (repeated) - > 2 observed within 24 hrs
Acidaemia (arterla! pH < 7.25)WHO
Acidosis (plasma bicarbonate concentration < IS mmolll)WHO
Haernoglobinuria
L ther manifestations
Impaired consciousness (rousable)
Hyper parasitaemia (> 5% parasitaem'a in non immune patients) WHO
Hyperpyrexia ( rectal temperature> 390C )WJIO
Jaundice (detected clinically or by definition- bilirubin level> 50IAmolll;
> 3.0mgldl)WHO
Prostration /extreme weakness (no obvious neurological explanation)
* see Table 5
IIAbbreviations: DIe, disseminated intravascular coagulation
Warrell, 1993
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(ii) Enhancing the production of Nitric Oxide (NO) by inducing the enzyme nitric oxide
synthase (NOS). This cytokine induced NOS has no negative feedback mechanism
which implies that the generation of NO can reach concentrations that are lOOO-fold
greater than physiological levels. In addition the 'plugging' of the vessels, concentrates
the source of the NO within the cerebral microvz- culatnre, resulting in disturbed
neurotransmission and ultimate neurotoxicity (Anstey et al, 1996).
The clinical manifestation of raised TNF levels namely the fever has been shown
experimentally to have an inhibitory effect on parasite growth thereby regulating parasite
density (Kwiatkowski, 1995). This has been postulated to be an early non-specific host
mechanism that regulates parasite numbers before specific immune mechanisms
intervene (Mendis and Carter, 1995). Other cytokines with pyrogenic properties
detected in malaria patients include IL-1~, IL-1a, IL-6 and macrophage inflammatory
protein -1 which are produced by monocyte / macrophage type cells; lymphotoxin a
(LTa) produced mainly by lymphocytes. It is difficult to assess the exact contribution to
the clinical manifestation of malaria by these cytokines as their activity/regulation is not
as simple to measure as that ofTNF (Kwiatkowski, 1995).
1.4.2 Cerebral Malaria
Cerebral malaria is one of the complications of severe malaria that is most feared,
accounting for approximately 10% of all cases of falciparum malaria admitted to ~ospital
(inmany parts of the world) (Warrell, Molyneaux and Beales, 1990) and is often fatal.
Neurological sequelae have been described in recovering patients, especially children,
and vary in seventy. As focal signs and neurological symptoms like impairment r C
consciousness with or without fever may result from other central nervous system
30
infections or even CNS vascular disease, a 'strict' definition of cerebral malaria has been
recommended (Warrell et al, 1982). In clinical practice however, , j patient (with a
headache, neck stiffness, drowsiness, febrile convulsions or fo .1 neurological signs)
with any degree of impaired consciousness who may have be, . exposed to malaria ,
should b- treated for 'cerebral malaria' with some urgency. Table 5 summarises the
important clinical manifestations of cerebral malaria in adults and children.
'1.4.2.1 The pathopllysiology and pathology of Cerebrall' ~. il!,
The exact mechanism remains a topic for debate; early h; es were based on
pathological observations made in animal models or in fatal cases offalciparum malaria
(Warrell et al, 1990).
~ the 'sludging' hypothesis: PRBC adhering to each other would reduce and
eventually stop the flow of blood through the cerebral capillary bed. The subsequent
pathology was the result of the obstructed microcirculation andlor the release of
unidentified toxins from the malaria parasites.
- the 'permeability' hypothesis: In severely ill animals ( malaria infected rhesus
monkeys) the primary abnormality was postulated to be an increase in the cerebral
capillary permeability (which was mediated by various kinins) with leakage of plasma
from the microcirculation which resulted in the development of cerebral oedema, and
local haemoconcentration. This theory was the basis for the use of corticosteroids in
cerebral malaria. Cerebral oedema resulting from 'k';11<y' capillaries does not appear to
be a consistent,or even common .feature of cerebral malaria. It is possible that this is a
post mortem observation,resulting from agonal events occurring prior ;0 death e.g
hypotension, severe acidosis etc.
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TabR~5: The signs and symptoms of cerebral malaria
I Sign or symptom Adult I Children I
Duration of symptoms prodrome of several acute onset of symptoms
before neurological days of fever and often <2 days.~ .
non-snecific
.Neck stiffness Common Common
Abnormal posturing:
opisthotonus in severely ill patients in severely ill patients
decorticate Common Common
decerebrate Common Common
Convulsions Common in 112 of Very common; usually
adults; this may indicate indicates cerebral
cerebral involvement or involvement or
hypoglycaemia hypoglycaemia but it rna!
(usually generalised be a non-specific symptom
seizures) offever (usually generalized
but persistent focal
seizures have been observed)
Coma vanous revers/aegree or unrousame persisting coma
unconsciousness have may follow a generalized
been observed convulsion
(these are assessed us; g
the Glassow Coma Scale)
Papilloedema Uncommon Uncommon
Retinal haemorrhages Common Common
Disorders of conjugate Common Have been observed in
gaze African children
Corneal/eyelash reflexes Usually intact May be absent
Hypoglycaemia Uncommon (usually Common (usually pre-
quinine induced) treatment) -especially
in children < 3 years.
Is often associated with
convulsions and deep coma.
May be a feature of
-Neurological sequelae
hyperparasitaemia
Uncommon (but the Occur in about 10% of cases.
after cerebral ma1ar:ia following have been Hemiplegia is common;
described: cranial nerve others include: ( .. tical
lesions/neuropathiesiextra blindness; ataxiajbehavioural
pyramidal signs/Guillain disturbances; reactive
Barre like syndrome; psychosis in recovering
reactive psychosis in the patients.
recovering patient.
_!
Adapted from Warrell et ai, 1990
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- the 'mechanical' hypothesis: (a) Red blood cells need to undergo some degree
of deformability inorder to pass through the capillary vasculature. Infected erythrocytes
have been shown to become less deformable . this appears to be directly proportional to
the maturity of the intracellular parasite. One of the consequences is microvascular
obstruction, (b) Cytoadherence and rosetting are also important mechanisms in the
obstruction of cerebral vasculature. These concepts have been discussed and illustrated
indetail under section 1.3.1.2 (a) (iii) and will not be elaborated further here.
(c) The role that cytokines (esp 1NFa.) play in the pathogenesis of cerebral malaria has
already been discussed at the beginning of this section (1.4.1.1).
- the 'immunological' hypothesis: Immune mechanisms have been described in the
pathogenesis of certain severe disease manifestations of malaria e.g glomerulonephritis
and cerebral lesions, in rats and mice (Warrell et al,1990). In 1978, Toro and Roman
proposed that the neuropathological findings evident in cerebral malaria were due to an
immune complex mediated vasculitis of :he cerebral vessels resulting in perivenous
demyelination, Histological evidence of vasculitis ,in fatal cases of falciparwn malaria
however, is absent (Warrell et al, 1990).
1.4.3 Anaemia and thrombocytopenia
Several haematological changes have been described in malaria, these include anaemia,
neutropenia, reactive lymphocytosis, monocytosis, eosinopenia, and thrombocytopenia
(Abdalla, 1990; Warrell et al, 199m Of these, anaemia is often associated with
considerable morbidity especially among children and pregnant women. Malaria causes
varying degrees of anaemia ranging from life-threatening levels to levels slightly below
normal values. Severe anaemia (Hb < Sg/dl or haematocrit < 15%) is a life-threatening
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complication of malarial infection. and its development is often related to the degree of
parasitaemia and schlzontaemia (Warren et al., 1990). The pathogenesis of malarial
anaemia will be elaborated further in the discussion. In patients with acute malaria,
severe anaemia often contributes to cardiovascular signs (gallop rhythm, hepatomegaly
and pulmonary oedema) and cerebral signs ( confusion, restlessness and coma).
Thrombocytopenia is a common finding in falciparum malaria and not necessarily a
feature of severe malaria. Inmost cases it is not associated with bleeding. Significant
bleeding usually occurs in association with other haemostatic abnormalities for example
when thrombocytopenia is present in the setting of a disseminated intravascular
coagulopathy (DIC). Possible causes of a decreased platelet count include reduced
platelet survival due to peripheral consumption, as is found in a DIe, or due to immune
mediated mechanisms, increased splenic uptake/sequestration and decreased or
ineffective thrombocyte production. most likely from infection related marrow
suppression (Warrell et al, 1990).
1.4.4 !lenal4.Ysfunction
This complication appears to be commoner in adults than in children. There are several
distinct patterns of renal involvement in malaria: a transient and self-limiting
glomerulonephritis which appears to be associated with the presence of immune
complexes within the glomeruli and circulating in the serum and which is rarely of
clinical significance, and that of an acute .....mlar necrosis, the mechanism of which is not
clearly understood (Francis and Warrell, 1993). Cytoadherence of PRBC in the
glomerular capillaries may playa contributiug role. In addition many of the patients are
dehydrated at presentation, and often renal function is restored by simply rehydrating.
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1.4.5 ;§:l7")~lycaemia
Hypoglycaemia is an important manifestation of falciparum malaria, with more than 5%
of children with severe malaria presenting with suboptimal glucose levels, on admission
to hospital. It is also commonly seen in pregnant women with malaria and in patients
with severe disease and hyperparasitaemia, There are several possible causes (Warrell et
al, 1990):
(a) Drug induced hypoglycaemia
(b) Increased glucose consumption by the host and the parasite
(c) Impaired gluconeogenesis or glycogen depletion
1.5 IMMUNITY IN MALARIA
Two systems of immunity arise when a host is exposed to an infectious agent: a)
innate/natural immunity and b) acquired/specific immunity (Fearon and Locksley, 1996).
Innate/natural immunity
Innate/natural immunity seems to be selected through evolutionary pressure. Individuals
exhibit variable susceptibility to infection, and some of this resistance is inherited. It is
safe to say that most of the red cell defects recognised today are polymorphisms which
have arisen from exposure to malaria e.g HbS, a and p thalassaemia etc.(see also section
1.3.1.1 (c) (ill». The protective effect of alpha and beta tbalassaemia against malaria
seems established.; or is it? Rec=ntly an article appeared in Nature that showed a
higher incidence of malaria in a population of homozygous alpha thalassaemic
Melanesian children compared with normal or heterozygous children (Williams,
Maitland and Bennett et al, 1996). Is tl-e malaria hypothesis wrong? (Yuthavong and
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Wilairat, 1997). The authors felt that the alpha+ gene (in homozygous children) gives
rise to increased susceptibility to malaria in early childhood (under 5 years of age),
which may result in improved immunity in later years. In this group of children a high
incidence of both P.falciparum and P. vivax was noted. The questions that are now
being raised include whether infection by Pfalciparum in alpha thalassaemic children in
the 1st four years of life give protection against more severe attacks later in life ?
(Yuthavong and Wilairat, 1997).
Maitland et al (1997) have introduced another hypothesis. They postulate that
increased susceptibility to P.vivax infection in homozygous alpha+ thalassaemic children
may induce crossprotection against subsequent severe "falciparum malaria This
theory may be supported by the observation that homozygous children older than five
y,;, irs of age had a reduced incidence of P.falciparum infection compared to the normal
and heterozygote group. This theory needs to be tested by looking at large scale
epidemiological studies in appropriate populations (i.e those naturally exposed to both
malarial species), since volunteer studies are not ethically feasible.
To complete the list of disorders/polymorphisms that have been implicated in resistance
to malaria and especially to Plasmodium falciparum we have to include recent evidence
that suggests the effect of HLA variation on malaria susceptibility (Hill, 1992).
Associations were found between two HLA classes: HLA Bw53 and HLA DRB 1*1302.
These were shown to strongly protect individuals from cerebral malaria and severe
malarial anaemia.
Acquired/Specific Immunity
Immunity tv malaria parasites involves both cellular and antibody mediated mechanisms.
The cellular and molecular bases of acquired immunity in malaria is not well understood,
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but most people would accept that the development of acquired immunity involves an
initial cell mediated phase that is mediated through macrophage/neutrophil activation
and by the release of cytokines such as interferon gamma (IFN y) and tumour necrosis
factor alpha (TNF a); the effects of TNF a in the pathogenesis of malaria have been
discussed under section 1.4.1.1. This cellular response is controlled by CD4+
T helper (Th1) cells, and is oft ~n associated with the production of oxygen and nitrogen
intermediates. The effect of this mechanism is to limit parasite replication.
This is gradual' replaced by a CD4+ T helper (Th2) cell mediated response. This is
predominantly an antibody-depen+ '1tmechanism. Antibody has been shown to prevent
red blood cell invasion, to increase the removal of merozoites and infected erythrocytes
by monocytes and even to have a role in the displacement of PRBC from the endothelial
cells of the brain capillaries. After the initial IgM production following acute infection,
there is an isotype switch towards immunoglobulins of the IgGl and Ir,G3 subclasses
(Ferreira, Kimura, De Souza and Katzin, 1996). These are cytophilic antibodies and
have been shown to act via an association with the monocyte/macrophage systems
(Figure 10) to effect parasite-killing mechanisms (Druilhe and Perignon, 1997) •
Antibody-mediated protective immunity is gradually acquired over a long period of
time (Baird, 1995), and generally requires uninterrupted exposure to the infectious
antigen. One of the reasons why antibody-mediated immunity takes time to develop and
become effective is because the parasite has been shown to display considerable
antigenic variation/diversity (Pologe and Ravetch, 1986; Nowak, 1995), and the host
has to experience a large number of strains and variants before an effective immunity
develops.Protective immunity, however, may fail to develop and may be rapidly lost
after it has developed, with interrupted exposure, like with seasonal malaria,or if there is
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extended travel out of an endemic area. The half life of the IgG subclasses is variable:
IgG3 has a tY2 of 9-10 days, the remaining subclasses have a half life of 13-25 days
(Ferreira et al, 1996). The mechanisms that effect immunity following malaria infection
have been studied mostl, in murine models, however the model that is illustrated in
Figure 11, can easily be applied to the human counterpart.
The detailed mechanisms that prevent parasites multiplying exponentially in humans are
still not well understood, however it has been suggested that the severity of the infection
especially with Plasmodium falciparum may be determined by the degree of activation
of the CD4+(Thl) T cell mechanism (Taylor-Robinson, 1995b). The mechanisms
described above, may result in a state of protection that prevents the occurrence of
clinical symptoms and high parasitaernias.
Figure 10: Antibody-dependent monocyte-mediated
mechanism of growth inhibition of P'faiciparum:
[Cytophilic antibodies crosslink monocytes,Mo
to merozoites and this leads to release of
monocyte derived mediators (dotted arrow)
which block intraerythrocytic parasites (bold
arrow)].
Reproduced from Druilhe and PCll'ignoD, 1997
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I
Parasite killing
pathologywC\ Parasite !Q]!iiilgAntibly
Primary parasltaemla Chronic infection;reinfection
Figure 11: Schematic diagram of the cell mediated and
antibody-dependent mechanisms of
protective immunity to asexual erythrocytic
stages of Plasmodium infection.
Reproduced from Taylor-Robinson, 1995b
No matter what the duration of exposure is, a few parasites will still be found circulating
in the blood In areas of'high malarial transmission more than half the adults have been
shown to have a low grade parasitaemia (Druilhe and Perignon, 1997). The cause of
this low grade 'chronic'infection is thought to be the presence of antigenic variation.
The parasite appears to successfully evade the hosts immune system by expressing a new
variant type. While the hosts immune mechanisms are being evaded parasite densities
can fluctuate between very high and undetectable, until the new immune responses are
raised.
The above discussion regarding malaria immunity has been simplified. It is becoming
increasingly clear that there is more than one distinct defence mechanism against blood
stages, and there appear to be many polymorphic and variant antigens that can evoke
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specific immune responses; these antigens are also used by the parasite to escape the
direct effects of the antibody-mediated mechanisms. The final outcome of continous
antigenic exposure is a compromise between the parasite and the host with the
establishment of a 'chronic' state.
The crusade for the development of the perfect vaccine, may bring to light more
definitive defense mechanisms that are elicited in the war between host and parasite.
1.6 MALARIA IN PREGNANCY
Pregnant women (especially primigravidae) have an increased susceptibility to parasitic
infections like malaria (Warrell et at, 1990; Francis and Warrell, 1993), among a number
of other pathologies. This increased risk is associated with miscarriages, stillbirths, and
placental infection that is often the cause of low birth weight babies. The effects of
malaria on pregnancy are summarised in Table 6.
1.6.1 Pregnancy and immune suppl'ession
Pregnancy is a time when important physiological events occur in the mother, which
help the foetus to adapt to a new environment, and prevent its rejection. This includes a
degree of immune suppression which is characterised urimarily by a depression of cell
mediated immunity/type 1 cytokine responses but impairment of humoral immunity/type
2 cytokine responses has also been implicated (Fievet et al, 1995; Menendez, 1995;
Smith, 1996).
Humoral immunity
IgG titres appear to fall as pregnancy advances. This however seems to be a relative
decrease and is probably related to (a) the haemodilution that occurs in the 2nd trimester
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and (b) transplacental transfer ofIgG from the maternal to the foetal circulation. The
data regarding malaria-specific antibodies is contradictory; a reduction in malaria -
specific antibody titres has been reported in parasitaemic women (Deloron et al, 1989;
Mvondo et al, 1992). Other investigators, however have failed to det=o! any difference
in malaria antibody titres between pregnant and non-pregnant women (Riley et at, 1989;
Rasheed et al, 1992), nor has there been a difference in malaria specific antibody titres
demonstrated among women of diffc- it parity groups.
Cell-mediated immunity
Pregnancy is associated with the increased production of many proteins including
hormones that are responsible for maintaining the foetus (Guyton, 1981). Among these
cortisol and oestrogens have been associated with suppression of cell-mediated events
in vitro. Interestingly these two hormones are found in higher levels in primigravidae
compared with multiparous women (Menendez, 1995). The placenta appears to be a site
for preferential parasite sequestration and development. An explanation for this has been
based on the local role of immunos : • 'esive factors produced by the placenta, like the
oestrogens. This suppression in local immunity appears to decrease as the pregnancy
progresses, possibly due to decreased production of hormone from the infected placenta.
41
1.6.2 EPidemiology of malmria in pregnancy
A few important features regarding the epidemiology of malaria have been summarised
below (Menendez, 1995);
1. Pregnant women appear to acquire malaria more frequently and are at an
increased risk of developing severe malaria, compared to non-pregnant women.
2. The level of pre-pregnancy immunity usually determines the frequency and severity
of the malaria infection. Women from areas where malaria transmission is low
are likely to have poorly aquired immunity prior to pregnancy. Women from highly
endemic malaria areas have significant protective immunity and the effects of the
infection are usually less severe.
3. Among non-immune women the susceptibilty to infection is increased regardless of
parity. Inholoendemic areas where the level of protective immunity is expected to be
high, primigravidae appear to be more at risk (for reasons already described in section
1.6.1).
4. Although the effects of genetic factors e.g sickle cell trait, on malaria have been well
described, the importance of these in the setting of pregnancy we contradictory.
5. Nutritional factors like the maternal iron and folate status may affect susceptibility
to malaria infection.
Menendez (1995) puts it in a nutshell- " ...effects of malaria in the pregnant women and
the foetus, have been well described, but there are still many aspects of the
relationship that are poorly understood."
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Table 6: The effects of mamma on pregnancy
-
~
Malarla Endemicity
Effects of Malaria Low Higb
On the mother
Severe disease, including death not infrequent indirectly
through anaemia
Acute disease/anaemia frequent frequent
(all parities) (primigravidae)
Hypoglycaemia not infrequent not known
Placental infection infrequent frequent
(primigravidae)
On the foetus
Abortion/perinatal death not infrequent not known
Intra Uterine Growth Retardation frequent frequent
(all parities) (primigravidae)
Prematurity not infrequent not known
Congenital infectio.'1 not infrequent infrequent
On the infant
Reduced birth weight not infrequent frequent
Increased risk of death not infrequent not infrequent
Increased susceptibility to malaria not infrequent frequent
Adapted from Menendez, 1995
1.7 PREVENTION AGAINST MALARIA
Researchers and malariologists have spent more than 20 years trying to develop methods
for malaria control (WHO, 1993). However, in some parts of the world e.g Tropical
Africa, the malaria situation is worsening. As the number of casea detected every year
continue to increase, measures for the prevention, diagnosis, and treatment gain greater
importance.
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1.7.1 Vector Control
Controlling the insect vector has been an effective way of reducing ~he transmission of
disease - causing organisms to human hosts. A variety of methods have been employed
(Curtis, 1994; Luxemburger et al, 1994; Crook and Baptista, 1995), including the
elimination of breeding sites with chemical insecticides (Onori et al, 1993). Insecticide
use however, is not without hazard and the dangers of continuous exposure to these
chemicals by the individuals spraying, and those exposed to the fumes (residents of
sprayed homes) are receiving considerable attention (Kreiss et al, 1981; Bouwman et al,
1994; Bouma and Nesbit, 1995). In addition the emergence of resistance to these
chemicals has necessitated the development of new compounds with additional costs,
and possiole detrimental effects on the environment. Parasitologists have therefore
needed to assess alternative methods to suppress vector populations, or to change their
ability to transmit disease- causing organisms,
Recently researchers have identified the insect vector's genome and other sites e.g. the
insect midgut as appropriate molecular targets for genetic manipulation, Insect vector
populations may be created that have been "programmed" with certain characteristics
e.g insecticide susceptibility, temperature sensitivity or altered transmission of disease
causing parasites (Billingsley, 1994; Crampton, 1994).
1.7.2 Antimalariai Vaccines
Malacia control programmes and treatment strategies are proving to be less effective
than anticipated, as evidenced by the increasing malaria transmission worldwide. As our
options to control this disease appear to be running out, the need for the development
of a malaria vaccine has become a priority. Our evergrowing knowledge of the immune
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responses elicited in the host by ~ narasite allows us to believe that vaccines to malaria
are biologically possible (refer to section 1.5). In fact, it has already been demonstrated
that vaccination can protect humans against malaria, In the early 1971)'s, volunteers who
were previously unexposed to malaria were exposed 1.:0 the repeated bites of irradiated
mosquitoes that had been infected with P .falciparum or P. vivax. This produced a solid
immune response (Clyde et al, 1973; Clyde et al, 1975). Clearly the method of
immunisation is not a practical one to use on a large scale. In order to achieve a
worldwide vaccination program the candidate vaccine would have to be either
chemically synthesised or be produced using recombinant DNA tecbnology (Jones ana
Hoffman, 1994).
In the late 1980's Patarroyo and colleagues introduced the "First Malaria Vaccine"
(Patarroyo et al, 1988; Valero et al, 1993; Tanner et al, 1995). The vaccine is a
chemically synthesized polymeric hybrid protein of 150 kDa - SPf66, which was shown
to induce partial or complete protection in experimentally infected monkeys (patarroyo
et al, 1987). Preclinical and clinical human trials established that the innoculum was
safe and immunogenic, and appeared to have some protective efficacy against malaria in
areas of low endemicity (Valero et ai, 1993). In Africa, in an area of high malaria
transmission, the overall efficacy of the vaccine was 31% (Alonso et al, 1994). The
vaccine did not demonstrate any pre-erythrocytic immunity,but rather acted as an
asexual blood stage vaccine, reducing the incidence of clinical malaria. Recent clinical
trials of this vaccine however have shown disappointing results, and the overall
conclusion is that SPf66 may not effectively protect against clinical malaria (Nosten et
al, 1996).
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1.1.2.1 Vaccine strategies
1.7.2.1.1 Target populatlons
The criteria for the success of a malaria vaccine are often different for different groups
of individuals exposed to the infection. It is therefore important to identify the target
populations for whom the vaccine is being designed. Infants and children in malarious
(endemic) areas will require a vaccine that will reduce the morbidity and mortality
associated with the malaria but at the same time will allow the development of natural
immunity through repeated re-infection. Vaccines for non-immune individuals who are
exposed to malaria transiently, e.g tourists, business travellers will be required to
prevent asexual infection completely.
1.7.2.1.2 Vaccine design
The life cycle of the malaria parasite (refer also to section 1.3.1) bas certain stages which
appear to be more prone to immune attack than others. Vaccines incorporating antigens
from these stages would theoretically be capable of blocking infectivity.
Table 7 summarizes the candidate antigens from the various stages in the malaria
parasite's life cycle, highlighting some important properties.
1.7.2.1.2a Cytoadherence
An important factor responsible for the severe pathology of P.falciparum is the ability of
the PRBC to adhere to endothelial cells. A vaccine that induces antibodies to the
components of adhesion (e.g. knoblike projections) could eliminate attachment to the
endothelium and reduce the development of cerebral malaria and its ')' (, iiated morbidity
and mortality. Several proteins have been implicated in the mechanisms of
cytoadherenee and these have been reviewed under section 1.3.1 .2.
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Table 7: Cafjdidate antigens from the malaria life cycle: -
tamets for the development of an antimalarial vaccine.
Stage Antigen, Loeation.Propernes References
Sporozoite Circumsporoloite(CS); expressed on Khusmith et al, 1991
the surface of the sporozoite; has a highly Reber-Liske et ai, 1995
immunogenic area (Ifrepeated amino acid Sherwood et ':11,1996
sequences (NANP)"; [ a number of Stoute et ai, 1997
vaccine trials have reported m :T·P.d
results].
Sporozoite surface protein 2 (SSP-2);
this is a 140 kDa protein; has a multiple
tandem repeat sequence of six amino
acids (NPNEPS)"; [mice immunised
with this protein were shown to develop
a partial immunity which was CD8+
dependent].
LIver stage LIVf .stage specific antigen 1 (LCA-I); Guerin-Marchand et ai,
expressed on the surface ofhepatocytes; 1987
a 230 kDa protein that contains an Aidoo et ai, 1995
immunogenic! 7 amino acid repeat.
Pre- Merozoite surface protein l(MSP-l); Enders et ai, 1992
Erythrocytic a 195 kDa protein synthesized at the Hui et al, 1992
schizont stage; precursor offour major Pasvol et al, 1993
polypeptides found in a non-covalently Jones and Hoffman et al
bound complex on the merozoite 1994
surface; polymorphic antigen, also has Egan et al, 1996
conserved regions; a small 19 kDa
fragment (MSP-119) is derived after RBC
invasion; [this fragment is protective
against clinical malaria]. MSP-l has
been used in fusionlhybrid proteins and
has demonstrated protection from
experimental malaria infection in animals.
Merozoite surface protein 2 (MSP-2);
has not been shown to successfully
-b .
protect against infection in animal models.
Eryt rocytle Erythrocyte binding antigen 175 Howard and Pasloske,
(EBA-175); a 175 kDa protein expressed 1993
on merozoites and has been localised to Perrin et al, 1984
the micronemes at the apical end.
Ring infected erythrocyte surface antigen
(RESA); a 155 kDa protein localised to the
dense granules of the merozoite; after
invasion the protein is expressed on the
RBC surface; has regions of'rpeated amino
acids - an octapeptide (EENVEHDA)" and
tetrapeptide (EENV)"
Serine repeat antigen (SERA);
a 113 kDa protein characterised by a stretch of
37 serine residues, found in the parasitophorous
vacuole and is released when PRBC lyse;
[shown to induce partial protection in Saimir
monkeys].
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"1 Abbreviations (Table 7): A -Alanine; D- Aspartate; E - Glutamine;
H ~Histidine; N - Asparagine; P -Proline; S - Serine; V - Valine.
1.7.2.1.3 Transmission-blocking vaccines
Most treatment protocols are unable to treat or eliminate the sexual stages of the
parasite, that are largely responsible for the continued transmission of malaria from the
host to the vector. Here is another target that would fit within the scope of vaccine
development. If antibodies could be generated in the host against antigens of the sexual
stages, these could be transmitted to the mosquito during a blood meal, and in this way
disrupt sexual reproduction. The most obvious targets include: antigens on the surface
of gametocyte-infected red blood cells; molecules on the plasma membrane of the
extracellular gametocyte/gamete/zygote and molecules associated with the ookinete that
interact with the insect midgut (Sinden, 1997) These vaccines would not be capable of
protecting the vaccinated individual from infection, however if sufficient individuals
within an endemic community were to be immunised, the cycle of'trsnsmission could be
broken thus confering protection against subsequent infections.
1.7.2.104 Vaccines of the future
To date antigenic material for the development of vaccines has been derived primarily
from: (1) live attenuated, or killed forms of the whole organism; and (2) defined proteins
or recombinant protein components of the organism, most likely derived from
biochemical purification or by genetic engineering (Cheung et al, 1986; Patarrovo et al,
1987; Patarroyo et al, 1988; Chatterjee et al, 1995). The major problem witt the live
vaccines, however, is the risk that the organism may revert to a pathogenic form. To
overcome this problem without compromising the T cell mediated responses that the
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conventional vaccine methods try to induce, researchers found a novel way of
innoducing the desired immunogen into the host. A DNA (or RNA) construct,
encoding the protein of interest is delivered to the cells of the organism to be vaccinated.
It is taken up and expressed by the host cells.whereupon it induces a protective immune
response. Several questions however need to be answered before this type of DNA
vaccine is available for human trials, like what is the best method ofadministrntion of the
relevant construct, what are the advantages OV"!7 conventional vaccines, and are there
any safety issues to be considered? (Waine and McManus, 1995). There was some
concern about the generation of anti-DNA antibodies,in the mice DNA vaccine trials,
and the possible development of autoimmune disease.
Gilbert and Hill (1997) recently reviewed the use of viral coat proteins to produce
hybrid particles carrying Plasmodium sequences. These protein particles were found to
be highly immunogenic in animal studies , and may represent a new type of vaccine that
may be effective: against malaria. Several types of particles have been developed as
curriers of P.faiciparum sequences, including Hepatitis B surface antigen (HBsAg) and
Hepatitis B core antigen (HBcAg). These hybrid proteins are produced in
microorganisms. In a recent phase I human trial, the protein particle vaccine RTS,S
(HBsAg incorporating (NANP)19 repeats of the CS protein) was tested in 17 volunteers,
using a new adjuvant combination. All 17 subjects developed antibodies against the CS
antigen. Seven individuals agreed to undergo repeated challenge, and 6/7 showed
complete protection from the infection (Stoute et al, 1997). These results are impressive
enough to persue along this avenue of new vaccine candidates.
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1.7.2.1.5 Vaccine delivery systems
The component of the delivery system , the adjuvant, is a non-specific immunogenic
mediator that often induces high antibody titres. The only adjuvant used at present is
aluminum hydroxide (alum) but newer methods have been described that induce
significantly higher antibody responses; these include the use of bacterial cell walls e.g
mycobacterium; liposomes, oil emulsions and microencapsulation systems using
biodegradable and free-flowing spherical particles are also showing promise (Eldridge et
al, 1993). Other novel approaches include the use of recombinant live vectors and
rnuttiple - antigenlepitope peptide systems (MAPsIMEPs) (Chatterjee et al, 1995; Jones
and Hoffinan, 1994).
The degree of protection achieved with the various vaccine preparations has varied from
partial to complete. Variations in the antigen preparations, immunization protocols,
animal species, the parasite inocuh ...f used, and the virulence of the parasite strains could
account for the differences observed among the vaccination studies.
1.8 DIAGNOSTIC TECHNIQUES
1.8.1 Microscopy
The laboratory diagnosis of malaria depends on the demonstration of the parasite in
thick films of peripheral blood (a screening tool) and the differentiation of the species
and the determination of the parasitaemias is made on the thin films (Hira and
Behbehani, 1984). Blood may be obtained by fingerprick or venipuncture [specimens
are sent in an anticoagulant ethylenediamine tetra-acetate (ED1 A) ], and the slides made
according to standard operating procedures (see Materials and Methods), are usually
stained with a Giemsa stain. Most laboratories fire able to offer this service on a 24 hour
'50
basis and report th result of a thick film examination as soon as possible (ideally within
one to two hours).The urgency placed upon this test often results in poor quality
specimens with questionable interpretations. Laboratories must have an effective policy
to assure malaria smears are made correctly and quickly (Hira et a1, 1984). Despite
careful handling +/- 10% of the specimens made over a year are classified as being of
poor quality. When performed by a skilled microscopist,examination of stained blood
films is a sensitive but laborious method. N, few as 10 - 20 parasites /J.lIof blood can be
detected.. Occasionally errors occur and among the common mistakes are confusing
platelets or light spots and even debris in distorted red cells with parasites. Identifying
the species of the parasite usually poses a challenge from the onset. If the clinical
history is suspicious of malaria but the first slide is negative, the smears should be
repeated every 6-8 hours for 48 hours. Blood should, if possible, be taken during or
after pyrexin and before the administration of any antimalarial drugs. The parasuaemia is
important to quantify as it has value as a predictor of clinical severity and prognosis
(White et al, 1992). On thin smears parasites per 500 -1000 red blood cells are
determined and converted to percent parasitized erythrocytes. The appearance of late
trophozoites and schizonts in Pfalciparum appears to correlate as a predictor of
mortality (Silamut, 1993; Warhurst arid Williams, 1996).
Aft, r therapy begins, the parasitaemia should ideally be monitored one to two times a
day to assess the therapeutic efficacy of the drug regimen. This however is not always
practical and a daily parasite count may need to suffice. Initially parasite levels may
increase in the first 12-24 hours as the available antimalarial drugs do not usually inhibit
schizont rupture and release of merozoites. The time Irom init.ation of therapy to
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repeatedly negative blood smears is known as the parasite clearance time (PCT). Most
of the currently used drugs produce a PCT of2 to 4 days (Murphy and Oldfield, 1996).
Although microscopic detectior, of the malaria parasite remains the gold standard of
diagnosis, many techniques have been tried and tested in the attempt to find a quick,
accurate, sensitive, early and cost effective method of diagnosis
(Mcl.aughlin et ai, 1992). Below I have reviewed some old and new methods of
parasitic detection.
1.8.2 DNA/RNA probes and hybridization for the detection of
P.falciparum mala~ia
Plasmid bome repetitive DNA and RNA prober that have been labelled with radioactive
isotopes have been described (Franzen et aI, 1984; McLaughlin et al, 1985; Holmberg
et a1, 1987; McLaughlin et al, 1987; McLaughlin L at 1991).
These tests appear to be highly sensitive, detecting parasitaemias of 0.0001% (+/- 40
parasites). Total genomic DNA appears to be 5 fold more sensitive than synthetic DNA
probes. They have also been shown to be highly specific as each probe has sequences
that recognise one malaria species and no crosshybridization was observed. This method
is useful for detecting current infections, several hundred blood samples can be
processed simultaneously and the procedure is completed within 24 hours. Despite this
microscopy still remains mort; sensi..ve than the DNA prcbe in detecting low level
parasitaemias (Lanar et al, 1989). The test can be modified to use fingerprick whole
blood (Pollack et al, 1985; Barker et al, 1986), and has been 'adapted further to a
nonisotopic enzyme linked synthetic DNA detection, using a rapid lysis and filtration
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processing procedure (McLaughlin et al, 1988; Barker et al, 1989; McLaughlin et al,
1991).
In addition to DN 1\ probes, rRNA sequences have been USt ,I as genetic markers for
species or strain identification. Ribotyping has been used for pathogen identification
among bacterial species to identify virulent "trains (McLaughlin et al, 1992; Weiss,
1995). DNA from the pathogenic organism is digested with restriction endonucleases
and then hybridised with rRl\JA or r DNA. The resultant band size polymorphisms
provide a DNA fingerprint of the organism.
1.8.3 Serology
Serology is not used routinely as a diagnostic tool, as acute malaria is satisfactorily and
more quickly detected on the blood films, however there are clinical situations inwhich
this technique may be of benefit e.g in treated patients who no longer have
demonstrable parasites in the peripheral blood, in infections with extremely low-level
parasitaemias. The traditional role for serological testing remains in the epidemiological
studies. Other applications include:
• Transfusion blood screening (Bruce-Chwatt, 1982; Espinal and
Morales. 1>1~;..j.).
• Retrospective diagnosis
1.8.3.1 ELISA ( enzyme linked immunosorbent assay)
The surface of the Plasmodium sporozoite provides a target for immune responses from
the host. There has been tremendous progress in the characterisation of the surface
antigens of the sporozoite, in particular the circumsporozoite (CS) protein, which has
been implicated as the target for host antibody responses (Jones and Hoffman, 1994;
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Chatterjee et at, 1995; Gilbert and Hill, 1997; Nussenzweig and Zavala, 1997). Enzyme
linked immunosorbent assays have been developed to detect antibody against a whole
host of antigens, e.g the synthetic peptide (NANP)3, derived from the repeating amino
acid sequence on. the surface of the CS protein (Campbell G et at, 1987), and a
recombinant protein of glutamine rich residues of Pfalciparum called GLURP (Dziegiel
et al,1991). A major drawback of this assay is the variability of nonspecific reactions
resulting in false positive results. Microtitre well formats tor malaria show pre. , for
uniform large scale monitoring of falciparum malaria in epidemiologi-al studies, but
further improvements in the technologies are necessary to improve costs and duration of
the assay. Commercial kits are becoming available (CeLLabs Malaria IgG CELISA®-
NSW Australia).
1.8.3.2 !FAT (indirect fluorescent antibody test)
The IFAT was developed more than 20 years ago but still remains one of the most
widespread reference methods for the estimation of antibodies against Plasmodium
specific antigens (Collins et a1, 1964a; Collins et al, 1964b; Spencer et al, 1919). For this
test antigen spots or thick films are made on glass slides. The antigen is usually derived
from in vitro cultures of Plasmodium strains. The slides are then dried and stored
frozen. Under these conditions the antigen can remain stable for years (Warhurst and
Williams, 1996). Serum samples are then screened under various dilutions
(1:20;1:40;1:80). A fluorescein-labelled anti-human immunoglobulin IS used as a
conjugate and the samples are analysed under a microscope that is equipped for FITC
epifluorescence (Bush and Frean, 1996).This technique is however veri time-consuming
and subjective.
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1.8.4 peR (polymerase chain reaction)
The addition ofPCR to the "molecular biology bag of tricks" has made a considerable
impact on medical research as a whole. PCR offers maximum sensitivity for the direct
detection of infectious organisms (Viriyakosol et al, 1995). In a recent review of
molecular diagnosis of parasitic infections, Judith Weiss (1995) describes several
techniques used inPCR assays for the optimisation of parasite detection. PCR proved to
be significantly mote sensitive than direct microscopic evaluation at detecting
P.falciparum DNA in human blood,especially in samples with low-level parasitaemias,
detecting many specimens that were negative by microscopy.
Another major advantage is the ability of peR to detect mixed infections by analysis of
polymorphisms encoding cell surface molecules that contain regions of repeat
sequences. By modifying the technique PCR may provide invaluable information
regarding phenotypic characteristics of various Plasmodium strains e.g. amplification of
DNA from chloroquine resistant (CQR) and chloroquine sensitive (CQS) falciparum
malaria infected blood, yielded different banding patterns (Kain and Lanar, 1991).
1.8.5 Antigen detecting tests
In the quest to develop the ultimate quick, accurate, sensitive, cost-effective and easy
method of detection that will facilitate early diagnosis of malaria, a number of tests have
been introduced in the Jast five years, all claiming to be the solution to any diagnostic
problems (Figures 12 and 13). All these tests share a few basic features: (a) the
identification of a Plasmodium species specific antigen, (b) they comprise of a non-
automated ,easy to follow step-by-step procedure that requires very few skills to master
the technique and is thus suitable for use in field clinics and their associated laboratories
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(c) the results are simple to interpret and usually available within "" 10 minutes. Most of
the tests are limited by the fact that they can only detect one species Plasmodium
falciparum, albeit it is the most life threatening of the malaria species infec ing ....J.11.
Table 8 summarises the available tests.
Figure 12:
~;".;~r}""--ccl.. " ..:Jj.. .. - ~~~l~~test~ t.1 CO['!'Di<!as"cs
The Plllrra§igM IFantigen capture assay
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Table 8:
Tradename Antlgen detected
AntigeJ!_ca~turemethods used for the detection of malaria
Seilsitivity SpecificityManufacturer References
Para Sight ®F Becton Dickinson Histidine-rich protein 2
(USA) (P.falciparum)
Can detect 88%-95%
down to
10 parasites/ill
(-94%)
Schiffet al, 1994;
Beadle et a1, 19~'4;
Uguen et at. 1995;
Verle et aI, 1996
leT ® Malaria Pf leT Diagnostics Histidine-rich protein 2 -100% ~96%
(NSW Australia) (Pfalciparum)
unpublished data
OptiMAL® no data availableFlow Inc.
(USA)
parasite lactate
dehydrogenase (PLDH)
(is able to differentiate
between faIciparum and
non-falciparum species
based on antigenic
differences between the
pLDH isoforms)
Can detect
100 -200
parasites/ill
?
OptiMAL ®is not a FDA approved diagnostic test and is manufactured to be used for research and development
only.
U1
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1.8.6 QBC (qualitative buffy coat)
In this method blood samples are placed in acridine orange coated heparinised capillary
tubes, and centrifuged. The are? below the buffy coat is then examined in situ under a
fluorescent microscope to f.!.etectthe parasitised cells, the malaria parasite stains with
acridine orange (Levine et al, 1990). This test has been found to be as sensitive as the
detection of malaria using thick smears, however as certain stages of the parasite cycle,
like the late trophozoites and the gametocytes may be missed in the buffy layer of the
sample, it is advisable to further determine the presence of parasites by making thin and
thick smears in pa' illel, Although it provides only a rough estimate of infection
intensity, it is a te ,t vhich is easier to teach and interpret than a thick or thin film. The
techique is also quick ~and does not require any special preparation, drying or staining
(Warhurst and Williams, 1996). Disadvantages associated with this test include the
initial high cost of equipment and the high cost of consumables.
1.9 THE CHEMOT1ffiRAPY OF MALARIA
The treatment of malaria and the prophylaxis against this infection using
chemotherapeutic agents is an important aspect in the fight against malaria. The
discovery and the development of these compounds have been topics of discussion in
chapters and books on malaria, and it is therefore not possible for me to ellaborate in
detail on the various drugs, their mode of action and their side effects in this dissertation.
I have however attempted to cover the commonly used drugs and I have tried to briefly
introduce the new antimalarials under development. Drug resistance in malaria (White,
1992; White and Olliaro, 1996), albeit relevant in any malarial discussion will not be
featured in this introduction.
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Malaria is one of the oldest infections, being described in early Egypt .India and China.
1.9.1 Historical overview (see also Section 1.1 Milestones in the Hist~.....·
of Malam0
It stands to reason that attempts at treatment have been made by our ancestral
colleagues. The "Jesuit's Powder" derived from the bark of the Peruvian Cinchona
"fever tree" in the early 1600's was possibly the first record of the use of "quinine" for
the treatment of certain 'fevers"(B1ack et al, 1981; Gilles, 1993)). This new remedy was
introduced into Europe by the Spanish priests in the mid 1600's and gained popularity
on the European continent with its spectacular cures of "fevers and agues". The active
ingredients of the bark, however were only isolated more than 250 years after its first
application as a therapeutic agent.
1.9.1.1 Chloroquine - the drug of choice?
During the second world war, following the Japanese invasion of Pearl Harbour in
December 1941, the world's regular supply of quinine (from Indonesia, which was
occupied by the Japanese army) was denied to the Allied Forces, who were engaged in
campaigns in some of the most malarious areas of the world. This prompted a
concentrated move to stimulate production of synthetic antimalarials, which had already
been initiated as early as 1939. Among the 16 000 compounds screened the most
important was SN - 7618IResochin (a derivative of 4 aminoquii .cline), now known as
Chloroquine. Chloroquine received its first human trial in the United States in early
1944 and by 1946 > 5 000 individuals had been studied. The drug was found to
manifest very few side effects and it could be produced at a moderate cost (Coatney,
1963).
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1.9.1.2 Chloroguine - Mode of action
Chloroquine is a antipiotozoal drug used in the prophylaxis and treatment of malaria. Its
mode of action is not fully understood, Several mechanisms have been proposed:
1.9.1.2.1 DNA binding hyporhesis
Early studies demonstrated that chloroquine (CQ) acts by inhibiting DNA dependent
enzyme synthesis of DNA and RNA, and produces rapid degradation of ribosomes and
rRNA. The drug was thought to act by intercalating between the strands of the double
stranded DNA to form a complex. It was postulated that this complex inhibited the
actions catalysed by DNA and RNA polymerase, and deoxyribonuclease (Allison et al,
Ciak and Hahn, 1966; Cohen and Yielding, 1965). This theory has been dismissed.
1.9.1.2.2 Ferriprotoporphyrin IX (FP IX) hypothesis
Ginsburg and Warshurst proposed that CQ accumulates in the acid food vacuoles of
the intraerythrocytic stage of the malarial parasite and by inhibiting haem polymerase
disrupts the conversion of haemoglobin-bound haem into haemozoin (Ginsburg, 1988;
Warshurst, 1988). The unconverted haem in the form of ferriprotoporphyrin IX (FP IX)
appears to be toxic to malarial proteases and thus further degradation of haemoglobin is
blocked, "starving" the intracellular parasite. At certain concentrations FP IX is
directly toxic to the cell and to the parasite, and can cause lysis. CQ demonstrates high
affinity binding to FP IX, which seems to interfere with its (FP IX) removal. The drug
also forms i~ "lytic" complex which appears to alter the permeability of the cell
membrane by interfering with membrane bound proton pumps (Chou et al, 1980; Fitch
et al, 1983; Surolia and Padrnanaban, 1991).
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1.9.1.2.3 Weak Base hypothesis
The intracellular accumulation of CQ results in alkalinization of the acid vesicles within
the parasite. TIns has two possible effects:
(i) A number of malarial proteases mentioned earlier, are most .ffective at an acidic pH,
consistent with their presence in the food vesicles. The raised pH interferes with their
action.
(ii) The raised pH results in an increase of the intracellular osmolarity and swelling of the
organism.
The use of CQ as a chemotherapeutic agent against malaria has become increasingly
hampered by the emergence and spread of resistant Pfalciparum strains (Cowman,
1991; Alene and Bennett, 1996). Resistance appears to have emerged in the late 1950's
and has rapidly spread to all regions of the world where malaria is endemic. In southern
Africa the countries affected the most are Malawi and within South Africa, Kwazulu-
Natal.
1.9.2 Rationale of Malaria Chemotherapy
The available antimalarial drugs have a well defined range of action against different
species of malaria parasite as well as against the different stages of development of the
plasmodia within man and the mosquito. Tables 9 a-e summarise the commonly used
chemotherapeutic agents.
The development of antimalarials is costly and time consuming, however with the
emergence of malaria strains that are resistant to the standard drugs newer and better
compounds will be required for the future. At this point only a few drugs are at the stage
of preclinical or clinical development. These include artemisinin and related compounds
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(used by Chinese scientists for over 2000 years), new antifolate combinations, a new 8-
amino quinoline with more activity and less toxicity than primaquine, iron chelators and
the use of novel monoclonal antibodies (Looareesuwan et al, 1995; Olliaro and Trigg,
1995; Cabantchik et al, 1996; Hien et al, 1996; Looareesuwan et al, 1996: Mabeza et
al, 1996; van Hensbroek et al, 1996a; van Hensbroek et al, 1996b).
1.9.3 Q!inine - Why so special after 350 Y!:.3I S of use?
When the use of almost every antimalarial drug is compromised by the development of
resistant strains, Quinine "old faithful' is still going strong. There are a few possible
explanations why nollirnited resistance has emerged to this drug, and these will be
discussed in section 5. Quinine has remained effective against P.falciparum for 350
years. "This could serve as a lesson to us as we look for ways to preserve the efficacy
of our current antimalarials and other drugs" (Meshniek, 1997).
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Table 9a: Pharmacology of the commonly used chemotherapeutic agents,against miliaria parasites
Drug Structure Cont-aindicatlonsSpectrum
cf actfvity
Pharmacokinetics Tolerance
and toxicity
Quinine
(Cinehcna Alkaloid)
Quinino
(63.'1R) 6' melhoxycinchonan_g,ol
Spcrezoites-no action
1·exoerythrocytic
stages -nr- action
Asexual forms -fast action
Gametocytes - immature
(P.falcipaTllm)
Gametocytes - immature
and mature (P.vivax;ovale;
P.malariae)
Latent exoerythroeytic
stages -no action
No spcrontecldal action
Absorbed from the upper
intestinal tract.
Circulates as a base.
Excreted in the urine.
t lI2 -10 hrs
Dizziness,tinnitus
tremors.blurred vision.
IV -itypotelloian
IMI ISUDcut- caustic
(may lead to flbrosis)
oraf - bitter taste.
General- hypoglycaeruia
Caution in patients
with renal failure.
Caution in pregnancy.
PdIDllquiu{:$
(8-aminoquinoline)
G6PD
ca3Wo~l
~ ~ CH· NIl2NH . ell CH2- Clf2, 2
I
cn
PrimaqUiflo_8_14'a~i"~ "Iine
~·~~~~~~rYluminO}qUlnO
Sporo:wites - no action
f excerythrueytic
stages - highly effective
against early liver stages
Asexual forms - no
action
Gametocytes - direct and
fast acting
Latent exeerythrocytic
stages - active
Active spcrentccldal
action
Rapidly absorbed from
the gastrointestinal tract.
Excreted in the urine.
tlI2 - 6 hrs
Anorexia.nnusea.cyanosls
epigastric distress.cramps
and abdominal pain.
Dlscoloratlon of urine.
Occasionally -vague chest
pain, vomiting and
weakness.
Haematological: leukopenia,
anaemia,methaemogiobinaemia,
myelosuppression.
liaemolytic anaemia in individuals
withG6PD
First trimester of
pregnancy.
~Weiss et ai, 1995
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Table 9b: Pharmacology of the commonly used chemotherapeutic agents, sgainst malaria parasites
Drug Structure Tolerance
and toxicity
ContraindicationsSpectrum
of activity
Pharmacokinetics
Mepacrine(*)
(9-nminoacridinc)
yHj /lHS
NH.CH.CH,.CH,.CH,.N
.-<;' i ~ \("'Ir/~l/'~:,..OCHJ C,Hs
L _ ~ J
Cl"'~/ -".N"" ...;;.'/
Sporozoites - no action
l' exoerythrocytic
stages - no action
Asexual forms - fast action
Gametocytes -as for
quinine
Latent exoerythrocytic
stages - no action
No sporontocidal action
Rapid absorption from
the gastrointestinal tract.
High affinity for organs and
tissues.
Slowly eliminated in the
urine
Abdominal cramps,
nausea, vomiting and
diarrhoea.
Dermatitis.
Varlous reversible CNS
symptoms.
Syphilis of the CNS.
Simultaneous use of
mepacrine and the
8-aminoquinolines.
Chlo-r-quine
(4-amino'luinoline)
TH, c,«,
NH.CK.CH,.CH •. CH,,~!
I.--. \(~/""j(/-"'':-. (;H~
(I J",,_J.")
As above Rapid absorption from the
gastrointestinal tract.
High affinity for tissues
especially cells of the liver
parenchyma, and melanin
containing organs.
Slowly eliminated from the
tissues.
EKe.,,;,.! in the faeces (10%),
and in the urine (--60%).
Her dache.pruritus and
bh ..rringofvision (WaIl high
doses). Ocular damage
Skin lesions - pigmentation
problems.
IV - hypotension
oral - bitter taste
Collagen disease
(*) - Mepacrine shobid no Ienger be used for the prevention or treatment of malaria ns safer lind more effective drugs are available.
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Table 9c: Pharmacology of the commonly used chemotherapeutic agents, against malaria parasites
Drug Structure ContraindleationaSpectrum
of activity
Pharmacokinetics Tolerance
and toxicity
Proguanil
(Bigunnide)
/CH3-Q-NIl-C-NH C-NH CH\CI n n
NH NH CH3
Prcquanu
N'(p -chtcrcpnonytj-N -tso-
propyidlguanldo
Sperozoltes - no action
1" exoerythrocytic
stages - highly active
Asexual forms - active
but stow action
Gametocytes - no action
Latent exeerythroeytlc
stages - no action
Highly active sporontocldal
actloa
Rapid absorption
and slow elimination
mainly in the urine.
40% is excreted in
urine .•
Converted to an active
metabolite.
Abdominal discomfort,
loss of appetite,vomiting
and diarrhoea.
Nonelmown
Pyrimethnmine(*)
(Diamino-
pyrimidine) NH2
\ tlCI-Q---(:;-NI!2
Pyrimethamlno
2,4 -dtamtnc -6· p- ctnoropnonvt 6·
olhypyrirric!lno
Sporozoltes - n',}action
r exoerythrocytlc
stages - as proguanil
Asexual forms -as
prflguunii
G.lm~tocytes - no action
Latent exoerythrocytic
stages - some action on
P.Vil'ax
No evident sporontocidal
action
Slowly absorbed from
the gastrointestinal tract,
Binds to tissues and
body fluids
20-30% excreted in
the urine
Long term use may
cause megaloblastic
anaemia
Prcgnacy(althougb
teratogenic abnormalities
have not been reported if
used in the prophylactic
doses)
(*) Pyrimethamine is used mainly in the prophylaxis against malaria; it is a dihydrofolate reductase inbibitor.
Other dihydrofolate reductase inhibitors include progucnll/cycloguanll and trimethoprim.
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Drug Structure
Table 9d: Pharmacology of the commonly used chemotherapeutic agents, against malaria parasites
ContraindicatkmsSpectrum
of activity
Pharmacokinetics Tolerance
and toxicity
Sulpbonamidcs
and Sulphones(*)
-0 N~IIfl2 S02N"~
CH20 OClI3
Sulfado)(if10
W· -(5.6 dimoillolty· 4 -oyriml
dinyiJ·5ullaOiam,de
Sperozoites - no action
1" exoerytbrocytic
stages - no action
Asexual forms - bighly
active against Pfalciparum
Gametccytes - given alone
tbey increase prcduction of
? non infective formsf "')
Latent exceryrhrocytlc
stages - no action
No evidence of sporontocidal
action
Variable rates of absurptlon
and excretion lml!mg the varions
drugs, following the oral route.
Excreted mainly in urine
t 112 ~ 100-200 hrs (#)
Skin reactions like
urticaria.
Haematologicnl: mild
grnnulocytopcnias -
agranulocytosis.
Hnemolytic anaemia in
G 6 P D individuals.
Methaemogloblnaemia.
Hypersensitivity
Premature or newborn
infants -flrst month of
life.
Use cautiously in hereditary
enzyme deficiencies.
Tetmcyclines
HaC CH3"/N
011
GONll
2
Spnrozoites - unknown
1" exoerythrocytic
stages - active against
Pfalciparum
Asexual forms - highly
active, especially in
stralns resistant to other
standard drugs.
Garnetocytes - no action
Latent exoerythrocytic
stages - 110 action
No evident sporontocidal
actlvity,
Most are of low solubility.
They are absorbed throughout
the gastrointestinal tract hut
poorly.
Excreted in bile and in the
urine.
Nausee.vnmiting and
diarrhoea.
Teeth discoloration.
Affects bone growth in
developing foetuses and
young infant.
Enamel hypoplasia.
May cause hepatotoxicity
in pregnancy.
Hypersensitivity
Renal impairment.
Pregnancy
(*) Sulphonamldes and Sulphones can potentiate the effect of pyrimethamine if used in combination with this drug.
The commonly used drugs arc sulphadnxlne and dapsone. (#) t 1/2 of sulphadoxine, ("') (Puta and Mnnyando. 1997)
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Drug Structure
Table ge: Pharmacology of the commonly used chemotherapeutic agents, against malaria parasites
ContraindicationsSpectrum
of activity
Pharmacokinetics Tolerance
and toxicity(*)
Mefloquine(. )
(4-quinoline
methanol)
H
H I
Ho_d-QN
r7'Y\'-VtrC'3
CF3
Sporozoites - no action
f exoerythrocytic
stages - no action
Asexual forms - marked
action
Gametocytes - as quinine
Latent exoerythrocytic
stages - no action
:'110 evidence of sporoutocidal
action
Absorbed adequately from
the gastrointestinal tract.
Excreted in the bile.
t 1/2 - 2 weeks.
Duration of action may be
prolonged.
CNS disturbances
including Ilghtheadcdness,
gastrointestinal distress
occasional skin rashes,and
rarely phototoxicity.
Other CNS effects include:
psychosis.depression nnd
anxiety.
Use cautiously in
divers and individuals
operating dangerous
equipment, pilots and
long distance drivers.
Hnlofautr'iaef • )
[Phenanthrene
methanol) (eli2' ellI 3 3
~
HOCH{C" ) N{C"2)3C"3
CI
- ,
F3C CJ
Spcrczoltcs - 110 data found
1·exoerythrocytic
stages - 110 data found
Asexual forms - rapid
action
Gametoeytes - no data
found
Latent exoerythrocytic
stages- no data found
Sporontocidal action -110
data found.
Fairly rapid absorption
with peak blood levels
reached within 3-6hrs,
t 1/2 -2,6 days
Gastrointestinal
distress including
nausea and vomiting,
occasional dlarrhcea,
Neurological
disturbances like
headaches, tinnitus.
Skin manifestations are
rare - rash.itcbiness.
Mild elevation of liver
enzymes. ? Cardlotoxicity
(e) (White, 1994; Jacobs et al, 1931)
(*) (ter Kuile et al, 1995)
(.) (Restrepo et al, 1996; Nosten et al, 1993; Rinehart et al, 1976; Cosgriff et al, 1982)
These tables (a-e) have been adapted from Black et al, in Bruce-Chwatts Chemotherapy of Malaria.
Second Edition. Geneva: World Health Organisation, p 56-91
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2.0 AIMS AND OBJECTIVES OF THE STUDY
1. The study is structured into 2 major parts:
Part I - thc retrospective study
To review the hospital records for all the malaria cases that presented to the Chris
Hani/Baragwanath Hospital between January and March 1994, inclusive.
The patients were assessed socioeconomically, clinically, and haematologically.
Part IT - the prospective study
To characterise all the patients with malaria that presented to the Chris
HanilBaragwanath Hospital and/or its surrounding clinics between January and March
1995 (inclusive) according to the social, clinical, haematological and immunological
aspects of the disease.
2. To provide some insight into the high incidence of malaria at the Chris
Hani /Baragwanath Hospital.
3. To assess whether the entity of 'bus stop? 'taxi rank' malaria exists ,and whether
the climatic conditions in the suburbs surrounding the hospital and the clinics are
permissive for transmission ofmaIaria, by infected mosquitoes.
4. To propose some recommendations for the education of our affected population
groups, with regards the risks of malarial infection and , the important
prevention strategies.
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3.0 MATERIALS AND METHODS
3.1 MATERIALS AND METHODS - Part I
(Retrospective Study)
3.1.1 Geyeral Considerations
The clinical data, including the relevant history at presentation, tor this part of the study
was collected by reviewing the hospital/medical records of all the patients that were
diagnosed with malaria at the Chris HanilBaragwanath Hospital during January 199/. to
March 1994. The hospital records were in the form of (a) the admission and inpatient
day -to-day medical:file (bed letter), and (b) the outpatient medical record card.
A list of the patients' names and hospital numbers was obtained from the Departments
of Haematology and Microbiology of the South African Institute for Medical Research,
at the Chris Hani/Bragwanath Hospital where the original diagnosis of malaria was made
by routine methodology (i.e examination of thin and thick peripheral blood smears).
Special permission to access these records was granted by the superintendant of the
hospital and various administrative personnel in the adult and paediatric departments.
3.1.2.1 Social history
The Chris Hani/Baragwanath Hospital serves predominantly the black communities that
make up the Soweto area. Other population groups that have access to this hospital
include the Indian communities e.g Lenasia ,Lenasia South; the communities of
Eldorado Park and very occasionally communities that are located in the Vereeniging
area, which are predominantly whit- l'l this study the patients were classified according
to their age, sex, socioeconomic status (this was c etermined mainly by family income)
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and whether the" vere permanent residents of Soweto and its surrounding suburbs, or
whether they resided outside South Africa, in which case the noted address may belong
to a relative or friend. Inmost cases a Soweto address will be reflected on the patient's
medical records. An a. native residence may be suspected in the event of a travel
history documented, but this was difficult to prove on the retrospective data.
3.1.2.2 Clinical aspects
In addition to the age and sex distributions mentioned above , other relevant medical
history included information regarding recent or past pregnancies, as well as the
pregnancy state of the patient at the time of admission; a previous history of malaria ;
particular importance was placed on drug history. Regarding malaria prophylaxis, a
record was made whether any drugs were prescribed, by whom they were prescribed ,
what drugs were given ,at what doses, and for how long. It was also important to note
the patients' compliance. Often no record at all was available.
Once the patient was admitted, therapy was initiated in the wards. A list of available
drug therapies was made from the recorded data (a number of standard drugs are
recommende ~. The type of drug(s) used, the doses administered and any possible side
effects were documented. The duration for which the drug was given was also an
important parameter, as this helped determine whether the therapy was optimal.
The presenting symptoms and signs as recorded by the examining doctor at the time of
admission were noted. Aspects such as the duration of the symptoms, prior to seeking
medical attention, the presence or absence of fever, the presence or absence of
organomegaly and especially splenomegaly, the assessment of the cardiovascular and
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respiratory systems and careful note was made of any neurological manifestations like
loss of consciousness (LOC) and/or seizures.
The outcome of the disease for this admission was documented, and a record was made
of any follow up visits to the hospital after discharge.
3.1.2.3 Laboratory investigations
Following admission patients, (in this case those suspected of having malaria or those
who presented with a pyrexia of unknown origin [PUO] ) had a number of routine blood
investigations. These comprised a full blood count (FBe) and differential count, renal
function tests (U + E), and malaria smears - thick and thin :films. Other optional tests
included a random baseline glucose level and liver function test'S. The results of these
investigations were r.zcessed from the online computer network.
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3.2 MAT~RIALS AND METHODS - Part II
(Prospeetive Stu~.y)
3.2.1 General consid~rations
All patients who were diagnosed with malaria by the Departments of Haematology and
Microbiology of the SAIMR at the Chris Hani/Baragwanath Hospital between January
1995 to March 1995, were considered for inclusion in this part of the study. Blood
samples for investigation of malaria were received from patients who were already
admitted to the hospital wards, from patients that were attending the outpatient facilities
lL(e "Med Reg"( a daily outpatient facility that is staffed by medical registrars and
consultant physicians) or from patients that were attending the surrounding clinics. The
patients from the clinics were usually referred to the hospital, as the staff had been made
aware of the study through poster advertisements that had been circulated via the
community health services. However, a small number of patients were not sent through
for admission especially if the clinical presentation was not urgent; they would receive
treatment and be sent home to return to the relevant clinic for follow up. Clinical data
from these individuals was difficult to obtain telephonically, and travel to the various
clinics was impractical.
A list of the patient's names and hospital numbers was obtained from the Haematology
and Microbiology departmental records. An a'tempt was then made to interview and
examine all the patients who presented with malaria to the hospital.
An informed written consent (see Appendix A) was obtained from each patient before
inclusion into the study. In the event of a minor, consent was obtained from a parent,
guardian. or next-of-kin. The services of an interpretor (usually a nursing sister or a
nursing assistant) was often necessary to ensure no misunderstanding and to reassure the
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patients that should they wish not to take part in the study, this would not compromise
their medical care in anyway.
3.2.2 Data collection
3.2.2.1 'Jocialand clinicalaw~
Essentially the same parameters as described in the first part of the study were assessed.
The patients were classified according to their age, sex, socioeconomic status , whether
they were residents of South Africa or immigrants ( this data was often difficult to
obtain, as very few individuals volunteered this information, possibly because of their
illegal presence in the country). A detailed travel history was obtained, including the
country that was visited and the duration of the stay. The duration of the symptoms
prior to admission was noted.
A thorough drug history was asked as previously mentioned. Enquiry was made whether
medical travel advice had been given, and if so by whom. A history of previous malaria
and the treatment that was received was documented.
A detailed history of the presenting symptoms was taken and a full general examination
to elicit signs was conducted initially by the attending doctor and then by myself. All the
clinical findings were recorded. Important negative signs were also noted.
3.2.2.2 Laboratory investigations
Routine blood investigations included a FBC and differential, U + E, malaria smears,
blood glucose and liver function tests. Once the patient agreed to take part in the study
and the consent form had been signed, a few additional aspects were considered .like the
antimalarial immunological status of the patient. Blood was taken for immunoglobulin
levels and a protein electrophoresis, and serum was sent to the Department of
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Parasitology to identify the presence of antimalarial antibodies,via an indirect
fluorescence antibody test (IFAT).
3.2.3 Recording of dalta and results.
The clinical data in the retrospective study was initially recorded on patient information
sheets (Appendix B) while the laboratory results were collected as a computer print
out/form.
In the second part (prospective study), the patients were given a carefully structured
questionnaire to answer (Appendix C), usually with the assistance of an interpretor and
myself. The questionnaire addressed all the important aspects regarding the clinical
presentation and the history leading up to the admission. Attached to this questionnaire
was a clinical information sheet on which the findings IQfthe clinical examinations, and
the:final outcome of the disease were recorded.
A data base of the clinical and laboratory results was created us 'ng Microsoft® Excel
(Microsoft® Office '95 for Windows ). The clinical results were coded prior to their
entry onto the data base. This information was then analysed with the aid of a statistical
consultant, Mr John Mansefield (BSc Hons in Mathematical Statistics and Actuarial
Science, Wits,1990). The statistical analyses was performed on a standard statistics
package, the SAS system, versicn 6.12 (SAS Institute,Cary,NC) using the BASE and
STAT modules.
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3.3 METHODS - Specimen Analysis
3.3.1 Haematological assessment
The haematological analysis of peripheral blood samples taken routinely from the
patients was performed on a H3 Technicon™ blood analyser (TechniconiAmes, Bayer
Diagnostics, Bayer, Evans House Hamilton Close, Basingstoke Hants RG 21 21"E
England).
The following parameters were measured:
(a) Hb (this is based on the cyanmethaemoglobin method) - all forms
of haemoglobin are readily converted to cyanmethaemoglobin, which
is then accurately measured with a photometer at an absorbance of 540nm)-
determined in grams per decilitre (g/dl)
(b) HCT (haematocrit or packed cell volume ,PCV) - determined as a ratio
(c) MCV (mean cell volume)- measured in femtolitres (fl)
(d) MeH (mean cell haemoglobin)- measured in picograms (pg)
(e) MCHC (mean cell haemoglobin concentration)- measured ingrams per
decilitre (g/dl)
(f) WCC (white cell count) - x 10911
(g) PLTS (platelet count) - x 109/1
3.3.1.1 Reticulocytecounts
These were not requested routinely on every patient. Where the request for this
investigation was made, the counts were done manually following the method described
by Dacie and Lewis (1995). The results were reflected as a reticulocyte percentage.
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3.3.1.2 Differential counts
The method used for the differential count is described in the SAIMR method file under
Standard Operating Procedure (SOP) for a Differential Count (Appendix D). The
differential counts were done by a haematology technologist, who also commented on
any relevant morphological features,including the presence of intracellular parasites. The
slides on which the identification of malaria was made, were then referred to myself for
microscopy and recording of the findings.
Table 10 lists the normal haematological reference ranges used in the haernatology
laboratory for adult blacks living on the Witwatersrand (Tickly et al.,1987). The ranges
for infants and children are shown on Table 11.
Table 10: Normal haematological reference ranges for adult
Blacks living on the Witwatersrand.
PARAMETER MALES FEMALES
WCC (x 109/l) 4.0-11.0 4.0-11.0
Hb (g/dl) 14.0-18.0 12.0-16.0
RCT 0.41-0.51 0.37·0.49
RCC (x 1012/1) 4.43-6.03 4.07-5.13
MCV (ll) 82-100 82-100
MCH(pg) 27-32 27-32
MCHC(gldl) 32-36 32-36
PLTS (x 10911) 140-400 140-400
Neutrophils 40-75% 40-75%
Lymphocytes 20-1;1,' 20-45%
Monocytes 2-1,<; ;, 2-10%
Basophils 0-0.5% 0-0.5%
Eosinoj)hils 1-6% 1-6%
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Table 11: Normal haematoleglcal reference ranges for
infunts and chiId,'en
AGE wee Hb HCT RBC MCV MCH MCRC PLTS
(xl 09/1) (glrll) (xl 012/1) (fl) (pg) (gldJ) (xl09/1)
Birth 9.0-30.0 18.0-27.0 0.47..{).71 4.0-7.1 109 38 38 140-400
1week 5.0-21.0 16.0-25.5 0.43.0.68 4.5-6.4 104 36 36 140-400
1month 5.0-19.5 12.0-21.8 0.34.0.62 3.9-5.9 78 25 33 140-400
6 month 6.0-17.5 10.0-15.0 0.29.0.44 3.9-5.3 78 26 33 140-400
1-2 years 6.0-17.5 10.5-13.7 0.31.0.41 3.4-5.6 79 26 33 140-400
4-5 years 5.5-15.5 11.1-14.7 0.33.0.44 3.9-5.6 83 27 34 140-400
8-13 years 4.5-13.5 10.3-15.5 0.3 L..{).46 3.S-5.4 &5 27 33 140-400
by courtesy: the Department of Haematology, SAIMR, Chris Hani Baragwanath Hospital
3.3.2 Preparation of malaria smears
In this study the identification of malaria was formally made on thick and thin blood
smears that were prepared in the Department of Microbiology of the South African
Institute for Medical Research at the Chris HanilBaragwanath Hospital, Occasionally the
presence of the malaria parasite was initially detected on the peripheral smear that was
prepared for differential counting in the Department of'Haematology, After the clinicians
were notified an additional sample was usually sent for thick and thin smears to the
Microbiology department.
The thick :film was used primarily for detection of the parasites (as previously
described), and was particularly useful in scanty infections, while the thin :film was
examined for species identification and for determination of parasite densities, The
methods of sample preparation that follow are based on the standard operating
procedures for the preparation of blood smears used in the Department of Microbiology:
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3.3.2.1 Thick blood smears
3.3.2.1.1 Preparation oHhicl1:blood smears
a. Slides are cleaned with alcohol to remove ally greasiness that may result in
suboptimal smears.
b. A drop of blood is placed in the centre of a slide. The blood is then made into
a 10-15mm diameter circle by spiralling :fromthe centre outwards with the
comer of another slide.
c. The blood films are air-dried (no heat must be used).
3.3.2.1,2 Staining of thick blood smears
d. The air dried slide isNOT FIXED prior to staining ( this allows the water-
based stain to lyse the red cells)
e. The stain used is a. Giemsa stain (which has been pre-prepared in a phosphate
buffer of pH 7.2) • The stain is fresbly prepared and filtered regularly.
f. The stain is poured onto the slide and left for 20 minutes.
g. The stain is washed offby fiooding the slide with flowing water.
h. Stand the slide on end and allow to air-dry.
3.3.2.1.3 Examination of thick blood smears
a. The thick smear is examined under the microscope using a x 100 oil
immersion objective.
b. At least 50 fields (or time spent examining the slide -5 minutes) should
be examined before the slide is reported as negative.
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The malaria parasites are usually visible in a clear homogeneous layer of cellular
debris (see figure 14 ).
•
,:.
Figure 14: Peripheral blood (x 10(0) - malaria thick smear
3.3.2.2 Thin blood! smears
3.3.2.2.1 Preparation of thin blood smears
a. Slides are cleaned with alcohol to remove any greasiness that may result in a
suboptimal smear.
b. A small drop of blood is placed towards the frosted end of the clean slide.
c. A second slide is used as a spreader. Placing this slide at a 30° angle to the first,
the blood is streaked in a thin film (slide to slide technique) - see
Appendix D pg 2.
d. The slide is allowed to air-dry and then stained.
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3.3.2.2.2 Staining of thin blood smears
e. Thin smears are FIXED in methanol for 10 seconds.are removed from the
fixative and allowed to air-dry (heat must not be used); fixing the smear
allows the red cells to remain intact after staining.
f. A Giemsa stain (as described above) is used to stain the thin smears.
g. The stain is either poured over the slide or the slide is immersed into the stain
for 20 minutes.
11. The stain is removed by flooding the slide with flowing water, and the slide is
allowed to air-dry .
3.3.2.2.3 Examination of thin blood smears
a. The slide is screened first under low power (x 40 dry objective) to identify
malaria schizonts and gametocytes.
b. The slide is then examined under x 100 oil immersion objective.
c. Up to 150 fields (or time spent on examination of slide ~20-25 minutes)
should be examined before the slide is reported as negative.
Thick and thin smears (described above) were prepared directly from a fingerprick or
from fresh blood (less than 3 hours old) submitted in a tube anticoagulated with EDTA
(ethylenediamine tetra-acetic acid).
81
3.3.3 Determining ~he pannsite count (Pan'§it~mia/parasite densi1Yl
The percentage parasitised red blend cells is generally estimated on the thin blood film.
The number of infected cells per 1000 red blood cells is counted, and converted to
percent parasitised erythrocytes. Whether the cells contain one or more parasites they
are counted as one.
3.3.4 SerologicaL~ethods - the !FAT
3.3.4.1 Samplecollection
Blood for the detection of malaria antibodies was taken from the patient after written
consent was given (as discussed in section 3.22.2).
Blood was pulled in a red top tube (contains no anti-coagulants or other additives) and
allowed to clot. The specimen(s) was then centrifuged in a Beckman GS- 6R series
centrifuge ( Beckman Instruments Inc.,Palo Alto,California,U.S.A) for 15 minutes at
3000 revslminute(rpm) to separate the serum from the cellular elements of the blood.
The serum was pipetted out and stored in plastic tubes at - 70° C. Each tube was
labelled with a number (e.g specimen Lspecimen 2 etc), which corresponded to the
patient's name and hospital number. The samples were then batched ( batches of 12
samples) and taken to the Department of Parasitology for processing.
3.3.4.2 §nmple analysis - the IFAT
Malaria antibodies in patient's serum, especially against P .falciparum are detected by a
fluorescence - labelled (FITC) antihuman globulin. A fluorescence - equipped
microscope is used to read the test.
In my study a commercially available kit (Falciparum - Spot IF TM, bioMerieux,Lyon)
was used (see figure 15 ).
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The hatched samples were processed by a technologist in the Department of
Parasitology of the South African Institute for Medical Research, using standard
operating procedures (see Appendix E).
For the purpose of i.he study. the antihuman globulin used was not a polyva'cnr
conjugate as described in the SOP, but an IgG or IgM specific conjugate.
The result of the IFAT was interpreted with the assisstance of Dr John Frean of the
Department of Parasitology.
r'igillre 15: The Indirect Fluorescence Test (IFAT)
83
-
The manufacturers of the kit suggest the following interpretation of results:
[ TITRE rnTERPRETATION
~ 1:80
absence of active infection.
most likely suggests past exposure or possibly
active infection caused by a non-falciparum sp,
present and active infection.
< 1:20
1:20 to 1:40
The results of the tests were recorded initially on a result information sheet .This
information was then entered onto the Excel @ data base.
3.3.5 Es~imation of immunog!Qbulin levels
3.3.5.~ Sample lI:;ollection
Blood for the estimation of serum immunoglobulin levels was taken in a red top tube
(containing no anticoagulants or additives) and allowed to clot. The specimens were
then centrifuged (as described earlier) and the serum separated from the cellular
elements of the blood. The serum was stored at - 70° C until enough samples were
collected (batches of 12). Each tube was labelled with a number (e.g
specimenl.specimenz) which corresponded to the patient's name and hospital cumber,
The same number that was used for the IFAT was used to identifYthese specimens.
3.3.5.2 Sample aualysis A Immunoglobulin levels
The imrmmoglobuuu molecule is Y-shaped and comprises four polypeptide chains ( two
heavy chains, H ; and two light chains, U which are linked by disulphide bonds. The H
chains (within parenthesis) determine the class of the immunoglobulin. There are 5
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immunoglobulin classes; 19A (a), IgG (y), IgM (u), IgD (3), and 19E (s), There are two
L chains - K and 'A. In this study the levels ofIgG and IgM were determined.
The specimens were processed by the teclmologists of the Department of Chemical
Pathology of the South African Institute for Medical Research, at the New
Johannesburg Hospital. Standard operating procedures for the determinatioon of
immunoglobulin levels were used (see Appendix F).
The irrr- globulin that is analysed is detected via an immunoprecipitation reaction
that occurs 'len a specific antibody ( test antisera for specific classes i.e anti -IgG or
anti -IgM) is brought into contact with the specific antigen. The complexes formed are
detected as particles in suspension, through which a beam ,light is passed. The
intensity of the scattered light is measured by an electronics analyser and the signal is
then converted into concentration units.
3.3.5.3 Interpret~n of results
The immunoglobulin levels were interpretated by a senior registrar or consultant inthe
Department of Chemical ~Jathology. Each result was interpreted in conjunction with a
corresponding protein electophoresis , total protein and albumin estimation. Table 12
shows the reference ranges used in this study for the various age groups.
The results of the tests were made available initially on a computer generated hard copy.
This information was then entered onto the Excel" data base(Appenrlix G).
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Table ].2: IImmllilogKobufuR reference rnung!l!l !for l8llacRtadults
and cllillrlhrellil
IAGE RANGE IgG(gIO ][gA(gIil) =
0-2 weeks 5.3-19.6 0.02-0.12 0.02-0.9
2-4 weeks 4.8-13.4 0.03-0.9 0.3-2.8
4-6 weeks 4.1-15.2 0.05-3.2 0.3-3.8
6-:2 weeks 4.1-15.1 0.2-2.1 0.4-3.4
3-6 months 4.2-16.3 0.2-2.3 0.6-2.9
6-9 months 4.8-17.1 0.3-2.0 0.6-2.8
9-12 months 5.3-16.2 0.4-2.0 0.8-2.5
1-2 years 5.6-18.9 0.3-2.7 0.7-3.3
2-3 years 6.4-20.4 0.S-3.3 0.7-3.1
3-6 years 7.4-22.8 0.6-3.4 0.7-3.1
6-9 years 8.4-28.5 0.6-5.S 0.8-3.2
9-12 years 6.9-~6.3 1.1-5.1 0.9-3.2
12-15 years 10.1-24.7 1.3-5.0 1.0-2.9
ADULTS 10-20 1.4-4.7 0.5-2.7
by courtesy: the Department of Chemical Pathology, SAIMR, Chris Hani Baragwanath Hospital
3.3.6 lVIATERIALS - Tempera ~umeand rainfall data
The temperature and rainfa', Jata for Johannesburg ,Gauteng was obtained from the
Weather Bureau, in Pretoria. Daily rainfal' /mm) with monthly totals, and monthly
minimum and maximum temperatures tor the period 01/01/1994 - 31/12/1996 were
received via facsimile. An attempt was made to obtain a similar breakdown of rainfall
and temperature data for Maputo.Mozambique, firstly through the Mozambiquan
Embassy and Weather Bureau and then by eonducting an intc. ,:;;:t search using l'T~tscape
Navigator version 3.0. The information 'lrough the above sources was unfortunately
not available without a substantial monetary expense.
I was howe, er able to obtain 'histoncal weather data' for Maputo.Mozambique via the
internet through the International Station Meteorlogical Climate Summary, which was
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available on the Washington Post web site (WashingtonPost.com). This data is a
cumulative summary of high and low temperatures over the last 17 years, and average
rainfall measurements for the past 100 years.
3.3.1 Analy,!.isand intereretation of data
The laboratory and clinical data were analysed using frequency tabulations from the
information extracted from the data base. A univariate analysis comparing the various
haematological parameters, the clinical presentations and outcome of disease was
performed using the t-test and the Fisher's exact test. Significance was indicated as a
probability < 5%. A logistic regression model was applied to try and determine which
varlable(s) contributed the most to survival or death.
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4.0 RESm.lTS
The Chris Hani! Baragwanath Hospital is one of'tne largest hospitals in the world, and is
situated in Soweto.Gauteng. With more than 3000 beds and over 7000 staff the
hospital serves a population of around 3 million people.
During the period of this study there were approximately 100 new adult medical
admissions and about 30 new paediatric admissions per day. In addition, the hospital
attended to over 300 000 adult outpatient consultations. The paediatric outpatient
facility (which operates a 24 hour casualty service) attended to over 48000 children per
year.
During the period of January to March 1994 and January to March 15 • 263 patients
(175 male anr' 88 female) were diagnosed with malaria by the Departments of
Haematology and Microbiology of the SAIMR, at the Chris Hani/Baragwanath hospital.
Ninety-one of the two hundred and sixty-three patients (35%) were children [< 13 years
old]. Figure 16 shows the age distribution of the study patients, The median age was 27
years, ranging from 5 months to 76 years. The mortality rate during my study period
was 3% (6/203); clinical date! including the outcome of disease was unavailable in 60
cases. Thirty-three of the sixty patients presented to their local community health clinic
or outpatient department and were not referred to the hospital for admission; of the
remaining 27 cases that were admitted, there was one death prior to the clinical
interview, 7 patients were admitted to the short stay ward overnight for observation and
confirmation of the diagnosis, and discharged before I was able to interview them and
examine them clinically. Within the childhood cases, signed written consent .for
inclusion into the study, from a parent or next of kin was unable to be obtained for 6
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patients. Two other parents were unhappy to have their children in th' study. Among
the adults,3 patients were concerned about their participation in the study and were
particularly concerned about the personal details I was oollecting.e.g residence, income,
nationality .
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These were non English speakers, who appeared to be non-residents of South Africa,
and may have been in the country illegally. I was unable to locate 4/60 patients admitted
to the hospital, and 4 adult patients were discharged from the hospital before I was able
to conduct an interview and clinical examination. There were 15 leU admissions with
five recorded deaths belonging in this group.
The annual incidence of malaria for 1994 and 1995 was 209 and 233 respectively.
Figure 17 illr rates the incidence of malaria per month over the years 1994-1996. It is
evident from the graph that the number of diagnosed cases are steadily rising from year
to year but also from month to month, with the majority of cases presenting between
January and May. This indicates a disease prevalence during the summer months. The
number of cases for 1996 were included on the graph to demonstrate the persistently
increasing trend. The difference between the total incidence per year was shown to be
statistically significant (p <0.05). The difference from month to month was highly
significant (p<O.OOOI), confirming the seasonal cycle demonstrated on the graph. In
addition til\! incidence of malaria per month was found to be statistically significant
across all three years (p == 0.0131), with January having the highest incidence of
malaria in each year. This data concludes that the number of patients in 1996 (422)
appears to have increased significantly over 1994 and 1995.
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4.1 SOCIOECONOMIC ANALYSIS
The majority of the patients, 138/203 (93%), that were included in the study were
residents of Soweto, with a small proportion of patients ,151203(-7%), residing in
endemic areas, outside and within South Africa (Mozambique- 7; Malawi- 2; Angola- 1;
Zaire- 1; Gazankulu- 1; Venda- 1; Bophntatswana- 1 and Nelspruit-I). In the present
political climate with new socioeconomic classes emerging among the black
communities it was difficult to find a generally accepted social classification. If we
judge social standards according to the annual family income, 3 major groups wer
identified with an additional more "affluent" group emerging. Family income was
stratified into the following groups based on frequency analysis: a) R 1 000.00
- R 4999.99 I annum (40%); b) R 5000.00 - R 9999.991 annum (36%); c) RIO 000.00
- R 14 999.991 annum (18%); d) R 15 000.00 - R 1) 999.99 I annum (4%);
e) > R 20 0001 annum (2%).
4.2 CLINICAL PARAMETERS
4.2.1 Clinical prc§entatiQ!!
Most of the patients presented with a flu-like illness. with the major presenting signs and
symptoms listed in Table 13. Fever, the presence of pyrexia (;:: 38°C) on admission
.headache, malaise and joint pain were the most common presenting manifeste: 1ns of
malaria infection. The median duration of symptoms prior to the diagnosis of malaria
was seven days (range 1- 21 days).
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Table 13: Clinical signs and symptoms at presentation
(in order of frequency)
Symptoms and Signs No.of patients % J
fever 183 70
hyperpyrexiatz38°C) 143 54
headache 134 51
malaise and joint pain 124 47
rigors 104 39
weakness 94 36
splenomegaly 92 35
nightsweats 85 32
hepatomegaly 71 27
jaundice 67 25
abdominal pain 66 25
vomiting 63 24
pallor 61 23
respiratory symptoms 46 17
diarrhoea 34 13
CNS (localising) 17 6
CVS manifestations 12 5
nausea 9 3
CNS (coma) 3 1
More than one ...ign and symptom was present in most patients
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4.2.2 Laboratory data
4.2.2.1 HacI!1i]2tologicai Paromctell'il
The most Common presenting abnormalities included a thrombocytopenia
(pLTS < 140 x 10911) in 77% of patients, with a mean platelet count of 103 (± 72.4)
x 109/1 and an anaemia (Hb < 12 g/dl) in 55 % of patients, with a mean haemoglobin
value of 11.23 (± 3.2) g/dl (mean values and standard deviations are for both adult and
paediatric groups). Severe anaemia (Hb < 5 g/dl) was observed in 13/246 cases (5%). A
leucopenia (Wee < 4.0 x 109/1) was identified in 48 patients (18%). The mean white cell
count was 7.1 (± 3.8) x 109/1. Table 14 summarises the haematological data across the
children and adult patients.
You will note that haeznatological results were available on only 24")i263 cases. This is
because among the community health clinic patients a full blood count was not always
requested when a diagnosis ofmalaria was suspected.
An additional important parameter which is not reflected on the table is the reticulocyte
count. This is a fairly good indicator of how active haemopoiesis is, especially
erythropoiesis. Only twenty patients (6 adults and 14 children) had a reticulocyte count
requested and this is too small a number to provide any meaningful results.
Nevertheless, the mean reticulocyte CI)l..!rt for both groups was 3.36 (± 5.04) with a
range of 0.5 to 18.2.
4.2.2.1.1 Peripheral blood smear mor, .logy
8rythrocvtes
A normoc bromic normocytic anaemia was present in the majority of patients at
presentation especially among the adult grou», In the paediatric group a more
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T. :lIe 14: Summary of haematologleal data for adults and
children
ADULT CHILD I
PARAMETER n MIN MAX MEAN MEDIAl SID II MIN bLU MEAN MEDIAl SID I
WCC(x 10'/1) 165 1.2 15.5 6.30 5.70 2.569 81 1.9 29.6 8.73 6.80 5.215
RCC(x 101>/1) 165 0.94 5.82 4.20 4.44 1.085 81 1.0 5.7 3.76 4.01 1.084
HB (gfdl) 165 3.:5 17.4 U.S 12.5 3.043 81 2.8 16.0 9.97 10.4 3.186
HCT 165 0.039 0.5 0.358 0.386 0.093 81 0.090 0.78 0.311 0.32 0.109
MCV(t1) 165 67 113.7 86.69 36.6 7.707 31 61.2 103.2 80.7S 79.8 7.607
MCH(pg) 165 21.3 33.7 23.4 28.7 2.919 81 18.2 34.3 26.4 26.5 2.798
MCHC(gfdl) 165 30.0 36.0 32.8 32.9 1.241 81 29.6 36.4 32.7 32.8 1.339
PLTS (x 109/1) 165 16 501 91.9 71 67.383 81 14 489 125.f llO 77.372
microcytic picture was noted. The meanMCV was 86.6 (± 7.7) fland 80.7( ± 7.6) fl
respectively. The mean MeR for the combined group was 27.7 (± 3.03) pg and the
MCHC was 36.4 (± 1.2) gldl.
Undo r a x 50 and x 100 oil immersion objective various stages of intraerytarocytic
parasites were identified. The distinguishing characteristics were not always obvious e.g
Schuffners dots, as the stain used on the peripheral smear is of a more acidic pH. Early
ring forms and late trophozoites (Figure 18) were the most commonly seen forms of the
Plasmodium. The presence of multiply infected red blood cells often suggested a
diagnosis of falciparum malaria in the ruajority of cases. Gametocytes, when present,
especially the characteristic banana shape of P.falciparum were easily identified within
the infected erythrocytes (Figure 19), however it was difficult to distinguish between the
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male and female forms. Schizonts were not seen. possibly due to their sequestration
from the peripheral circulation.
•
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Figure 1tl: Peripheral blood smears (x 1000) demonstrating early
ring stages and! late trophozoltes of P.jalcipaf'um-
closed arrow. [Ear;j ring forms in multiply-infected
red blood cells-open arrow; applique forms-double
arrow)
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"Figu re RI}:
..
Peripheral blood smears (..dOOO) demonstrating :n
male (M) and female (IF) gametocyte of P.faldparum.
Morphological abnormalities noted in the erythrocytes included the appearance of
fragmented cells, irregular membrane outlines (occasional infected cells had a 'burr cell'
like appearance), and atypically haemoglobinised cells. Figure 14 (page80) demonstrates
the features noted on the thick smear which was used initially as a screening test for the
presence of malaria.
Leucocvtes
Lymphocytes - Lymphopenia has been reported in patients with malaria (Abdalla, 1990).
In the present study 21% of the cases had an absolute lymphocyte count < 1 x 106/1 .
The majority of the patients (67%) had normal lymphocyte counts, with a small
proportion (12%) presenting with a lymphocytosis (> 4 x 106/1).
A reversed neutrophil lymphocyte ratio was noted predominantly in the paediatric cases.
Reactive lymphocytes and plasmacytoid forms (Figure 20 and 21) were often seer ",
the blood smears. Morphologically atypical lymphocytes however are not specific for
malaria infection.
Granulocytes - A neutrophilia was commonly seen in the peripheral blood smears of
both the adult and paediatric patients. Morphologically the neutrophiIs appeared left
shifted (hypolobated) and occasional forms appeared vacuolated. Malaria pigment
(haemazoin) was readily identified within some cells.
Monocytes - Peripheral blood monocyte numbers were increased in most of the patients
with counts ranging between 0.3 x 106/1 and 2 x 106/1. The cells appeared large with
abundant vacuolated cytoplasm (Figure 22). Monocytes were noted readily engulfing
malaria pigment (Figure 23) and occasionally erythrocytes (infected and non-infected).
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Figure 20: A peripheral blood smear (x 1000)
demonstrating reactive lymphocytes (L)•
..•
"
o--~~ --- " ._--_--- ,~.______--
Figure 21: Perlpheral blood smear (x 10M) demonstrating
an atypical plasmacytoid lymphocyte (Lj.The
background shows 2 disordered neutrophil (N)
and! parasitised red blood cells (P),
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Figure 2:2:
!Figure 23:
~f'
Peripheral blood smear ( x 10(0) illustrating the
various monocytic forms noted in malaria
•
A peripheral blood smear ( x 1000) illustrating
the phagocytic properties of monocytes, here
engulfing haemozoln (arrow).
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Other granulocytes - Commonly malaria is associated with an eosinopenia, which was
evident in this study. One patient however presented with increased eosinophils
(absolute count 0.9 x 10611)- other causes of an eosinophilia were excluded in this
patient.
Platelets
Overall platelet numbers were reduced on the blood film. as mentioned earlier. The:
thrombocytes appeared morphologially normal Occasional giant platelets were seen,
especially in patients who presented with a severe thrombocytopenia.
4.2.2.1.2 Bone Marrow Features
Two patients, were unfortunately subjected to a bone marrow aspirate and trephine
procedure to investigate an unexplained thrombocytopenia. The malaria smears in these
cases were initially reported as negative. The morphological and numeric features
described above were essentially reflected in the bone marrow aspirates. The main
changes however where noted in the erythroid series. Erythropoiesis was noted to be
fairly active and one of the patients had an erythroid hyperplasia. Various degrees of
dyserythropoiesis was noted e.g cytoplasmic basophilic stippling, fragmentation and/or
multinuclear normobJasts and sideroblastic changes (Figures 24 and 25).
4.2.2.2 Malaria data
All 263 patients had malaria thick and thin smears for the quantitation of the
parasitaemia. and for species identification.
The most common infecting species was Pfalciparum which occurred in 240 patients
(91.3%). Ten patients (3.8%) had mixed infections (falciparum: vivax - 7; fa1ciparum:
ovale- 3); four patients were infected with P. vivax (1.5%), six with P.ovale (2.3%),
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•Figure 2"~: Bone marrow smear (x 1(00) showing
dyserythropoletic features.jl'unetate basophilla-
arrow; nuclear fragmentation (NF).
s
Figure 25: A bone marrow smear (x 1000 ) showing
sideroblastie changes within erytllufJid
precursors, [ -ringed sideroblasi (S) ].
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one with P.malariae «1 %) and in two patients the type of infection was not identified
(0.8%).Table 15 lists the regions were malaria was thought to have been contracted.
In four patients a travel history was not identified. Inone family (five patients) the exact
region where the infe. on was contracted was difficult to determine, as they had been
travelling through many endemic countries inAfrica, however the most likely region has
been noted ( the family were stranded in Botswana for one week after their vehicle
broke down; during this time their malaria prophylaxis finished).
Table 15: Regions where malaria was contracted
-
I Region No. of patients ( n=184 ) %J
Mozambique (Maputo) 109 58
Swaziland 16 9
Malawi 15 8
Northern Province 10 5
Botswana 7 4
Zambia 7 4
Zimbabwe 7 4
Kwazulu-Natal 5 3
Mpumalanga 5 3
Kenya 1 <1
Nigeria 1 <1
Uganda 1 <1
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Among the patients where a travel history was identified, 32/184 had no available data
regarding chemoprophylaxis against malaria; these individuals were mainly from the
retrospective analysis. Twelve patients (8%) admitted to taking some kind of
prophylaxis (Table 16). The remainder of the patients studied i.e 140/184 (76%) had
used no prophylactic agents. When questioned why they had not taken any medication
prior to their travel, the most frequent response was that they were not aware that any
prophylactic medication was necessary. The patients who had taken the prophylactic
agents were informed to take them either by a friend (two patients) who had visited an
endemic area, had sought medical advice (the family of :five), were frequent visitors
(three patients) to an endemic region due to their type of employment e.g driver, or had
previously contracted malaria while not on any prophylaxis (two patients).
Of the twelve patients who had taken prophylactic agents, :fivehad an insufficient supply
of medication, only seven patients had used the correct dosage, and none continued to
take the medication upon returning from the endemic area. The most common side
effects of the drugs were abdominal discomfort and diarrhoea, and the unpleasant taste
of the tablets.
Table Hi: Drugs taken for prophylaxis
I Drugs No. of patients ('7:, ]
Chloroquine 5 (42)
Chloroquine and Proguanil 1 (8)
Pyrimethamine and Dapsone (Maloprim) 5 (42)
Pyrimethamine and Sulphadoxine (Fansidar) 1 (8)
24/203 (-12%) of the patients gave a history of previous admissions for malaria. One
individual had contracted malaria eleven times. This patient is employed in a trucking
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company and frequently takes Fansidar as a form of prophylaxis. On his latest trip
however, he did not have enough time to organise the tablets before his departure. It is
important to note at this sta~e that Fansidar is not recommended routinely as a
prophylactic agent.
Based on a frequency analysis, the levels of parasitaemia were divided into three main
groups; < 1% ,1-5% and > 5%. A level of> 5% is defined as hyperparasitaemia
according to the World Health Organisation (Warrell et al., 1990). One hundered and
thirteen patients (43%) presented with a parasite density of< 1%, 116 (44%) had a
parasitaemia beween 1-5% and 34 (13%) presented with a hyperparasitaemia, Table 17
shows the parasite prevalence among adults and children.
Table 17: Parasitaemia frequencies for adult and
paediatric patients
I Parasitaemia Adult (%) Child (%) Total (%) I
<1% 71 (27) 42 (16) 113 (43)
1-5% 76 (29) 40 (15)
. 116 (44)
>5% 25 (10) 9 (3) 34 (13)
Total no. of patients 172 9] 263
The median parasite density was 1 (± 4.9) % with a range of < 1% to 36 %. The
average time for parasite clearance from the blood after initiation of therapy was 4 days
(range 1 to 14 days).
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4.2.2.3 Cbemistry Results
A number of routine investigations were done on admission. Table 18 summarises the
data, and also indicates the number of patients on whom test results are available.
Table lR: Summary ofbiocbemieal results
PARAMETER II MIN MAX MEAN MEDIAN STD NRang
UREA (mmollI) 218 1 56.6 7.74 5.70 7.46 2.6·8.0
CREAT(f.UllollI) 218 13 586 107.8 94 76.9 60·),20
GLUe (mmol/l) 81 1.7 38 6.62 5.6 5.24 3.0· 6.0
TP (gil) 156 30.0 99.0 68.5 69.0 9.16 60·85
ALBUMIN (gil) 156 16.0 48.0 35.7 36.C 5.95 35 ·55
GLOBULIN(gIl) 156 14.0 57.0 32.5 32.0 6.38 23 ·35
TB (umol/l) 103 6.0 381 44.1 33.0 48.3 4.0 ·21.
I
DB (umol/l) 103 3.0 235 20.1 12.0 29.1 2.0· 6.0
IB (umol/l) 103 2.0 146 24.0 18.0 21.3 < 15
AST (V/l) 103 11.0 379 72.5 445 73.0 5.0 ·40.(
ALT (U/I) 103 8.0 144 38.7 32.0 28.0 5.0 ·40.C
y- GT (VII) 103 7.0 656 47.4 27.0 73.3 o- 60.0
AlkPHOS (VII) 103 14.0 316 97.8 80.0 53.6 50 ·130~
-* Creatinine ram .,' ioJrNeonates: 27 • 62 umol/I; Creatinine ranges for children up to 13years: 44 - 88 ",molll.
On analysis of the above results, 3% (7/218) of the patients presented with renal failure
(creatinine > 265 umol/l), f,U~ approximately 5% (4/81) had hypoglycaemia on
admission (glucose < 2.2 mmolll). Raised bilirubin levels (total bilirubin> 50 umol/l)
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and raised liver enzymes (AST > 40 UIl; ALT > 40 UIl) were recorded in 32%
(33/103) of cases. The parameters described above are all indicators of complicated
malaria, as defined by the World Health Organisation (Warrell et al, 1990); see also
table 4, page 29.
4.2.2.4 SemRogicalremits
To assess the immunological status of the patients at the time of diagnosis, blood was
taken for IgG and IgM levels and the presence of malaria antibodies against a
P'falciparum antigen was determined using the !FA test described earlier. These tests
were performed only on the cases admitted between January to March 1995, i.e 147
patients. One hundred and one cases were analysed.
The mean IgG and IgM levels were 19.8 (± 6.43) gil and 2.59 (± 1.08) gil respctively
(IgG range: 7.9 to 44.5 gil; IgM range: 0.6 to 5.1 gil).
The results of the IFA test were difficult to analyse accurately as this test can be
subject to human bias. Frequency analysis cs.egorised the results across the various
titres i.e ;::::1:80; > 1:40; = 1:40; > !:20; = 1:20; ar: < "~O for both IgG and IgM
antibodies. In 94% the IgG titre was found to be ;::::1:80, with 3% of cases
demonstrating a negative result «1 :20). The IgM titres were strongly positive (:i! 1:80)
in only 65% of the patients tested. In23% a negative result «1:20) was documented. A
model was then derived which incorporated the interpretation of the various titre
combinations according to the manufacturers of the !FAT kit (see section 3.3.4.3). This
reflected a positive result in 65 % of patients, with 3% of cases being negative. The
remaining 32% were interpretated as positive with either past exposure to malaria or
possibly having an active infection with a non-falciparum species. It was difficult to
correlate the IgO and IgM titres against the IgG and IgM levels, as the immunoglobulin
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levels documented comprised of both specific anti-malaria antibodies and polyclonal
antibodies. Specific malaria induced subclasses e.g IgG 1 and IgG 3 were not measured.
The most consistent finding, among the patients who had been previously exposed to
malaria, was the low parasitaemia at presentation (Table 19). (!eventeen of the twenty-
four cases presented with a parasite density ~ 1%. The remaining patients had parasite
counts ~ 2% ,yet did not present witl: clinically significant disease.except for patient RK
a 30 year old female who had a ~~<rrasitaemiaof 17%. The Indirect Fluorescence
Antibody Test did not reveal any differences between the previously exposed and non-
exposed groups. Only 6/24 patients had a test result which suggested an underlying
protective immune state.
4.2.2.5 Pregnancy data analysis
Among the 88 female admissions, 7 pregnancies were documented. Three were
primigravidae, two women presented in their second pregnancy and two were
multigravidae. A further two patients presented in the peri-partum period. Of the seven
patients, two were discharged with a viable pregnancy and lost to follow up. Among the
remaining women, all five pregnancies (2:first trimester; 2:second trimester; 1:unknown)
were spontaneously terminated prematurely. Two of the five patients ( at 12 weeks and
26 weeks gestation) died from complications of'their infection.
4.2.2.5.1 Haematologieal data
The haematological consequences in pregnancy, especially anaemia and its causes (both
physiological and non-physiological), have been well described in the literature
(Lampirelli, 1988; Fleming, 1989; Fleming, 1996) and are therefore not ellaborated here
any further. The only haematological parameters that were analysed in detail were a
haemoglobin level < 5 gldl (i.e a severe anaemia) and a platelet
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Table 19: Malaria data 0; patients with a history of previous infection
Patient Details Malaria Data
Patient Sex Parasitaemia Immunoglobulin In terpretaticn
Titres
(%) - IIgG IgM
- . ----- ..._-_..- -_------ --- ----+--
IG.M. 32 male <l N/A N/AL.M. .B male <l N/A
I
N/A
M.L. 30 male <1 N/A N/A
M.R. 23 male 1 NiA
I
NfA
M.M. 22 male <1 N/A NfA
F.N. 19 female 1 N/A N/A
3.M. 55 male 7 N/A NfA
A.P. 34 male <1 NfA I N/A
1995
E.S. 39 male B :21:80 <!;1:80 Present and active infection.
I.M. 9 female <I ;;:1:80 ;;:1:80 Present and active infection.
F.S. 26 female 1 >1:80 <1:20 Early active infection, possible pr evior s exposure.
G.M. 19 female 2 >1:80 <1:20 Early active infection, possible previous exposure.
S.M. 34 female <i ;;:1:80 ;;:1:80 Present and active infection.
J.B. 61 male <1 ;;:1:80 ;;:1:80 Present and active infection.
R.S. 59 male 1 ;;:1:80 ;;:1:80 Present and active infection.
J.M. 36 male 5 >1:80 ",,1:20 Early active infection, recent or previous exposure.
N.M. 11 female <] ~1:80 ~1:80 Presen t and active infection.
B.C. 2.4 male <1 >1:80 <1:20 Early active infection, possible previous exposure.
R.M. 3 male <] >1:80 <1:20 Early active infection, possible previous exposure.
J.M. 42 mak 4 >1:80 ",,1:20 Early active infection, recent or previous exposure.
R.K. ::0 fernale 17 ;;:1:80 ;;:1:80 Present ,.~ active infection.
H.P. 46 3 i ~1:80 ~1:80 Present :..ld active infection.
I-' I
E.M.* 29 <1 I ;;:1:80 ~1:80 Present and active infection.
0 J.N. 20 <] ! ;,;1:80 ;;:1:80 Present and active infection.
\,,;)
* Repeated mr.lar in infections, (11 admissions) .
count < 140 X 109 /l (i.e a thrombocytopenia). No significant differences were identified
between the pregnant and non-pregnant groups for these two variables.
4.2.2.5.2 Chemistry datu
The Fisher's Exact test was used to compare the data between the pregnant and non-
pregnant groups. Among all the variables tested, pregnancy was shown to be
significantly associated only with glucose levels, especially with a glucose level
< 2. 2 mmol/l (hypoglycaemia), p < 0.00605.
4.2.2.5.3 Malaria data
The parasite densities among the pregnant group were as follows: 1 patient presented
with a parasitaemia < 1%, 3 patients had a parasite count between 1-5% and 3 women
presented with a hyperparasitaemia (> 5%). There was in.ufflcient evidence to show
that pregnant women exhibited different levels of parasitaemia than the non-pregnant
females (p = 0.367).
4.2.2.6 Data analysis ofICU admissions
4.2.2.6.1 Haematological and Chemistry data
15 patients( SF : 5M adults and IF : 1M child) were admitted to leU during the study
period. A third (5/15) of the patients died (4 adults and 1 child). Among the 4 adults that
demised ,2 were pregnant women. Tables 20 and 21 summarise the clinical
presentations and laboratory abnormalities within the adult and paediatric age groups.
Fever and rigors , pyrexia, jaundice and headache were among the most common
presenting signs and symptoms.
llO
Table 20: Clinicai signs and symptoms within leu cases by age
group.
(More than one sign and symptom was present inmost patients)
Age GJrO"!.llJPl
LSymptoms and Signs Adult(%) Cbild(%) Total I
-
fever 9 (67%) 1 (-7%) 10
pyrexia (:?; 38°C) 9 1 10
jaundice 9 1 10
pallor 8 (53%) 1 9
weakness 7 (47%) 1 8
headache 7 1 8
rigors 7 1 8
hepatomegaly 6 (40%) 1 7
CNS (localising) 6 0 6
malaise am.jeint pain 5 (33%) 1 6
splenomegaly 5 1 6
vomiting 5 0 5
nightsweats 4(27%) 0 4
diarrhoea 3 (20%) 0 3
respiratory symptoms 2 (13%) 0 2
CVS manifestations 1 (-7%) 0 1
Abdominal pain 1 0 1
CNS(coma) 1 0 1
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TabUe21: Summary of haemateloglcal and ehemistry data
in the leu cases by age group.
ADULT CHILD
PARAMETER n MIN MAX MEAN sm n MIN l\iA.'l: MEAN SID_j
WCC(x 10911) n 1.2 14.3 8.78 4.129 2 8.8 20.4 14.6 8.2021
RCC (x 101211) 13 1.15 S.35 3.09 1.110 2 1.75 3.30 2.52 1.096
HB(gldI) I3 4.5 15.l 8.79 2.92 2 4.2 9.2 6.7 3.535
HCT 13 0.13 r.44 0.265 0.037 2 0.13 0.26 0.195 0.091
MCV(f1) 13 70.9 113 87.9 10.28 2 75.9 73.9 77.4 2.121.
MCH(pg) 13 22.4 32 28.6 3.223 2 24.1 27.6 25.35 2.474
MCHC(gldI) 13 30 35.5 33.1 1.71ll 2 31.7 35 33.35 2.333-
PLTS (x 10'n) 13 21 199 61:, 45.755 2 65 169 117 75.539
~l-
UREA(mmolll) 49.6 i 13.624 3.4 3.413 5 21.89 1 3.4
f
CREAT{lImolll) 13 66 536 276.311 I 185.818 1 66 66 66
GLUC{mmclll) 10 2 37 9.25 1O.l61 2 3.9 5.8 4.35 1.343
TP{g/l) 13 59 91 69.23 10.191 1 64 64 64
ALBUMlN(gIJ) 13 24 47 33.53 6.995 I 36 36 36
GLOBULIN(gII) 13 23 53 35,S3 6.837 1 23 23 23
TB(flmolll) 13 8 70 46.311 22.137 1 43 43 43
DB (j.lmolll) 13 3 44 22.34 13.433 1 23 23 23
IB (llmolll) 13 5 46 23.23 13.0LtO 1 20 20 20
ss: (UII) 13 20 277 100.692 36.034 1 379 379 379
ALT(UII) 13 14 144 42.76 32.353 1 ,1 93 93
)'GT(UII) 13 14 1.:.:; 45.30 46.31,t I 23 23 23
ALKPHOS (Un) 13 14 246 105.07 59.355 1 163 16~ 163
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The average haemoglobin across the entire leU group was 7.74 (± 3.2) g/dl with a
mean platelet count of 89 (± 59.6) x 109/1. Severe anae.nia (Hb < 5 g/dl) was
documented in only two of the fifteen cases.
Analysis of the chemistry results indicated that five of the fi:G.cenpatients (33%)
presented in renal failure (creatinine > 265 umol/I). 4 patients (27%) had a
hypoglycaemia (glucose < 2.2 mmolll) at presentation and 8 patients (53%) had a
documented hyperbilirubinaemia (TB > 50 umol/l) and raised liver enzymes (AST and
ALT> 40 U/l).
The median values have not been included in the tabulation of the laboratory results as
these were found to be fairly close to the mean.
4.2.2.6.2 Mabuia data
Two thirds of the patients in leU (67%) had a parasite density of > 5%
(hyperparasitaemia). Four patients (26%) had parasite counts between 1-5% and only
one patient had a parasite level of < 1%. The median parasite density for the entire
group was 9.61 (± 6.14) % ( range <1% - 36 %). The average time for the parasites to
be cleared from the blood after treatment was 5 days, ranging from 3 to 8 days.
Seven patients had highly positive IgG and IgM antibody titres ( ~ 1:80) in keeping with
active malarial infection. The mean IgG and IgM levels in the adult patients were
22.2 (± 7.78) gil and 3.21 (± 1.35) gil, and in the paediatric case, 15.3 gil and 1.4 gil
respectively. The infecting species was P .faloiparum in all 15 patients. Ten of the
fifteen patients had a travel history to an endemic area. One patient died before a history
could be obtained, and in four cases (retrospective analysis) data regarding travel history
was unavailable.
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4.2.2.7 ('~emoti!~.rapy used no the treatment of malaria
Data regarding the drug therapy of malaria was available in 167 patients, The most
frequently used drug ( in 93% of patients) was quinine, alone or in combination with
other drugs (Table 22). The most common route of administration was orally (88% of
cases), but a small proportion of patients (12%) received their W·· "ose of quinine
intravenously. Side effects to these drugs were poorly documented in the medical
records used for the retrospective analysis. Inthe prospective arm of the study the only
reported complications were that of tinnitus or ringing in the ears in two patients and
hypo glycaemia in seven patients. All nine patients were on intravenous quinine at the
time. The symptoms settled with reduction of the dose and changing the route of
administration. Dextrose saline was administered to overcome the hypoglycaemic effect
of the drug. Standard doses were used and the drugs were administered for seven days
in the case of quinine and fourteen days for tetracycline/doxycycline; the course was
often completed after discharge.
Tabl~22: Drugs used in the therapy of malaria
I Drug % (of patients) IIQuinine alone 48
Quinine and Tetracycline 36
Quinine and Doxycycline 9
Tetracycline alone 2
Chloroquine 4
Primaquine 1
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4.2.2.8 Complicated Malaria
Severe anaemia , renal failure, hyperparasitaemia and liver derangements associated with
complicated malaria have been discussed under the relevant headings. An additional
manifestation of severe malaria that needs to be addressed is cerebral malaria.
Regarding the retrospective analysis it was difficult to app\v Warrell's (1982) strict
definition and I had to rely on the doctor's documented diagnosis. In the prospective
analysis the definition was more easily applied. Among the entire study group twenty
patients (7%) were diagnosed with probable cerebral malaria, but only 3 patients (1%)
could fit the criteria of'unrousable coma in the presence of a P.falciparum parasitaemia,
with no other causes of unconsciousness.
4.Z.2.9 Analysis ofbiood transfusion practise in the malaria patients
Transfusion data was available in 203 cases. Forty-two patients (16%), including the
leU cases, received blood transfusions the main indication being anaemia. Six patients
received one unit of packed cells, twenty-six patients were transfused with two units and
five patients received more than two units of blood. The patients were grouped into
those receiving a transfusion with a HB < ') g/dl, and those with a lIB ~ 5 g/dl, The age
group, patient type, pregnancy state and the outcome of the infection have been
summarised in Table 23. Five patients of which three were in ICU, received exchange
blood transfusions, the main indication here being a hyperparasitaemia (> 5%).
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Tabfie 23: Summary of patients receiving blood
transJi'l!Isnolll§
I ADULT I CHILD "J
I NotP=U=! IMALE I FEMALE IMALE]Pregnnnt
Hb Transfaslen Outcoml
<5 No Alive 1 3 1
Yes -1 unit Alive 1 1 1
Yes - 2 units Alive 1
Yes ->2unitl Alive I
;::5 No Alive 31 3 94 13 16
Dead 1
Yes -1 unit Alive 1 2
Yes -2 units Alive 2 10 I 4
Y¢J ->2 unit Alive 2 I
I Dead I
Exchange Txo Alive 1 I 1 1 1
Dead i 1
a Abbreviation: Tx - transfusion
4.3 UNIVARIATE AND MULTIVARIATE ANALYSIS OF
LABORATORY DATA
Categorical and continuous data were analysed using the Fisher's exact test and t- tests
in order to determine which of the variables was significantly associated with a poor
outcome. Among the categorical data (parasite load, haemoglobin, creatinine and
glucose level, and bilirubin levels) only hyperparasitaemia (>5%), p=O.000438 and renal
failure (creatinine> 265J.1molll), p=O.00852 were significantly associated with reduced
survival. A univariate analysis (Table 24) of the continuous data comparing survival and
death identified a significant difference between the WCC (p=O.0281) and the lIB
(p=O.0084) levels in the survivors versus the patients who died.
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Tabl.e24: Univariate analysis comparing survival! and
death with regard to continuous data ( mean ±
standard deviations)
Survivors Deaths
IVariable n Mean±STD n Mean ± S'T'''1I I v-valuel
Age 195 26.8 ± 15.63 6 29.8 + 12.51 1o.626~
wec 195 7.14 ± 3.84 6 10.7 ± 5.41 0.0281
HB 195 11.3 ± 3.25 6 7.7 ± 2.22 0.0084
PLT 195 99.9±68.82 6 68.6 ±53.41 0.2725
UREA 181 7.49 ± 6.09 6 18.7 ± 18.61 0.1991
CREAT 181 104.9 ±66.2 6 238,3 ± 223.0 0.2032
TB 82 44.2±49.3 6 46.0 ± 13.5 0.8310
AST 82 73.7±72.3 6 136.3 ± 123.2 0.2726
ALT 82 40.5 ±29.8 6 41.5 ±25.4 0.9380
A logistic regression model was applied to the continuous and categorical data. This
showed high parasite loads [p==O.0070;O.R=O.891( 95%CI: 0.811 - 0.981)] and raised
creatinine levels [p=0.0016; O.R=O.992 (95%CI: 0.987-0.997)] to be significant
predictors of poor outcome. The statistical analysis suggested a strong colinearity
between these two variables.
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4.4 TEMPERATURE AND RAINFALL
MEASUREMENTS
Monthly and annual rainfall tots were obtained for the Johannesburg area, Gauteng,
for the period January 1994 to December 1996. These are summarised in Figure 26.
Minimum and maximum monthly temperatures for the same periods are illustrated in
Figure 27.
Similar climatic data was obtained for Maputo, Mozambique (an endemic region) to
compare with local weather conditions ( a non-endemic region) in the bid to ascertain
whether the climate in the Gauteng province is suitable for malaria transmission. The
Maputo data (illustrated on the transparencies attached to figures 26 and 27) mainly
comprises cumulative values for temperature (collected over a period of more than a
decade) and rainfall (data for up to a hundred years). Temperature and rainfall
measurements for the Soweto area (Gauteng), unfortunately, were not available.
The annual rainfall, in Johannesburg, across the three years appears to have increased,
however the monthly minimum temperatures recorded may not be ideal to permit
parasite transmission in the city. The minimum t _",( rature required for the transmission
of P.falciparum if about 20°C; the :r~, 'e~·~minimum temperature recorded in
Johannesburg was 14.5°C, during the summer months.
Although the average annual precipitation is comparable, there appears to be a less
dramatic monthly temperature variation in Maputo. Here the highest minimum
temperatures recorded during the summer months average 22°C.
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Figure 26 Monthly rainfall (mm) Johansesbarg, Gauteng from January 1994 to December 1996
Average rainfall (mm) Maputo, Mozambique from 1894 to 1994 (average 100 years)
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Figure 27 Mon~hly temperature varlation (deg C) Johannesburg, Gauteng from January 1994 so December
1996
Monthly aver~ge temperature v, .•sn (deg C) Maputo, Mozambique from 1977 to 1994
(average 17 year's)
The differences in the weather patterns between the two regions (particularly the
minimum temperatures) alone may be sufficient to prohibit malaria transmission,
however there are more factors which need to be considered before any conclusions can
be made. One such factor is the mosquito vector (this will be discussed further in section
5.0).
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5.0 DISCUSSION
5.1 INCIDENCE OF MALARIA
"South Africa could be facing its worst malaria epidemic, .... , This appeared in a leading
newspaper in March 1996. At the Chris HanilBaragwanath Hospital, 422 cases were
admitted between January to December 1996, a significant increase over the previous
two years. These numbers do not necessarily mean that malaria is on the increase'; they
may indicate that more people are having access to the hospital, andlor that more
patients are being correctly diagnosed. Itmay also reflect that the number of travellers to
malaria areas has increased. In order to accurate.y conclude whether the incidence of
malaria is truly reaching epidemic levels, we would have to present the data of hospital
admissions as a proportion of the population infected. This was out of the scope of this
dissertation, Nevertheless the problem could be exacerbated by the heavy rains,
experienced during the summer months, which may leave behind pools of water that
may be attractive sites for breeding mosqnitoes. Extreme rainfalls on the other hand,
may wash away potential breeding sites and interrupt transmission. The environmental
conditions reflected in the data were not entirely conducive for malaria transmission in
the urban areas. Both the vector and the parasites are poikilotherms, and ~ nerally the
more elevated the temperature is the more enhanced the rate of development and
activity becomes, thereby increasing transmission. The average minimum temperatures
ranged from O.2°C to 14.5 ° C, and the maximum temperatures from 15.1°C to 27.so C.
The wide variation in the temperatures may illt be ideal for the development of the
mosquito, especially during its aquatic stages (eggs and pupae). There appears to be a
relationship between temperature and the rate of development of the vector. At lower
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temperatures the vector takes a longer time to develop (Lindsay and Birley, 1996). In
addition temperature has also been shown to affect the time it takes for the parasite to
become infective in the vector (sporogonic cycle). The warmer the temperature is, the
shorter the duration of the sporogonic cycle. The critical minimum temperature for
parasite development is uncertain. Values range from 16°C to 19°C for Plasmodium
falciparum. High temperatures are also important in transmission. Very high
temperatures -35° C are detrimental to the development of the parasite.
From the rainfall and temperature data presented above it appears evident that the
mosquito vector and the parasite will not survive the extreme weather conditions that
are noted on the 'Highveld' in winter and may not survive during the summer. Global
wanning however could see malaria transmission pushed up to higher altitudes (Lindsay
and Birley, 1996). In endemic areas, global warming has seen an extension of the season
of malaria transmission with increased number of cases becoming infected. Even if the
conditions were suitable for vector and parasite development, it has been documented
that the malaria transmitting Anopheles vector does not exist in Gauteng (Coetzee et al,
1993).
III the above study the majority of the patients (>88%) had contracted malaria, which
was predominantly of the falciparum type, from a neighbouring country with
Mozambique being the most popular travel destination (58%). The seasonal incidence
appears to coincide with the Christmas and Easter Holidays. The numbers are
particularly high during the January months across the three years. This is due to a
suspected high number of Mozambicans becoming ill while travelling between
Mozambique and South Africa as migrant workers or, while visiting relatives; and by
South Africans visiting Mozambique and returning with malaria. Among the four
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patients who did not travel, one patient gave a history of a relative visiting :'tom
Maputo. The data presented above appear to suggest that local transmission is unlikely
however, transported mosquitoes have been known to transmit infection outside the
immediate vicinity of the transporting vehicle. Could this be a case of malaria caused by
a 'travelling' mosquito?
5.2 MALARIA AWARENESS AND PROPHYLAXIS
The single most important issue that became apparent in both the retrospective and
prospective arms of the study, was the lack of awareness regarding the infection. Even
individuals who gave a history of frequent travel into endemic regions had no basic
knowledge of malaria and its consequences. The next most important problem identified
was the insufficient use of I poor compliance with, prophylactic agents. Only twelve
patients took some form of prophylaxis, and none continued to take the drugs after
they returned from the endemic region, mainly because of the unpleasant side effects of
the medication. Half of the patients were on a form of medicine that is no longer
acceptable! for prophylaxis e.g dapsone-pyrimethamine (Maloprim) snd sulphadoxine-
pyrimethamine (Fansidar), mainly due to the occurrence of serious side effects, but also
due to the reported pyrimethamine resistance. These drugs continue to be used in the
treatment of acute malaria, and certain health authorities e.g in Zimbabwe still
recommend maloprim as a form of prophylaxis (Lombard et al,1991). Generally
accepted forms of prophylaxis include CQ alone or in combination with proguanil,
mefloquine (La.ia=i) (the potential side-effects restrict its use in all individuals), and
tetracycline or doxycycline (this is particularly useful for travellers to CQR areas). Held
et al (1994) identified a few risk factors that may be associated with poor or non-
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compliance in the use of drug prophylaxis. Compliance increased with age, and shorter
duration of stay. The type of travel and travel destinations also influenced travellers'
behaviour i.e tourists on organized tours were more compliant than individual travellers.
Travellers to southern Africa were the most compliant, followed by those travelling to
East Africa. The compliance rate for those going to West Africa was -32% and for
Central Afric« was -22%. The final point that was addressed regarding prophylactic
behaviour was whether the traveller had made use of any information sources before
travel. Those who did not were significantly less compliant and often took incorrect
drug dosages. In the individuals who made pre-travel enquiries there appeared to be
more compliance among those who had made use of more than one source of
information. Antimalarial drugs must be taken reguiarly to be effective. The
Department of Health in collaboration wit', the TPS Drug Information Centre have
printed several brochures which are aimed mainly at the medical practitioner who
provides the travel advice, but may also be and should be aimed at the traveller. The
brochures provide comprehensive information regarding risk areas and provide easy to
follow tables with drug information and dosage schedules ( Department of Health, 1996;
Department of Health, 1994; TPS Drug Information Centre, 1993). These are often
available on request free of charge.
5.3 AVAILABILITY OF ANTIMALARIAL DRUGS
It is all very well educating the doctors to give better advice, and to educate the
travellers to seek these prophylactic agents, but these should be made more readily
available to the populations that are most at risk. At the Chris HanilBaragwanath
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Hospital the repertoire of drugs (that are affordable to the patient who seeks medical
attention at this government institution) is limited e.g chloroquine and doxycycline are
the only drugs available for prophylactic use, and clearly with the increasing CQR
strains emerging , the availabilty of an additional drug like proguanil is indicated. In
addition doxycycline is contraindicated in children < 8 years and preferably < 12 years
old, because of the complications associated with the tetracyclines e.g enamel
hypoplasia, abnormalities in bone growth, and the discoloration of teeth and bones
(Black. et al, 1981). Sulphadoxine-pyrimethamine (Fansidar) is on code for use but as
mentioned earlier it is not a suitable prophylactic agent and is reserved mainly for
treatment. Drugs like chloroquine, proguanil and meflcquine are naturally readily
available over the counter in non-government pharmacies, but the retail prices are often
unaffordable for most of the population that requires them especially since 76% of the
individuals in the Soweto area earn < RIOOO.OOper month (40% earn between R
1000.00 and R 4999.99; 36% earn between RSOOO.OOand R 9999.99). Often these
individuals have more important priorities than the acquisition of antimalarial drugs e.g
transport costs and food.
The various chloroquine preparations range between R 25.70 - R 28.83 for up to 20
tablets (chloroquine alone) and when in combination with proguanil the price increases
to R 66.10 for a 5 week course ( a family offour would require over R 250.00 worth of
tablets); proguanil alone retails at - R82.00 /100 tablets and mefloquine - RI02.50 /8
tablets (a minimum of 5 tablets is required, and a weekly dose is recommended for each
week in a malarial area). Unless more of these drugs are made available to the
government hospitals and the surrounding health clinics, the issue of chemical
prophylaxis will not be solved.
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5.4 GENERAL PROPHYLACTIC MEASURES
Prophylactic behaviour however, does not end with chemoprophylaxis, and this is not
100% effective as has been demonstrated in the patients on prophylactic agents who
develop malaria, albeit less severely. Alternate measures may help reduce the cost of
malarial control e.g the use of bed nets (Curtis, 1994; Luxemburger et al, 1994; Van
Bortel et a1,1996) and insect repellants (Department of Health, 1994; Department of
Health, 1996), the avoidance of being outdoors between dusk and dawn where possible,
and to wear protective clothing to minimise the risk of excessive contact with the
mosquito vector.
5.5 DIAGNOSIS AND TREATMENT
Travellers are at risk of developing malaria for up to 2 months after leaving an endemic
area, however cases of malaria have been reported to have developed as late as one year
after leaving the malaria area. Delays in diagnosis and subsequently treatment are
responsible for the mortality associated with this infection. In this study the median
duration of symptoms prior to diagnosis was seven days. The mortality rate was -3%
and deaths were related to complications of the infection e.g renal failure, anaemia and
cerebral malaria, rather than a delay in diagnosis and initiation of therapy.
5.5.1 Clinical presentation
The presenting clinical features were consistent with other studies in South Africa
(Jairam et al, 1990; Soni and Gouws,1996). Splenomegaly was documented in less
patients than usually reported, but this may be an underestimated figure, as I was unable
to confirm the clinical presentation of the patients in the retrospective arm of the study.
127
The prodrome offatigue, malaise, feverishness and headache was classical inmost of the
patients (>40%). At presentation few patients gave the classic 'textbook' episodic
description for fever (every 48 hours in P. falciparum malaria - tertian periodicity). This
is an observtion usually made in patients who present with untreated longstanding
infection (Warrell, 1993; Murphy and Oldfield, 1996).
The median age of the patients who presented with malaria was 27 years which is
consistent with other reports (Sharp et al, 1988; Jairam et al, 1990; Soni and Gouws,
1996), whether this reflects the population structure of the Soweto area is uncertain.
5.5.2 Laboratory analysis
5.5.2.1 Haematologicaldata
Analysis of the haematological data confirmed previously documented findings. In this
study severe anaemia was present in 5% of patients. Anaemia is an important cause of
morbidity and even mortality. A significant difference was found in the HB levels in the
patients who survived versus those that died. The mean HB in the patients that demised
(7.7 ± 2.22 gldl) was significantly lower than that of the survivors (11.3 ± 3.25 gldl),
p=O.0084; but only one patient who died had a HB < 5g1dl i.e a severe anaemia.
The mechanisms of anaemia in malaria are due to two main causes: a) haemolysis and b)
inappropriate marrow responses. Haemolysis can arise as a consequence of erythrocytic
parasitisation, with the infected red blood cells destroyed at schizogony; there may be an
immune mediated component, as some authors have reported a positive Coomb's test in
the setting of severe malaria (Abdalla, 1990; Newton et al,1997). This however is yet to
be confirmed. Erythrophagocytosis and sequestration in the reticuloendothelial system
has been described. Together with the PRBC, uninfected erythrocytes may also be
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removed in the spleen (Phillips and Pasvo~1992). Finally drug related causes may
predispose patients to anaemia. Certain antimalarials like artemisinin induce haemolysis
of the PRBC that are parasitised with trophozoite and schizont stages (Orjih, 1996).
Dyserythropoietic changes were found in the marrows of the two patients who were
investigated for thrombocytopenia and subsequently diagnosed with malaria. This is not
an uncommon finding (Abdalla,1990) and further potentiates the anaemia. The cause of
the dyserythropoiesis in malaria is not entirely clear; a few theories have been proposed
(Abdalla,1990; Weiss,1990) these include nutritional deficiencies, cytokine production
(e.g TNF), direct parasitisation of erythroblasts by malaria parasites (this has only been
demonstrated in vitro), and obstruction of the marrow sinusoids by PRBC which leads
to marrow hypoxia.
Cell cycle studies using spectrophotometry and thymidine uptake techniques have
demonstrated an increased proportion of cells in the S phase and the presence of
numerous cells that failed to demonstrate thymidine uptake. These disturbances in the
erythroblastic cell cycle would be in keeping with ineffective erythropoiesis
(Abdalla, 1990). This is usually echoed in the peripheral blood by the lack of a
reticulocytosis which is appropriate for the degree of anaemia. The mean reticulocyte
count was>- 4~ 0 (ranging from 0.5 • 18.2%) and the mean haemoglobin was 11.2 g/dl,
possibly indicating that in this study ineffective erythropoiesis was not the main
contributor of anaemia. We must bear in mind however that the reticulocyte counts
were not documented in the majority of the study patients, and that the contribution of
ineffective erythropoiesis to the anaemia may be underestimated,
A group of researchers from Denmark studying the effect of bone marrow inhibition in
the pathogenesis of'malarlal anaemia concluded that malarial infection is associated with
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inhibition of erythropoiesis (Kurtzhals et al,1997). As only two marrows 'were available
for assessment in this study group, this theory was difficult to confirm.
In the endemic areas the contribution of malaria to the development of anaemia,
especially in children, is often difficult to determine as I...'lereare often othe; causes of
anaemia e.g iron deficiency and haemoglobinopathies (Newton et al,1997). Of note was
the fact that within the paediatric group , a more microcytic type of anaemia was
evident. Ideally iron studies should be done to exclude the presenc ~of iron deficiency.
Morphologically, however, there were no gross features to suggest this or the presence
of a haemoglobinopathy.
5.5.2.1.1 Blood transfusion practise in the malaria patients
Sixteen percent of the study patients received a blood transfusion with anaemia as the
main indication. Generally a transfusion will be given if there is a severe anaemia
(HB <5 g/dl), or if the patient is symptomatic or is haemodynamica!1y unstable. For the
purpose of the study the transfusion data was documented based on whether a severe
anaemia was present or not. Among this group of patients one case fatality was
recorded, in a pregnant female who received a multiple transfusion for a HB of 7 gldI.
With greater improvement in blood screening especially for viral infections like HIV,and
the hepatitis viruses, blood transfusion has become an increasingly safer practise for the
management of anaemia. Nevertheless caution should be exercised not to unnecessarily
transfuse patients with excessive amounts of blood products. Four of the forty-two
patients received more than 2 units of blood. Five out of forty-two patients received an
exchange blood transfusion, the main indication being hyperparasitaemia. The aim of
treatment with exchange blood transfusion is to reduce the high level of parasitaemia as
quickly as possible, often in conjunction with intravenous quinine. The rationale is that
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since quinine is relatively slow acting, the exchange transfusion will reduce the
parasitaemia initially sufficiently until the effect of quinine is optimal. It also has the
advantage of removing any soluble toxins and pathogenic mediators (Warrell et al, 1990;
Eisenm,n et al, 1995). This modality of treatment however is still controversial (Marik,
1989; Miller et al, 1989; ed. Lancet 1990; Fontes and Munhoz, 1996).
Another interesting :finding, which to my knowledge has been well documented in
the literature as an important indicator of severe malaria, is the wee. A univariate
analysis of the continuous data identified a significant difference in the leucocyte counts
between the survivors and those that died. The wee was found to be significantly
higher in those that died (p=0.0281).
5.5.2.2 Analysis of chemistry dW!,
In non-immune adults, up to 113 of the individuals with falciparum malaria may have
biochemical evidence of renal dysfunction (Francis and Warrell, 1993). This may be
related to the underlying infection with obstruction of glomerular capillaries Ly PRBe,
or secondary to haemolysis, but may also only be related to simple dehydration and renal
function is then simply restored by rehydrating the patient with intravenous or oral
fluids. Previous studies have identified renal dysfunction and especially renal failure in
high numbers; Soni and Gouws (1996) had up to 17% of their patients presenting with
renal failure. In a retrospective study of malaria presenting at the Johannesburg Hospital,
Jairam et al (1990) documented 9% of cases with acute renal failure. Analysis of the
data in this study revealed only 3% of patients with biochemical evidence of renal failure
(creatinine> L.(S!!tnolll). Most authors identify high urea levels to be significant
predictors of poor outcome. Multivariate analysis and logistic regression models found
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high creatinine levels to be significantly associated with reduced survival, p=O.00852 and
p=O.0016 respectively. The mean serum creatinine level was 238.3 umol/l in those who
died as compared with 104.9 umol/l in the survivors. Surprisingly no statistical
difference 'p=O.2032) was demonstrated between the means. A possible explanation for
this includes the wide standard deviations derived as well as the small numbers for this
variable, in the non-survivors. In further contrast to what has been reported in the
literature by the group in Natal who documented hyperbilirubinaemia and jaundice in
10.4% of their cases (Soni and Gouws,1996), 32% of the study patients had evidence of
some liver dysfunction as noted by an elevation of the liver enzymes and raised bilirubin
levels. Impairment of liver function is associated with severe malaria. It is often rlifficult
to ascertain precisely what degree of dysfunction is present, as measurements of
bilirubins and liver enzymes may be elevated in the pre sence of co-existing haernolysis.
More aCCU.k~('measurements of hepatic dysfunction include the assessment of
coagulation abnormalities resulting from failure to produce clotting factors,
hypoalbuminaemia and reduced clearance of alanine and lactate (Warrell et aI,1990). Of
the parameters described above only albumin levels were determined. The mean albumin
level was 35.7 gil which is well within the normal range. This suggests that the results of
the liver function tests were probably influenced by underlying naemolysis rather than by
true hepatic failure. An accurate assessment however needs to take all the above factors
into account.
Hypoglycaemia is being recognised as an important manifestation offalciparum malaria.
In the present study 5% of the patients presented with low glucose levels
(glucose < 2.2 mmol/l), Hypoglycaemia was significantly associated with the
pregnant state. The cause of the low glucose levels in these
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patients is difficult to determine, It may be associated with increased glucose
consumption by the host /fever and infection) and/or by the parasite (anaerobic
glycolysis). Impaired gluconeogenesis 0:: glycogen depletion has also been implicated;
this may be the result of high circulating TNF levels and the presence of increased
plasma concentrations of insulin. Hypoglycaemia is also an important complication of
treatment with certain antimalarial drugs like the cinchona alkaloids, quinine and
quinidine. In vitro quinine has been demonstrated to stimulate the secretion of insulin
from the islet cells. This usually results in decreased hepatic gluconeogenesis and
increased uptake of glucose by the peripheral tissues (Wanell et al, 1990).
5.5.2.3 St:rological data and the assessment of immunity
One of the aspects that this project tried to assess, was the issue of underlying immunity.
In or ier to determine this the IFAT, looking for the presence of malaria antibodies, was
used together with a quantitation of IgG and IgM levels, at the time of presentation.
The results were compared between a group of patients with documenteu previous
exposure to malaria (24 patients;-12%) and a 'non-exposed' group ,which comprised
the majority of the study cases tested. Most of the patients had a rise in the total
immunoglobulin levels, which is a common observation after an acute malarial attack.
IgG levels ranged between 7.9 - 44.5 gil and IgM levels between 0.6 - 5.1 gil. The
normal ranges in adults are 10-20 gil and f).5-2.7g11respectively, What proportion was
specific anthnalarial antibody was not determined, as immunoglobulin subtypes were not
differentiated.
Overall the IFAT was difficult to analyse accurately, and it was difficult to correlate the
IgG and IgM titres against the IgG and IgM levels for the reasons mentioned above.
Interpretation of the IFAT was based on recommendations by the manufacturers of the
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kit. The test appears to be highly sensitive with 94% of the patients having positive
titles (IgG ;;::1:80), however in 3% of cases the test was negative (IgG <1:20). These
patients had thin smears positive for falciparum malaria. The reason why these
individuals would have a negative test is uncertain. The test appears to be highly
subjective, and even a skilled nacroscopist may experience some difficulty when
examining the samples under the fluorescent microscope. It is possible that these few
cases may have been weakly positive due to the presence of an early infection.
In the ideal situation where individuals have had no previous exposure to a particular
antigen, the initial antibody 'primary' response is predominantly IgM (Marsh, 1990).
Subsequent re-exposure results in u secondary response and the predominant
immunoglobulin then is of the IgG type. One would therefore expect to have the
majority of the patients in this study having a strong IgM response, however only 65%
had highly positive titres, th;' included 10/24 patients who had a history of previous
exposure.
Those individuals who had borderline or negative titres ie. <1 :20; 1:20;1 :40 may have
had a non-falciparum infection. This, however, would only account for 6% of the
patients. Falciparum antigen has been known to cross-react with antibodies directed
against other species, although at a lower titre. This can be ove come by ensuring that
the antigen that is used is adequately purified (Campbell et al, 1987). Another hypothesis
which may explain the low incidence of positive IgM titres is the possibility of the
presence of a different strain of Plasmodium falciparum against which antibodies have
been made. These antibodies may therefore not react with the antigens used in the
IFAT.
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Among the individuals with a history of previous infection only 6/24 (25%) had low IgM
titres, the remainder as described above showed an ]FAT which would be in keeping
with recent active infection. The explanation as to why these few patients have higher
IgM titres includes the possibility that they may have lost a previous 'immune' state,
and have become susceptible to acute infection again. Alternatively the IgM titres may
be reflecting a faIse positive result (Dr John Frean - pers.comm.)
The only consistent finding among the majority of the previously exposed group (17/24)
was the presence of a low level parasitaemia ( < 1% to 1%), which may be indicative of
a low grade chronic infection .This however did not correlate well with the !FA test.
Perhaps a better way to assess underlying immunity is by measuring specific malaria
Inouced subclasses of immunoglobulin e.g IgG 1 and IgG3.
5.5.2.4 Analysis of pregnancy data
The study patients were divided into two main categories: - the previously exposed
'immune' patients, and the non-immune cases. Within the latter an additional two groups
were identified, that of the pregnant women and those patients who required leU
admission. The first two categories have already ben discussed in some detail.
Analysis of the pregnancy data revealed what already has been documented in the
literature, that pregnancy is associated with an increased susceptibility to malaria
infection and that there is also an increased risk of foetal loss. Fievet et al (1995)
investigated the mechanisms underlying the increased susceptibility to malaria in
pregnant women, by studying a group of Cameroonian primigravidae. Their findings
suggested that an immunosuppression process occurs during pregnancy and this
immunosuppression appears to be due to a defect in the antigen presentation and
processing mechanisms, with an altered capacity oflymphocytes to proliferate, and a
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reduced IL-2 production. Similar defects.however were also present in response to non-
malarial antigens. The authors postulate that the alteration of malaria immunity might be
a non-specific phenomenon, but in pregnancy and particularly in the primigravidae.this
alteration of the immune response to malarial antigens is possibly restricted to a
particular subset of lymphocytes.
5.5.2.5 leu admissions
Review of the lCU data revealed a few indicators that may be used in the future to
identifY which patients are candidates for early intensive care, to reduce morbidity and
mortality from malaria infection. Fifteen patients were admitted into lCU, of which five
died. The important parameters that should be assessed on presentation of the patient
with malaria, and then on subsequent follow up of the patient in the general ward
include: the presence of a hyperparasitaemia (especially with falcipanun malaria), the
presence or development of renal failure, cerebral malaria, hypo glycaemia and the
pregnancy state of the individual. Finally if any of the above parameters are associated
with severe anaemia andlor a high wce the patient should be considered for rcu care.
Unfortunately this is often easier said than done as entrance into the lCU is often limited
due to the availability of beds. When the situation arises that the patient cannot have
immediate access to intensive care in an leU facility, if the clinicians are aware of the
high risk patient they may be able to provide more aggressive therapy earlier, like
exchange transfusions and renal dialysis in addition to the routine chemotherapy.
5.5.2.6 Trellltment
At the Chris Hani/Baragwanath Hospital the mainstay of treatment for acute infection is
oral quinine, given in 88% of cases, alone or in combination with drugs like tetracycline
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and doxycycline. Quinine may initially be given intravenously, as was observed in 12%
of the study cases, in the event of a severely ill patient and/or patients who are unable
for one or other reason to take the drug orally. Quinine and tetracycline/doxycycline
therapy was initiated simultaneously. After seven days quinine was discontinued and the
course of tetracycline/doxycycline was completed after fourteen days. In the event that
the patient was discharged prior to finishing the prescribed treatment, the balance of the
medication was given to take home. The only other treatment option available in the
event of failure with quinine, is Fansidar (although this was not used in any of the
patients during the course of the study).
With the emergence of resistant strains, why is it that we can still rely on quinine, after
centuries of use? Meshnick (1997) gives three possible explanations as to why
quinine is still effective as an antimalarial drug:
a) One of the mechanisms of resistance is the emergence of new parasite strains
(mutations) that are no longer sensitive to a particular drug; it is postulated that the
intraparasitic 1arget for quinine is so specific that mutations of this target site are
occurring at a very slow rate,
b) there may be some parasite strains that have developed resistance to quinine, relative
to those strains which existed centuries ago, and since this resistance may have occurred
gradually we may not have noticed ',,,"' the requirements (i.e doses) of quinine have
increased, and
c) the use of quinine may not have been so intense that it exerted evolutionary selective
pressure until now.
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Treatment for malaria can be divided into (i) therapy for uncomplicated disease,
(ii) management of severe /complicated malaria, and within these two groups the special
considerations that should be given when treating children and pregnant women. The
recommended drugs and treatment regimens have been reviewed in detail and will not be
discussed further (Kozarsky and Lobel, 1994; Olliaro and Trigg, 1995;
Schultz et al, 1995; Department of Health, 1996; White, 1996).
Among the treatment options is the entity of self administered therapy for acute malaria.
This is often employed in areas where the distance and the cost of seeking care from
health services may be great, or when traditional care from a healer is considered more
appropriate. The major shortfall with this is the lack of public awareness on malaria and
the subsequent lack of appropriate use of antimalarial drugs; this has often been
associated with further development of drug resistance (Foster, 1995; Ruebush et al,
1995; Mnyika et aI, 1995; Schlagenhauf et al, 1995). Perhaps one of the ways to
overcome this is to develop an easy to use and simple to interpret test, in a kit form
that will be suitable for self-diagnosis, Travellers can then start appropriate therapy once
a positive test is encountered, until medical advice is able to be sought
(Schlagenhaufet al, 1995).
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Malaria continues to be one of the most important health problems in the World but
especially in sub-Saharan Africa. In South Africa, only a few areas are endemic to this
infection, the remainder of the problem stems from imported malaria.
Despite efforts to control this disease worldwide and locally, the incidence appears to be
rising, Whether this is due to emerging resistant strains to antimalarial
chemoprophylactics, or aggrevated by climactic changes like global warming and the
EI Nino effect, or whether it arises from basic ignorance of the disease among the
affected populations and among travelers, is difficult to ascertain.
At present the incidence of malaria appears to draw strength from all of the above.
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6J) CONCLUSION
The important aspects that were revealed in this dissertation have been summarised
below:
a) The incidence of malaria at the Chris Hani/Baragwanath Hospital is increasing
annually with a significant rise in the number of admissions during 1996 compared with
those noted in 1994 and 1995.
b) There is a distinct seasonal pattern which appears to coincide with holidays, viz
Christmas and Easter.
c) The majority of cases are due to imported malaria :from the neighbouring countries.
Most (58%) of the imported malaria infections (predominantly Plasmodium
falciparumy were acquired in Mozambique. Four patients, who presented with
falciparum malaria, had no travel history and the source of infection is unidentified. ·1
them. Inone of the cases the possibility of 'taxi rank' malaria exists.
d) The most common infecting species was Plasmodium falciparum (95.1 % of cases).
e) Climactic data did not support the possibility of transmission of infection in Soweto.
There is also no definitive proof that the malaria transmitting vectors (Anopheles
gambiae and Anopheles arabtensisi are found normally in Gauteng. When asked
whether it would be possible for 'imported' mosquitoes to breed with local species,
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colleagues from the Medical Entomology department of Tropical Diseases of the School
of Pathology, at the South African Institute for Medical Research, responded that it
would be very unlikely for breeding colonies to be established with local Anopheles
mosquitoes (Drs M. Coetzee and R. Hunt - pers. comm.)
f) Clinical and laboratory results confirmed findings documented in the literature by
other authors. The prevalence of complicated disease among this study group seemed
less than previously reported in other South African studies.
Hyperparasitaemia and renal failure (based mainly on the creatinine level) were found to
be significant predictors of poor survival. In addition to the morbidity and mortality
associated with malarial anaemia, the WCC (and particularly a raised count) was found
to be an important prognostic indicator.
g) The findings among the pregnancy group confirmed the poor outcome associated
with this infection, both for the mother and the foetus.
h) The main criteria for lCU admission (provided availability of beds) appear to include
hyperparsitaemia, the presence of renal failure, cerebral oedema and the pregnancy state.
Additional factors that need to be taken into consideration are hypo glycaemia. and the
presence of a severe anaemia and a raised WCC.
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i) The mortality rate was 3% and the deaths were mainly associated with the adult
group. Only one of the six 'Pf~ientswho demised 'Wasa child. This is in contrast with the
high childhood mortality noted in endemic areas.
j) The underlying immune status of the patients was difficult to assess accurately by
using the IFAT. In the patients with a history of previous exposure the results of the
test were not consistent. Among the patients with no previous exposure to malaria, the
test successfully identified acute and active infection. The IFA test was reported os
negative in three patients, who had documented disease on thin and thick smears. The
reason for this is uncertain, however the possibility of an early infection cannot be
excluded. Factors that need t..J be taken into account when interpreting this test is the
presence of non-C.' 'lparum infections that may cross-react with the falciparum antigens,
and in 'immune' individuals the loss of a previously acquired immunity, with the
presence now of a 'primary' response to an acute infection. Immunity to malaria is
reported to be acquired slowly but may be lost rapidly if continuous exposure to the
malarial antigen is lost.
k) The single most important fact that became apparent was the lack of knowledge
regarding malaria and its consequences, even among individuals who regularly visited
endemic areas. In those individuals who sought pre-travel advice, the use of
prophylactic drugs was inconsistent and was not accurately completed. In addition the
drugs prescribed were often not suitable for prophylaxis.
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1) WIthin the hospital setting quinine is stili the mainstay of treatment for acute
infections. Specialised therapy like exchange blood transfusions for hyperparasltaemia
were limited but when used, successfully reduced the parasitaemia, Out of five p':ticnts
who received this modality oftherapy in conjunction with quinine, one individual died of
other complications.
It is apparent that the repertoire 0_' drugs for malarial prophylaxis and treatment is
limited at the Chris Hani/Baragwanath Hospital. The reason for this is uncertain but
may be due to the cost of these drugs. However with the emergence of CQR and now
also quinine resistance, the range of drugs needs to be increased, if effective therapy is to
be given for malaria patients. Wrth the emphasis now on prevention and primary health
care, the role of providing malarial prophylaxis Within the hospital sector will need to be
expanded.
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700 RECOlVIMENDATIONS
In 1957 the World Health Organisation launched its first formal global campaign for the
control of malaria. Now, more than forty years later, the WHO are still fighting an
apparently losing battle. The latest recommendation is that malaria control be an integral
part of the national primary health care system. With this is mind, the MANTEAU
project was launched in 1993: Managing Tropical disease Through Education and
understanding; the ultimate aim being to provide a well trained workforce who are
motivated and knowledgeable in the implementation of new technology to supplement
traditional methods of education and management.
The goals of this programme include:
a) human resources development through on-site training and action learning.
b) capacity building at local and national levels through enhancing comunications and
infrastructures.
c) strengthening national programmes in developing countries through the development
of tools and techniques for improved management and control involving training, data
management and decision support.
d) sustained tropical diseases management ensuring quality control through improved
clinician support.
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What can we do on our part to assist such a programme ?
In my opinion one of the most important 'needs' in order to make a pm gramme like this
successful is the development of health information systems. These may be hospital or
clinic based.
The first assignment of such an 'information system' would be to make a strong
statement about the extent of the malaria problem. This can take the form of a 'malaria
awareness day', where members of the public and in this case individuals who commute
to and from the Chris Hani/Baragwanath Hospital and the surrounding clinics, can be
bombarded with information regarding the iransmission of malaria and how best to
guard against this infection. Posters a..j pamphlets are an easy and cost effective way of
achieving this. The most appropriate time of the year to launch this campaign would be
in December before the Christmas holidays. The use of the media, mainly newspapers
and radio, and to a lesser extent the television ( as some of the population that we wish
to target may not have such a luxury) may be useful to promote this event, and later
may even be utilized to spread malaria awareness through special (malaria) education
broadcasts/editions.
The next step would be to target the health care providers, and to regularly update these
individuals with the latest developments in prophylaxis and treatment. This in part is
already in motion. With the collaboration of the Department of Health and the TPS
Drug Information Centre, guidelines for the prophylaxis and the treatment of malaria are
being circulated injournals to which clinicians have access.
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Inour multicultural societies, health care providers include traditional healers, herbalists,
homeopaths and the hawker who sells his wares on the street comer. We therefore need
to educate these individuals as v ell, and possibly to recruit their assistance in the fight
against malaria.
As part of the IV1.AJ."\ITEAUproject the WHO released a booklet for the
'non-pharmacist' selling antimalarial drugs. This originally was aimed at market place
shops in malaria endemic areas, however it can very easily be applied to our local
situation. The booklet provides comprehensive information on malaria, who gets it and
how it is acquired, It has a section which deals with the available drugs for the
prophylaxis and treatment of malaria. with dosage regimens illustrated in table forms. It
gives advice on what to do in the event the treatment option does not improve the
patient's condition and also describes the features of severe malaria and' gives
recommendations as to the best time to seek medical advice. As most of OUI malaria is
impr "-;:d,and as a result of travel to an endemic area. we may be able to provide travel
information in the form of this booklet.
In addition one could include a simple to use diagnostic test, like the antigen capture
dipstick tests that are available, for self diagnosis in the event of symptoms. Combine
this with (i) adequate prophylactic cover in the form of chloroquine and proguanil,
(ii) a topical or aerosol insecticide, tr 1 (ill) standby treatment in the event of an acute
infection e.g quin' ,e, and you have the 'new improved malaria travel kit'( Schlagenhauf
et, 1995). However, for such a venture to be successful there will be he need for
adequate education of those individuals who acquire the kit, in order to avoid confusion
1.,\6
regarding the treatment protocols included. The kit can be made available from state
hospitals, clinics, over the counter in privately owned pharmacies, even at border posts.
It should ideally be manufactured by a pharmaceutical company and made available to
the Department of Health, for distribution to the relevant sites as mentioned above.
The initial costs may be high (alternatively it may be subsidised by the manufacturing
company) but until a better option is available i.e the long awaited 'boly grail' - the
antimalarial vaccine, our choices are limited.
In the interim, a more realistic solution would include the availability of more
prophylactic agents at health clinics and state hospitals, an issue which the Department
of Health should list as number one 011their agenda.
000000000
Malaria is a common and serious disease. Each year hundreds of travellers are at risk of
acquiring this infection, and many more do fall ill with malaria, and even die. The
biggest problem is the lack of knowledge about this disease and what causes it. With
prevention and treatment of malaria becoming increasingly more difficult, we need to
educate our populations to be more aware of the dangers associated with malaria, to
take adequate precautions, and above all else to seek urgent medical advice ill the event
of suspected infection. Malaria especially falciparam malaria although dl'(;'dl~ is very
amenable to therapy and can be limited if it is detected and treated early.
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APPENDIX A
tJUB.TECT INFORMATION AND CONSENT FORM
You have been diagnosed as having Malaria. This condition results from the
bite of a certain type of mosquito. which is infected with the organism
(parasite) which causes the infection, Individuals that travel to areas where
these mosquitoes are plentiful. without adequate medical protection usually
become ill after they have become exposed to mosquito bites. The course of the
disease is usually benign. however some individuals may develop serious and
often life threatening complications e.g. renal failure and central nervous
system involvement (cerebral malaria). Early diagnosis and treatment leads to
a speedy and uneventful recovery. In January - March 1994 about 100 patients
were admitted to Baragwanatb with the same condition that you have. This
reflected a very high number of affected individu ...ls.
I tim conducting a project on malaria, to try and answer some important
questions which may provide some insight to the high incidence of this
infection in Soweto.
If you agree to take part in my study you will be expected to answer a very
simple questionnaire. and allow me to do a clinical examination not unlike the
one your doctors have done on your admission. This is done confidentially.
You might also be expected to undergo one or two extra blood laboratory
investigations which will provide us with important information with regards
your condition. Your refusal to participate in this research project will not
affect your medical care in any way.
At the bottom of this information sheet you will find a consent form which you
are expected to sign if you agree to be entered in my study. If you. are under
18 years of age. a guardian or next of kin will be expected to sign on your
behalf.
DATE. _ DOCTOR. _
I fully understana the information that was given to me
by and agree to take part in the abovementioned study.
I also understand that I may withdraw my consent and discontinue my
participation at any time. and that this will not affect my regular treatments
at this hospital.
DA1E. PATIENT, _
GARD;. :RXT OF KIN: _
WILNESS:
178
APPENUIXB
RETROSPECTIVE STUDY
PATIENT INFORMATION SHEET
SOCIAL HISTORY
Name: Age: Hosp.No:
Gender: Date of admission:
Present address: Permanent address:
Nationality: Income:
Travel history: Prophylaxis:
MEDICAL HISTORY
Signs and Symptoms:
Gestation:
Treatment: TTO:
OUTCOME:
Discharged Demised
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APPENDIXC FlGE:
QUESTIONNAIRE
MALARIA
Name: Hospital No: _
Age: , Sex: Occupatiion: _
Addre~: __
Tel: No.: Home: Work: Ward: _
Date: Admitted: Rrferred: • _
Nationality: _ Income. ___
HISTORY:
GENERAL:
Anorexia:
Fever:
Night Sweats:
Prurltis:
General well being (malaise): _
Fatique:
Weakness:
Lymphadenopathy:
Joint pains:
Thrombosis: (DVT. stroke)
Headaches + visual disturb-meet: _
Amenorrhoea:
Impotence:
180
R1GE: 2
Bleeding: (site, duration, amount)
Epistaxis:
llnematysis:
Harmatemesis + lIfalaena:
Hamuuuriar
Menorrliaagia:
Mucous membranes + Gums:
Skin (purprlra):
Venepunr:'.re sites:
Haemarthrosis:
SYSTEMIC ENQUIRY:
Head & Nec~ • ___
Respiratory: _
Cardiovascular: _
Gynae: Gestation: _
DRUG HISTORY:
MALARIAL PROPHYLAXIS: Was it givenlAdvised ? _
What Drugs were Issued
Who prescribed the Drugs ? _
For how long were they taken
OTHER:
Hosn7~L THERAP~ ___
PAST HISTORY: (Malaria I TBI !lPTI Diabetes! Malignancyl Chemotherepyt Radiotherapyl Illnessl Operations}
TRAVEL HISTORY: Destination? . _
Duration of Visit ?
Frequency of Travel to Malaria Areas ? _
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PAGE: 3
CLINICAL EXAMINATION:
To p~ B~ ,
Colour: __ Palke: Cyanosis: _
Jaundice: Oedema: . _
Lymphadenopathy: _
Head & Neck: , _
CVS: Chest: _
CNS; Fundi:
Sensory: • _
Motor: • _
Cranial Nerves: . _
Cerebellar: _
Reflexes: _
FINAL DIAGNOSIS:
OUTCOME OF DISEASE:
LABORATORY RESULTS:
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STANDARD OPERATll'TG PROCEDURE
FOR A DIFFERENTIAL COUNT
Pli'oc#HCEN0038.MET
(SAIMlPl Department of Haematology)
CLINICAL ASPECTS:
]..]. PbysiQ!Qg!cal ~y,[i)ects,clinical significance and indications foil' the test
A differential is not only requested for the diagnosis ofhaematological disorders
but also to provide information for diagnosis of'non-haematological diseases, for
indicating side effects of chemotherapy, and for monitoring patient therapy.
Reasons such as these make it essential that a blood smear be prepared correctly
and examined in such a way as to provide the physician with an accurate
interpretation. Blood smears are prepared from EDT A anticoagulated blood to
minimize degenerative changes in the blood cells. The collection tube must be
completely filled with the appropriate amounts of blood so that it can mix with
the anticoagulant. If there is an excess of anticoagulant, artefacts will occur. To
ensure good preservation of cellular morphology, blood smears should be made
as Goon as possible and no later than 3 hours after collection.
SLIDE PREPARATION
PRINCIPLE:
A small drop of blood is placed near the frosted end of a clean glass slide. A second slide
is used as a spreader. The blood is streaked in a thin film over the slide. The slide is
allowed to air dry and is then ....tained.
SPECIMEN:
EDT A, Finger prick
Patient preparation:
Nil
Typer
EDT A blood or unanticoagulated capillary blood.
Handling conditions:
The EDT A blood must not be older than 3 hours.
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Equipment:
1. Glass slides 3xl inch (precleaned with frosted ends;
2. Glass spreader (width slightly less than 3")
3. Capillary tubes, plain.
PROCEDURE:
1. Clean slides are essential.
2. Make a spreader with a perfectly smooth edge by breaking o.Scm from the width.
3. Fill a capillary tube three-quarters:full with the EDTA blood.
4. Place a drop of blood about 2 rom indiameter approximately 10 rom from the
frosted area of the slide.
5. Place the slide on a flat surface, and hold the narrow side of a the non-frosted
edge oetween your thumb and forefinger.
6. With your right hand, place the smooth clean edge of the narrower side of the
spreader on specimen slide, just in front of the blood drop.
7. Hold the spreader slide at a 30 degree angle, and draw it back against the drop of
blood.
8. Allow the blood to run along the width of the spreader by capillary attraction.
9. Push the spreader forward with one light,smooth, and fluid motion. The weight
of the slide should be the only pressure applied. A thin film of blood in the shape
of a bullet with a feathered edge will remain on the slide.
10. Allow the blood to dry completely before staining. This can be accomplished by
waving the slide in the air 'Vigorously or by placing the slide in a stream of cool
air.
Small drop
of blood \
Figure A: Preparation of a peripheral blood smear, slide to slide
technique
COM~ !ENTS AND LIMITATIONS OF THE PROCEDURE:
1. A good blood film preparation will be thick at the drop end and thin at the
opposite end.
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2. The blood smear should occupy the central portion of the slide and should not
touch the edges nor extend into the last 15 mm of the slide.
3. The thickness of the film is determined by:
-the volume of blood
-the angle of the spreader
-the speed (If spreading
Thicker films can be produced by increasing the angle of the spreader and the
speed of spreading, and vica versa to produce thin films.
4. The wedge slide is one of the most popular methods for producing a blood film.
but it does not produce quality smears. The WBC's are unevenly distributed and
RBC distortion is seen at the edges. Smaller WBC's such as lymphocytes tend to
reside in the middle of the feathered edge. Large cells such as monocytes,
immature cells and abnormal cells can be found in the outer limits of this area.
S. Excessi, elvthin films will distort red cell morphology, with a tendency to
accumulate WBC's at the margin and the tail.
6. Thick films will have insufficient area where the red cells are spread without
overlapping and the WBC morphology will be obscured.
7. Do not tap the capillary tube on the slide to try to get more blood out of the
capillary tube. This causes the RBC's and the WBC's to disintegrate.
STAINING OF THE BLOOD FILM
See staining section of the Manna' for manual and automated staining techniques.
EXAMINATION OF THE PlEEUlPHERAL BLOOD SMEAR
There are several necessary steps ,1the examination of a peripheral blood smear:
LOW POWER (Xl0)SCAN
1. Determine the overall staining quality of the blood smear.
2. Determine ifthere is a good distribution of cells on the smear.
a. Scan the edged and centre of the slide to be sure that there are no clumps of
RBC's,WBC's or platelets.
b. Scan the edges for abnormal cells.
3. Determine the WBe estimate.
4. Findan optimal area for the detailed examination and enumeration of cells.
a. The RBC's should not quite touch each other.
b. There should be no areas containing large amounts of broken cells or precipitated
stain.
c. The RBC's should have a graduated central pallor.
THE SOX OIL IMMERSION EXAMINATION
Note: the SOx oil immersion objective is recommended for the performance of the 100-
ceil differential for the experienced morphologist because it enhances speed without
sacrificing accuracy especially on low WBC counts (below 4.0 x 109/1. It is
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recommended that 100 x oil immersion objective be used by beginner morphologicts
until they become familiar with the various cell types.
1. Various counting patterns have been suggested to overcome the tendency,
present even in the best made wedge films, for the neutrophils to accumulate at
the edges and in the tail of the film. In an attempt to represent fairly the
neutrophils at the edge of the film the "battlement' pattern includes the edges of
the film, which, if the slide is poorly made, will result in counting excess
neutrophils.
[
Figure B: Scanning pattern illustration
Counting all the leucocytes in a longitudinal strip from head to tail of the film bas been
recommended on the premise that in a well-made film each strip will represent the blood
drawn out from a small volume of blood when it has spread out between the slide and
the spreader. The disadvantage of this method is that in the thicker part of the film
WBC's appear smaller and condensed making identification more difficult.
2. Perform a 100 WBC differential count and report the differential as a percentage
and as an absolute number.
3. Correct any total WBC counts that has greater than 10 nucleated red blood cells
(NRBC) per 100 WBC's.
When performing tl,c differential, do not include NRBC's in your count, but
report them as the number ofNRBC's/lOO WBC's.
ii Use the formula under the calculations heading to correct the WBC counts.
4. Perform a WBC estimate and evaluate the morphology (nuclear and
cytoplasmic).
Using SOxobjective count the number ofWBC's in 10 fields. These must be
counted in an area where the RBC's slightly overlap.
ii Divide by 10.
iii Multiply by 3.0 to get the estimate count.
5. Evaluate the red cells for size,shape,colour,and inclusion bodies. This must be
done in an area where the red cells are evenly dispersed and are just separating.
At least 10 fields should be scanned. In thick areas RBC morphology cannot be
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seen and in the thin areas the RBC's tend to look hyperchromic, and variation in
shape is lost.
6. Perform a platelt estimate and evaluate platelet morphology.
Using 100x objective count the number of platelets in 10 fields. These must he
counted inan area where the red cells are evenly dispersed.
ii Divide by 10.
iii Multiply by 20.
CALCULATIONS:
Absolute value (x 109/1) = % x WBC count
100
Corrected WBC (x 109/1) = WBC x 100
(NRBC-HOO)
PROCEDURE NOTES:
Reference Ranges: please see MATERIAL).ND lMETHODS, pg 77-78
Procedure for Abnormal Results:
As per laboratory SOP
Reporting format:
APEX or equivalent
LIMITATIONS OF TIlE PROCEDURE:
1. The best :films are made from unanticoagulated blood. If an anticoagulant is used
the film should be made immediately ifpossible, or nomore than 3 hours after
collection.
2. Comments made in the section covering slide preparation are also applicable
here.
3. Consultation should be sought for abnormal smears and for allnew cases with
abnormal haematological results.
4. Automated differential machines each have their limitations with regard to their
differential counts. The technologists must be familiar with the laboratory's
instruments.
REFERENCES:
I, Peripheral blood cell morphology. 1983
2. Hall R. and Malia R.G. Medical Laboratory Haematology, 2nd Edition
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STANDARD OPERATING PROCEDURE
MALARIA INDIRECT FLUORESCENT AN'fmODY TEST
(SAIMR Department of Parasitology)
PRINCIPLE:
Antibodies in patient's serum bind to P.falciparum on a slide and are detected by
antihuman antibodies labelled with FITC. A fluorescence-equipped microscope is used to
read the test.
EQUIPMENT AND MATERlALS:
Fluorescence/Fl'I'Cj-equipped microscope
Magnetic stirrer
Antigen slides
Phosphate buffer (PB) pH 7.4
Polyvalent FITC-labelled antihuman globulin *
Evan's Blue diluent(1:100 in PB)
Positive and negative serum specimens
Pipette with tips
PROCEDURE -STEPWISE:
Dilutions: to make 1/20 dilution of test serum, positive control and negative control
sera, place 500 III of phosphate buffer in an Eppendorf or similar tube. Take out 251-11
and discard. Add 251-11of test serum.control serum or negative serum to the buffer and
mix; for the test serum make doubling dilution up to 11160 dilution.
Antigen slides: Remove the slides with antigen :from the freezer and place in a Coplin
jar with phosphate buffer and magnetic stirrer. Wash for 10 minutes. Wipe the slides
with tissue paper except the area with antigen.
Test:
1.
5.
Place 201-11of the dilutions of test serum.positive serum and negative serum in
wells on the slide.
Incubate at 37 degrees for 30 minutes ina humidified chamber.
Place the slide(s) into a Coplin jar with phosphate buffer, a magnetic stirrer and
witn 3 changes of buffer for 10 minutes each.
Wipe excess buffer off the slide(s) with tissue paper but do not touch well
contents.
Place 20 1-11of polyvalent conjugate * at the appropriate dilution in Evan's
blue/buffer (dilution factor varies with each batch; consult package insert) onto
each spot and incubate at 37 degrees for 30 minutes ina humidified chamber.
2.
3.
4.
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6. Repeat step 3
7. Place coverslip over the spots and examine with fluorescent light under x 100 and
x 400 magnification.
REPORTING RESULTS:
Under ultraviolet light the plasmodia (rings and schizonts), which have reacted with
positive sera are seen as bright yellowish-green against a reddish-brown background.
Negative specimens show merely as reddish-brown,
* For the purposes of this study, the test sera were treated directly with specific IgG and
IgM (monovalent conjugates) antihuman globulins.
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STA1YIM.RD OPERATING PR.OCEDURE
FOR THE !!Jf"11'ERMINATION OF
IMMlDNOGLO!t~1L ..1~EVELS - e.,?! IgG
(SAIMR Department of Chemical Pathology)
CLINICAL DETAILS:
1.1 Phy_siologicallwpects:
IgG is the predominant serum immunoglobulin comprising about 75% of
total serum protein. There are 4 sub classess ofIgG in normal serum.IgG
is ofparticular importance in the bodies long term defence against
infection. IgCydeficiency is associated with recurrent and occasionally
severe pyogenic infections. IgG is the only immunoglobulin to cross
the placenta. IgG synthesis and serum levels are increased in response to
chronic or recurrent infections or auto-immune diseases.
1.2 Clinical Significance:
Auto antibodies are ofthe IgG class e.g antinuclear antibody, and anti-
basement membrane antibodies. A significant increase in IgG also occurs
ir patients with multiple myeloma of the IgG type; this is the most
common form of multiple myeloma.
1.3 Indications for the test:
PRINCIPLE:
As the central component of the Array Protea System, the rate nephelometermeasures
the intensity of the light as it is scatteres by particles in suspension in a semi-disposable
flow cell when a beam of light is passed through the cell. The particles are formed by the
immunoprecipitation reaction that occurs when a specific antibody is brought into
contact with the specific antigen. The resulting formation of complexes and the
consequent change in the intensity of scattered light occurs at a rate that increases
gradually at first, then rapidly, and finally proceeds through a peak rate of change (peak
rate value) for the cmponent being analyzed. For Beckman specific protein test kits, the
analyzer electronics system derives the peak value for the rate-of-change from the
scattered light signal, converts that value into concentration units, presents the results
on a CRT, and transmits it to the printer.
ANTIGEN EXCESS DETECTION:
For a constant amount of antibody, the magnitude of the rate signal will increase
as antigen levels in the serum sample increase until excessive levels of antige
cause a diminished rate response. It is therefore possible for two significantly
different concentrations of antigen in the serum to yield the same rate response.
T' ,\.:Array Protien System is programmed with a standard antigen excess check
mode to discriminate between a reaction that is in antigen excess and one that is
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in antibody excess. This mode tests for the presence or adsence of unbound
(excess) antibodies in solution after the primary reaction, in reactions identified
by the program as being ambiguous (i.e when the rate units measured could be
either antigen excess or an antibody excess primary reaction)
OUT-{}F-RANGE DETECTION:
The concentration of each lot of antibody in a Beckman Specific Protein Test
Pack has been adjusted to a level compatible with the prescribed dilution of
serum samples so that the measuring range of the reagent will cover
approximately 90% of expected values. Each antibody card contains
information which defines out-of-range high and out-of-range low limits for each
assay. samples producing rate values above or below these limits will
automatically be retested at the next appropriate dilution, unless a non-standard
dilution has been selected for the chemistry which is below the limit set on the
card.
SPECIMEN:
Clotted blood
Patient preparation: Fasting individual
Type:
Serum. freshly drawn from a fasting individual. It can be stored at 2 to 8 degrees
for up to 72 hours. If kept longer they should oe frozen. Plasma is not
recommended.
CSF; centrifuge to remove possible cellular or bacterial contaminants. Analyse
freshly or store in fridge.
Interfering substances:
Lipaemic specimens tend to cause light scatte, ing. The presence of dust
particles causes non-specific interference, and the use of polymer enhanced
buffers.
CSF; blood contamination may produce erroneous results.
EQUIPMENT AND MATERIALS:
Equipment:
Beckman Array Nephelometer
Materialse
Beckman IgG antisera. Reorder no: 446600
Storage Requirements:
1. Antibody, ready to use, comes with the Antibody card.
2. Ering reagents to room temperature before use.
3. Store at 4 degrees until expiry date.
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4. Do not mix reagents of different lot numbers.
CALmRATiON:
Standard Preparatlon:
NOTE:a) Each calibration Kit consists of:
1. A calibration card
2. A calibrator
They must always be used together.
b) The Calibration Procedure is the same for all the chemistries used on
the Array.
I: Ready for use, comes with calibrator card which has calibrator values or.
it. Use only same lot numbers together.
II: Reconstitutewith 1ml distilled water, let stand for 30 minutes. Use same
lot numbers for card and calibrator.
Callbration Procedure:
Calibrate on CAL 1.Use Control 1.
1. "Master Menu"
2. "Results recall" (F3)
3. "Clear current run" (F4) (You cannot calibrate unless all results have
been deleted).
4. "Master screen"
:5. "Ccl Status" (F2)
6. "Sc'ect chemistries to be calibrated"
7. PRESS "Read AB cards"(Fl)
8. Use the appropriate Array Antibody card (i.e the one in the,' .agent kits)
one at a time, checking that the correct reagent lot number is used.
9. Define the cup location of the calibrator.
10. Proceed to "Cal TIllYSet-up'{Fz) and insert the appropriate Array Cal
Cards (one at a time), Readf'al Card F2.
11. "Save cup" (FI) to store the program in memory.
12 Place 200~1 of the appropriate Cal sal : "..n into the outside well of the
dilution segment and place on turntable in the desired position.
13. PJ?~e all your antibody vials in the correct positions, mix and uncap. Also
check that you have got su:t.ricientantigen excess solution.
14. Press (START) to initiate catibration,
15. When the calibration is finished, the analyzer will print for each chemistry
a x-value and a y-value.The two values must be the same for the
calibration to be successful, ifnot the print out will say "CALIBRATION
FAILED". The procedure must then be repeated.
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QUALllT'll CONTROlL:
I: Ready for use. Inserts have target values for different chemistries.
II: Reconstitute with 1ml of distilled water, stand for 30 mins.
PROCIED1URJE" STEPW:SE:
1. "Master Screen"
2. "Clear Current Run" (F4)
3. "Sample Program" (FI)
4. "Cup" : enter position 1 - 40 (ENTER)
"Sample ID" : enter lab number (ENTER)
"Sex" : skip
"Age" : skip
"Panel" enter panel number or go to individual tests usi.ng arrow
keys and select. (Tests get highlighted)
5. "Save Cup" (FI)
6. Place a minimum of 150 III of your sample in the outside well of the
dilution segment and place on turntable it .:le desired position.
7. Gently mix your reagents, pat them in the correct position and open the
lids.
8. START
9. All results will be printed as the analyzer completes each test.
PRIORITY SAMPLE PROGRAMMING
Once a priority sample is entered as above, the analyzer will finish any test
presently in the optics and then run the priority sample irrespective of its position
on the tray. To designat a sample as a priority, simply press F3 any time before
saving the cup (FI).
CONTINUOUS PROGRAMMIN~ (ADDING-ON)
Additional cups can be programmed to an existing run by identifying the cup
position and loading, (preferabley when the analyzer is finished loading the initial
samples, so as not to interfere with the probe movements) otherwise press
"PAUSE" and load freely and then press "ST,t\RT".
llll.AJlLYSTART-UP
The power should be switched on at all times.
1. Check the syringes on the left outside for leakages.
2. Empty the waste container.
3. Check that the buffer, diluent,RHF reaction fluid levels are high enough.
4. Prime the appropriate lines i.e
System prime mosde 1 (lines 9 and 14) diluent and buffer.
System prime mode 2 ( lines 9 and 13) diluent and RHF fluid.
The system will prime itself automatically at 4 hour intervals.
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5. Go to the keyboard and press:
a. Master Screen
b. System set up
c. Optics update
d. Left optics (PI)
The probes align themselves, then follow the following prompts from the
screen,
i. "homing" (no action)
ii. "draining" (no action)
iii. "replace flow cell with 120 cell, press (ENTER) to
continue".
iv. "replace 120 cell with black cell, press (ENTER) to
continue".
v. " reading scatter standard" (no action).
vi. "Replace black cell with flow cell and press (ENTER).
,~Verify that the stir bar is in the flow cell beforep putting
it back in 'i'.
vii. Replace the flow cell and cap then press (ENTER).
DO THE SAME FOR THE RIGHT OPTICS (P2)
GAIN ADJUST
1. The gain adjust should be between - 15% ana + 15%.
2. Record the adjust % daily (should trend gradually in the negative
direction).
3. The gain 1,2 and 3 results should be 120 +/- 1.Gain 4 should read
"over", ifnot, repeat OPTICS UPDATE and ifstill out of limits then do
OPTICS SET.
4. Optic Set is normally done once in 6 months under normal circumstances
- follow instructions on the screen as for OPTICS UPDATE.
5. Once you do an OPTICS SET you will lose all calibrations,
6. The same 120 scatter cell used for OPTICS SET, should be used for daily
OPTICS UPDATE, handle the cell at the top with the numbers facing the
front.
If your calibrations are still valid, you are now readyto program your specimens,
Calibrations are done once a week (usually on a Monday).
CALCULATIONS: None
REPORTING RESULTS: in gil
REFERENCE RANGES: please see MATEPJALS AND METHODS page 86.
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